WO1999035146A1 - Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors - Google Patents

Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors Download PDF

Info

Publication number
WO1999035146A1
WO1999035146A1 PCT/EP1999/000048 EP9900048W WO9935146A1 WO 1999035146 A1 WO1999035146 A1 WO 1999035146A1 EP 9900048 W EP9900048 W EP 9900048W WO 9935146 A1 WO9935146 A1 WO 9935146A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
phenyl
methanesulphonyl
amine
amino
Prior art date
Application number
PCT/EP1999/000048
Other languages
French (fr)
Inventor
Malcolm Clive Carter
George Stuart Cockerill
Stephen Barry Guntrip
Karen Elizabeth Lackey
Kathryn Jane Smith
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10825153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999035146(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU22783/99A priority Critical patent/AU749549C/en
Priority to UA2000074012A priority patent/UA66827C2/en
Priority to IL13704199A priority patent/IL137041A0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to HU0100941A priority patent/HU227593B1/en
Priority to US09/582,746 priority patent/US6727256B1/en
Priority to JP2000527545A priority patent/JP3390741B2/en
Priority to CA002317589A priority patent/CA2317589C/en
Priority to DK04076762T priority patent/DK1454907T3/en
Priority to MEP-2000-448A priority patent/ME00757B/en
Priority to DE69918528T priority patent/DE69918528T2/en
Priority to DK99902522T priority patent/DK1047694T3/en
Priority to DE122008000048C priority patent/DE122008000048I1/en
Priority to KR1020007007635A priority patent/KR100569776B1/en
Priority to BRPI9906904-0A priority patent/BR9906904B1/en
Priority to SK1050-2000A priority patent/SK285405B6/en
Priority to NZ505456A priority patent/NZ505456A/en
Priority to EA200000637A priority patent/EA002455B1/en
Priority to SI9930663T priority patent/SI1047694T1/en
Priority to AT99902522T priority patent/ATE270670T1/en
Priority to EEP200000411A priority patent/EE04616B1/en
Priority to EP99902522A priority patent/EP1047694B1/en
Priority to APAP/P/2000/001861A priority patent/AP1446A/en
Publication of WO1999035146A1 publication Critical patent/WO1999035146A1/en
Priority to IL137041A priority patent/IL137041A/en
Priority to IS5549A priority patent/IS2276B/en
Priority to NO20003561A priority patent/NO316176B1/en
Priority to HR20000469A priority patent/HRP20000469B1/en
Priority to HK01102589A priority patent/HK1031883A1/en
Priority to US10/071,358 priority patent/US6713485B2/en
Priority to US11/050,033 priority patent/US7109333B2/en
Priority to US11/532,926 priority patent/US20070015775A1/en
Priority to US11/752,582 priority patent/US20070238875A1/en
Priority to LU91475C priority patent/LU91475I2/en
Priority to NL300360C priority patent/NL300360I2/en
Priority to CY200800015C priority patent/CY2008015I2/en
Priority to FR08C0038C priority patent/FR08C0038I2/en
Priority to NO2008017C priority patent/NO2008017I1/en
Priority to US12/691,784 priority patent/US8513262B2/en
Priority to US13/943,049 priority patent/US8912205B2/en
Priority to US14/536,896 priority patent/US9199973B2/en
Priority to US14/887,434 priority patent/US20160051551A1/en
Priority to US15/226,949 priority patent/US20160339027A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to a series of substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine.
  • the invention relates to quinoline, quinazoline, pyridopyridine and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
  • Protein tyrosine kinases catalyse the phosphorylation of specific tyrosyl residues in various proteins involved in the regulation of cell growth and differentiation (A.F. Wilks, Progress in Growth Factor Research, 1990, 2, 97-111 ; S.A. Courtneidge, Dev. Supp.l, 1993, 57-64; J.A. Cooper, Semin. Cell Biol., 1994, 5(6), 377-387; R.F. Paulson, Semin. Immunol., 1995, 7(4), 267-277; A.C. Chan, Curr. Opin. Immunol., 1996, 8(3), 394-401). Protein tyrosine kinases can be broadly classified as receptor (e.g.
  • non-receptor e.g. c-src, lck, zap70
  • Protein tyrosine kinases such as c-erbB-2, c-src, c-met, EGFr and PDGFr have been implicated in human malignancies. Elevated EGFr activity has, for example, been implicated in non-small cell lung, bladder and head and neck cancers, and increased c-erbB-2 activity in breast, ovarian, gastric and pancreatic cancers. Inhibition of protein tyrosine kinases should therefore provide a treatment for tumours such as those outlined above.
  • rheumatoid arthritis rheumatoid arthritis, autoimmune disease, allergy, asthma and graft rejection.
  • the process of angiogenesis has been associated with a number of disease states (e.g. tumourogenesis, psoriasis, rheumatoid arthritis) and this has been shown to be controlled through the action of a number of receptor tyrosine kinases (L.K. Shawver, DDT, 1997, 2(2), 50-63).
  • the present invention envisages that other disorders mediated by protein tyrosine kinase activity may be treated effectively by inhibition, including preferential inhibition, of the appropriate protein tyrosine kinase activity.
  • protein tyrosine kinase may not always provide optimal treatment of, for example tumours, and could in certain cases even be detrimental to subjects since protein tyrosine kinases provide an essential role in the normal regulation of cell growth.
  • protein tyrosine kinases such as EGFr, c-erbB-2, c-erbB-4, c- met, tie-2, PDGFr, c-src, lck, Zap70, and fyn.
  • protein tyrosine kinases such as EGFr, c-erbB-2, c-erbB-4, c- met, tie-2, PDGFr, c-src, lck, Zap70, and fyn.
  • a further object of the present invention is to provide compounds useful in the treatment of protein tyrosine kinase related diseases which minimise undesirable side-effects in the recipient.
  • the present invention relates to heterocyclic compounds which may be used to treat disorders mediated by protein tyrosine kinases and in particular have anti-cancer properties. More particularly, the compounds of the present invention are potent inhibitors of protein tyrosine kinases such as such as EGFr, c-erbB-2, c-erbB-4, c- met, tie-2, PDGFr, c-src, lck, Zap70, and fyn, thereby allowing clinical management of particular diseased tissues.
  • protein tyrosine kinases such as such as EGFr, c-erbB-2, c-erbB-4, c- met, tie-2, PDGFr, c-src, lck, Zap70, and fyn
  • the present invention envisages, in particular, the treatment of human malignancies, for example breast, non-small cell lung, ovary, stomach, and pancreatic tumours, especially those driven by EGF-R or erbB-2, using the compounds of the present invention.
  • the invention includes compounds which are highly active against the c-erbB-2 protein tyrosine kinase often in preference to the EGF receptor kinase hence allowing treatment of c-erbB-2 driven tumours.
  • the invention also includes compounds which are highly active against both c-erbB-2 and EGF-R receptor kinases hence allowing treatment of a broader range of tumours.
  • the present invention also includes compounds which are active against lck and/or zap70 receptor kinases; these may also be active against c-erbB-2 and/or EGF-R receptor kinases.
  • the compounds may be selective towards lck and/or zap70 in comparison to c-erbB-2 and/or EGF-R.
  • the present invention envisages that disorders mediated by protein tyrosine kinase activity may be treated effectively by inhibition of the appropriate protein tyrosine kinase activity in a relatively selective manner, thereby minimising potential side effects.
  • X is N or CH
  • Y is CR 1 and V is N; or Y is N and V is CR 1 ; or Y is CR 1 and V is CR 2 ; or Y is CR 2 and V is CR 1 ;
  • R 1 represents a group CH 3 SO 2 CH 2 CH 2 NHCH 2 -Ar-, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C ⁇ alkyl or C ⁇ alkoxy groups;
  • R 2 is selected from the group comprising hydrogen, halo, hydroxy, C alkyl, C ⁇ alkoxy, C ⁇ alkylamino and di[C lJ ⁇ alkyljamino;
  • U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1 H-indazolyl, 2,3-dihydro-1 H-indazolyl, 1 H-benzimidazolyl, 2,3-dihydro- 1 H-benzimidazolyl or 1 H-benzotriazolyl group, substituted by an R 3 group and optionally substituted by at least one independently selected R 4 group;
  • R 3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl;
  • R 3 represents trihalomethylbenzyl or trihalomethylbenzyloxy
  • R 3 represents a group of formula
  • each R 5 is independently selected from halogen, C, ⁇ alkyl and C 1J( alkoxy; and n is 0 to 3;
  • each R 4 is independently hydroxy, halogen, C ⁇ alkyl, C 2J , alkenyl, C 2 ⁇ . alkynyl, C ⁇ alkoxy, amino, C 1J ⁇ alkylamino, di[C ⁇ alkyljamino, C alkylthio, C ⁇ alkylsulphinyl, C M alkylsulphonyl, C ⁇ alkylcarbonyl, carboxy, carbamoyl, C ⁇ alkoxycarbonyl, C ⁇ alkanoylamino, N-(C 1J , alkyl)carbamoyl, N,N-di(C 1J , alkyl)carbamoyl, cyano, nitro and trifluoromethyl; with the proviso that the following compounds are excluded:
  • the group R 1 may be at the 6- or 7-position; the compounds in which R 1 is in the 7-position are of particular interest in the context of lck and/or zap70 activity. It will be seen that for compounds containing the basic ring system (2) the group R 1 may be at the 6- or 7-position; the compounds in which R 1 is in the 6-position are of particular interest in the context of c-erbB-2 activity whereas the compounds in which R 1 is in the 7-position are of particular interest in the context of lck and/or zap70 activity.
  • Ring systems (1), (2), (5) and (6) are preferred; ring systems (2) and (6) are more preferred.
  • Ring system (1) is also more preferred.
  • Alkyl groups containing three or more carbon atoms may be straight, branched or cyclised; preferably they are straight or branched. References to a specific alkyl group such as "butyl” is intended to refer to the straight chain (n-) isomer only. References to other generic terms such as alkoxy, alkylamino etc. are to be interpreted analogously.
  • R 4 and R 5 are as follows: halo is, for example, fluoro, chloro, bromo or iodo; preferably it is fluoro, chloro or bromo, more preferably fluoro or chloro;
  • C ⁇ alkyl is, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl; preferably it is methyl, ethyl, propyl, isopropyl or butyl, more preferably methyl;
  • C 2 . 4 alkenyl is, for example, ethenyl, prop-1-enyl or prop-2-enyl; preferably it is ethenyl;
  • C 2 _ 4 alkynyl is, for example, ethynyl, prop-1-ynyl or prop-2-ynyl; preferably it is ethynyl;
  • alkoxy is, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy; preferably it is methoxy, ethoxy, propoxy, isopropoxy or butoxy; more preferably it is methoxy;
  • C ⁇ alkylamino is, for example, methylamino, ethylamino or propylamino; preferably it is methylamino; di[C 1w , alkyljamino is, for example, dimethylamino, diethylamino, N-methyl-N- ethylamino or dipropylamino; preferably it is dimethylamino; C ⁇ alkylthio is, for example, methylthio, ethylthio, propylthio or isopropylthio, preferably methylthio;
  • C 1J ⁇ alkylsulphinyl is, for example, methylsulphinyl, ethylsulphinyl, propylsulphinyl or isopropylsulphinyl, preferably methylsulphinyl;
  • C 1J ⁇ alkylsulphonyl is, for example, methanesulphonyl, ethylsulphonyl, propylsulphonyl or isopropylsulphonyl, preferably methanesulphonyl;
  • C alkylcarbonyl is, for example methylcarbonyl, ethylcarbonyl or propylcarbonyl;
  • C ⁇ alkoxycarbonyl is, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl or tert-butoxycarbonyl;
  • C ⁇ alkanoylamino (where the number of carbon atoms includes the CO functionality) is, for example, formamido, acetamido, propionamido or butyramido;
  • alkyl)carbamoyl is, for example, N-methylcarbamoyl or N-ethylcarbamoyl;
  • N,N-di(C M alkyl)carbamoyl is, for example, N,N-dimethylcarbamoyl, N-methyl-N- ethylcarbamoyl or N,N-diethylcarbamoyl.
  • X is N
  • Y is CR 1
  • V is CR 2 (ring system (2) above).
  • X is N
  • Y is CR 2
  • V is CR 1 (ring system (2) above).
  • X is N
  • Y is CR 1
  • V is N (ring system (6) above).
  • R 2 represents hydrogen or C ⁇ alkoxy.
  • R 2 represents hydrogen or methoxy.
  • R 2 represents halo; more preferred R 2 is fluoro.
  • the group Ar is substituted by one halo, C ⁇ alkyl or C ⁇ alkoxy group.
  • the group Ar is substituted by a C ⁇ alkyl group. In a further more preferred embodiment the group Ar does not carry any optional substituents.
  • Ar represents furan, phenyl or thiazole, each of which may optionally be substituted as indicated above.
  • Ar represents furan or thiazole, each of which may optionally be substituted as indicated above.
  • Ar represents unsubstituted furan or thiazole.
  • the side chain CH 3 SO 2 CH 2 CH 2 NHCH 2 may be linked to any suitable position of the group Ar.
  • the group R 1 may be linked to the carbon atom carrying it from any suitable position of the group Ar.
  • CH 3 SO 2 CH 2 CH 2 NHCH 2 is in the 3-position of the furan ring and the link to the carbon atom carrying the group R 1 is from the 2-position of the furan ring.
  • the R 3 and R 4 groups may be bound to the ring system U by either a carbon atom or a heteroatom of the ring system.
  • the ring system itself may be bound to the bridging NH group by a carbon atom or a heteroatom but is preferably bound by a carbon atom.
  • the R 3 and R 4 groups may be bound to either ring when U represents a bicyclic ring system, but these groups are preferably bound to the ring which is not bound to the bridging NH group in such a case.
  • U represents a phenyl, indolyl, or 1 H-indazolyl group substituted by an R 3 group and optionally substituted by at least one independently selected R 4 group.
  • U represents a phenyl or 1 H-indazolyl group substituted by an R 3 group and optionally substituted by at least one independently selected R 4 group.
  • R 3 represents benzyl, pyridylmethyl, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl.
  • R 3 represents trihalomethylbenzyloxy.
  • R 3 represents a group of formula
  • Hal is Br or Cl, particularly Cl, more especially wherein the Hal substituent is in the position marked with a star in the ring as shown.
  • R 3 represents benzyloxy, fluorobenzyloxy (especially 3-fluorobenzyloxy), benzyl, phenoxy and benzenesulphonyl. In a further more preferred embodiment R 3 represents bromobenzyloxy (especially 3-bromobenzyloxy) and trifluoromethylbenzyloxy.
  • the ring U is not substituted by an R 4 group; in an especially preferred embodiment U is phenyl or indazolyl unsubstituted by an R 4 group.
  • the ring U is substituted by an R 4 group selected from halo or C M alkoxy; especially chloro, fluoro or methoxy.
  • the ring U is substituted by an R 4 group wherein R 4 represents halo, especially 3-fluoro.
  • U together with R 4 represents methoxyphenyl, fluorophenyl, trifluoromethylphenyl or chlorophenyl.
  • U together with R 4 represents methoxyphenyl or fluorophenyl.
  • the group U together with the substituent(s) R 3 and R 4 represents benzyloxyphenyl, (fluorobenzyloxy)phenyl, (benzenesulphonyl)phenyl, benzylindazolyl or phenoxyphenyl.
  • the group U together with the substituent(s) R 3 and R 4 represents benzyloxyphenyl, (3-fluorobenzyloxy)phenyl, (benzenesulphonyl)phenyl or benzylindazolyl.
  • group U together with the substituent(s) R 3 and R 4 represents (3-bromobenzyloxy)phenyl, (3- trifiuoromethylbenzyloxy)phenyl, or (3-fluorobenzyloxy)-3-methoxyphenyl.
  • the group U together with the substituent(s) R 3 and R 4 represents 3-fluorobenzyloxy-3-chlorophenyl, benzyloxy-3- chlorophenyl, benzyloxy-3-trifluoromethylphenyl, (benzyloxy)-3-fluorophenyl, (3- fluorobenzyloxy)- 3-fluorophenyl or (3-fluorobenzyl)indazolyl.
  • the group U together with the substituent(s) R 3 and R 4 represents benzyloxyphenyl or (3-fluorobenzyloxy)phenyl.
  • a compound of formula (I) or a salt or solvate thereof wherein X is N; V is CR 2 , wherein R 2 is hydrogen, halo (especially fluoro) or C ⁇ alkoxy (especially methoxy); Y is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted phenyl, furan or thiazole; U is phenyl or indazole; R 3 is benzyl, fluorobenzyl, benzyloxy, fluorobenzyloxy, bromobenzyloxy, trifluoromethylbenzyloxy, phenoxy or benzenesulphonyl; and R 4 is not present or is halo (especially chloro or fluoro), or methoxy.
  • a compound of formula (I) or a salt or solvate thereof wherein X is N; V is CR 2 , wherein R 2 is hydrogen, halo (especially fluoro) or C ⁇ alkoxy (especially methoxy); Y is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted furan or thiazole; U is phenyl; R 3 is benzyloxy, fluorobenzyloxy or benzenesulphonyl; and R 4 is not present or is halo (especially chloro or fluoro), or methoxy.
  • a compound of formula (I) or a salt or solvate thereof wherein X is N; V is CR 2 , wherein R 2 is hydrogen, halo (especially fluoro) or C 1J( alkoxy (especially methoxy); Y is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted furan or thiazole; U is indazole; R 3 is benzyl or fluorobenzyl; and R 4 is not present.
  • a compound of formula (I) or a salt or solvate thereof wherein X is N; Y is CR 2 , wherein R 2 is hydrogen, halo (especially fluoro) or C alkoxy (especially methoxy); V is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted phenyl, furan or thiazole; U is phenyl or indazole; R 3 is benzyl, fluorobenzyl, benzyloxy, fluorobenzyloxy, bromobenzyloxy, trifluoromethylbenzyloxy, phenoxy or benzenesulphonyl; and R 4 is not present or is halo (especially chloro or fluoro), or methoxy.
  • a compound of formula (I) or a salt or solvate thereof wherein X is N; Y is CR 2 , wherein R 2 is hydrogen, halo (especially fluoro) or C ⁇ alkoxy (especially methoxy); V is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted furan or thiazole; U is phenyl; R 3 is benzyloxy, fluorobenzyloxy or benzenesulphonyl; and R 4 is not present or is halo (especially chloro or fluoro), or methoxy.
  • a compound of formula (I) or a salt or solvate thereof wherein X is N; Y is CR 2 , wherein R 2 is hydrogen, halo (especially fluoro) or C ⁇ alkoxy (especially methoxy); V is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted furan or thiazole; U is indazole; R 3 is benzyl or fluorobenzyl; and R 4 is not present.
  • a compound of formula(l) or a salt or solvate thereof wherein X is N, Y is CR 2 , wherein R 2 is hydrogen, halo (especially fluoro) or C ⁇ alkoxy (especially methoxy); V is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted furan or thiazole; U is phenyl; R 3 is phenoxy; and R 4 is not present.
  • a compound of formula (I) or a salt or solvate thereof wherein X is N; V is N; Y is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted phenyl, furan or thiazole; U is phenyl or indazole; R 3 is benzyl, fluorobenzyl, benzyloxy, fluorobenzyloxy, bromobenzyloxy, trifluoromethylbenzyloxy, phenoxy or benzenesulphonyl; and R 4 is not present or is halo (especially chloro or fluoro), or methoxy.
  • a compound of formula (I) or a salt or solvate thereof wherein X is N; V is N, Y is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted furan or thiazole; U is phenyl; R 3 is benzyloxy, fluorobenzyloxy or benzenesulphonyl; and R 4 is not present or is halo (especially chloro or fluoro), or methoxy.
  • a compound of formula (I) or a salt or solvate thereof wherein X is N; V is N, Y is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted furan or thiazole; U is indazole; R 3 is benzyl or fluorobenzyl; and R 4 is not present.
  • a compound of formula (I) or a salt or solvate thereof wherein X is CH; Y is CR 2 , wherein R 2 is hydrogen, halo (especially fluoro) or C 1J ⁇ alkoxy (especially methoxy); V is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted phenyl, furan or thiazole; U is phenyl or indazole; R 3 is benzyl, fluorobenzyl, benzyloxy, fluorobenzyloxy, bromobenzyloxy, trifluoromethylbenzyloxy, phenoxy or benzenesulphonyl; and R 4 is not present or is halo (especially chloro or fluoro), or methoxy.
  • a compound of formula (I) or a salt or solvate thereof wherein X is CH; Y is CR 2 , wherein R 2 is hydrogen, halo (especially fluoro) or C M alkoxy (especially methoxy); V is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted furan or thiazole; U is phenyl; R 3 is benzyloxy, fluorobenzyloxy, phenoxy or benzenesulphonyl; and R 4 is not present or is halo (especially chloro or fluoro), or methoxy.
  • a compound of formula (I) or a salt or solvate thereof wherein X is CH; Y is CR 2 , wherein R 2 is hydrogen, halo (especially fluoro) or C 1J( alkoxy (especially methoxy); V is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted furan or thiazole; U is indazole; R 3 is benzyl or fluorobenzyl; and R 4 is not present.
  • a compound of formula(l) or a salt or solvate thereof wherein X is CH, Y is CR 2 , wherein R 2 is hydrogen, halo (especially fluoro) or C ⁇ alkoxy (especially methoxy); V is CR 1 wherein R 1 is as defined above in which Ar is unsubstituted furan or thiazole; U is phenyl; R 3 is phenoxy; and R 4 is not present.
  • Preferred compounds of the present invention include:
  • Other preferred compounds of the present invention include: (4-Phenoxyphenyl)-(7- (2-(2-methanesulphonyl)ethylaminomethyl)thiazol-4-yl)- quinolin-4-yl)amine; (4-Phenoxyphenyl)-(7- (4-(2-methanesulphonyl)ethylaminomethyl)thiazol-5-yl)- quinolin-4-yl)amine;
  • Particularly preferred compounds of the present invention include:
  • Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism). The individual stereoisomers (enantiomers and diastereoisomers) and mixtures of these are included within the scope of the present invention. Likewise, it is understood that compounds of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention.
  • Salts of the compounds of the present invention may comprise acid addition salts derived from a nitrogen in the compound of formula (I).
  • the therapeutic activity resides in the moiety derived from the compound of the invention as defined herein and the identity of the other component is of less importance although for therapeutic and prophylactic purposes it is, preferably, pharmaceutically acceptable to the patient.
  • Examples of pharmaceutically acceptable acid addition salts include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids, and organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic and methanesulphonic and arylsulphonic, for example p-toluenesulphonic, acids.
  • mineral acids such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids
  • organic acids such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic and methanesulphonic and arylsulphonic, for example p-toluenesulphonic, acids.
  • the compound of formula (II) as defined above is reacted with the appropriate reagents to substitute the group R 1 by replacement of the leaving group L' and then the product thereby obtained (of formula (V) below) is reacted with the compound of formula (III) as defined above, followed, if desired, by conversion of the compound of formula (I) thereby obtained into another compound of formula (I).
  • a chloro leaving group can be incorporated by reaction of a corresponding 3,4- dihydropyrimidone with carbon tetrachloride/triphenylphosphine in an appropriate solvent.
  • the group R 1 may, therefore, be substituted onto the basic ring system by replacement of a suitable leaving group. This may, for example, be carried out by reaction of the corresponding aryl or heteroaryl stannane derivative with the corresponding compound of formula (IV) carrying the leaving group L' in the appropriate position on the ring.
  • Y" is CT and V" is N; or Y" is N and V" is CT; orY" is CT and V" is CR 2 ; or Y" is CR 2 and V” is CT; wherein R 2 is as defined above and T is an appropriately functionalised group; and (b) subsequently converting the group T into the group R 1 by means of appropriate reagent(s); and, if desired, (c) subsequently converting the compound of formula (I) thereby obtained into another compound of formula (I) by means of appropriate reagents.
  • the group T would represent a group Ar as defined above carrying a formyl group (CHO).
  • T represents a group Ar carrying a formyl group
  • the compound (of formula (Villa)) may be suitably prepared from the corresponding dioxolanyl substituted compound (of formula (Vlllb)), for example by acid hydrolysis.
  • the dioxolanyl substituted compound may be prepared by reaction of a compound of formula (IV) with an appropriate reagent to substitute the relevant leaving group with the substituent carrying the dioxolanyl ring.
  • This reagent could, for example, be an appropriate heteroaryl stannane derivative.
  • a suitable process may comprise reaction of a compound of formula (Villa) in which T is a group Ar carrying a formyl substituent (i.e. a -CHO group) with a compound of formula CH 3 SO 2 CH 2 CH 2 NH 2 .
  • the reaction preferably involves a reductive amination by means of an appropriate reducing agent, for example sodium triacetoxyborohydride.
  • Another suitable process may comprise oxidation of a compound of formula (VI lie) in which T is a group Ar carrying a substituent of formula
  • Suitable methods for the oxidation to the desired compound of formula (I) will be well known to the person skilled in the art but include, for example, reaction with an organic peroxide, such as peracetic acid or metachlorobenzoic acid, or reaction with an inorganic oxidising agent, such as OXONE ® .
  • the compound of formula (Vlllc) in which T is a group Ar carrying a substituent of formula CH 3 SCH 2 CH 2 NHCH 2 or CH 3 SOCH 2 CH 2 NHCH 2 may be prepared by an analogous reaction to that described above, namely reaction of a compound of formula (Villa) in which T is a group Ar carrying a formyl substituent (i.e. a -CHO group) with a compound of formula CH 3 SCH 2 CH 2 NH 2 or CH 3 SOCH 2 CH 2 NH 2 respectively.
  • T could represent a haloketone group as shown in the compound of formula (IX) in scheme 1 below which, when coupled with an appropriate N- protected thioamide [compound of formula (XI) in scheme 2], would result in the formation of an N-protected amino-substituted thiazole system of formula (X).
  • Scheme 1 outlines, for example, the synthesis of derivatives carrying a substituted thiazole ring as an R 1 substituent:
  • halo is as previously defined (preferably iodo), and P' in the compound of formula (XI) is a suitable protecting group, such as trifluorocarbonyl.
  • the group R 2 will be present as a substituent in the basic ring system prior to the introduction of the group R 1 or the group NHU.
  • R 2 is other than hydrogen it may in certain circumstances be necessary to protect the group prior to performing the reaction steps to introduce the R 1 and NHU substituents.
  • suitable protecting groups to ensure non-interference with the subsequent reaction steps include the 2- methoxyethoxymethyl ether (MEM) group or a bulky silyl protecting group such as tert-butyldiphenylsilyl (TBDPS).
  • Suitable leaving groups for L and L' will be well known to those skilled in the art and include, for example, halo such as fluoro, chloro, bromo and iodo; sulphonyloxy groups such as methanesulphonyloxy and toluene-p-sulphonyloxy; alkoxy groups; and triflate.
  • the coupling reaction referred to above with the compound of formula (III) is conveniently carried out in the presence of a suitable inert solvent, for example a C ⁇ _4 alkanol, such as isopropanol, a halogenated hydrocarbon, an ether, an aromatic hydrocarbon or a dipolar aprotic solvent such as acetone, acetonitrile or DMSO at a non-extreme temperature, for example from 0 to 150°C, suitably 10 to 120°C, preferably 50 to 100°C.
  • a suitable inert solvent for example a C ⁇ _4 alkanol, such as isopropanol, a halogenated hydrocarbon, an ether, an aromatic hydrocarbon or a dipolar aprotic solvent such as acetone, acetonitrile or DMSO
  • a non-extreme temperature for example from 0 to 150°C, suitably 10 to 120°C, preferably 50 to 100°C.
  • the reaction is carried out in the presence of a base.
  • suitable bases include an organic amine such as triethylamine, or an alkaline earth metal carbonate, hydride or hydroxide, such as sodium or potassium carbonate, hydride or hydroxide.
  • the compound of formula (I) may be obtained from this process in the form of a salt with the acid HL, wherein L is as hereinbefore defined, or as the free base by treating the salt with a base as hereinbefore defined.
  • the compound of formula (I) prepared may be converted to another compound of formula (I) by chemical transformation of the appropriate substituent or substituents using appropriate chemical methods (see for example, J.March “Advanced Organic Chemistry", Edition III, Wiley Interscience, 1985).
  • a compound containing an alkylthio group may be oxidised to the corresponding sulphinyl or sulphonyl compound by use of an organic peroxide (e.g. benzoyl peroxide) or suitable inorganic oxidant (eg OXONE ®).
  • an organic peroxide e.g. benzoyl peroxide
  • suitable inorganic oxidant e.g OXONE ®
  • a compound containing a nitro substituent may be reduced to the corresponding amino-compound, e.g. by use of hydrogen and an appropriate catalyst (if there are no other susceptible groups), by use of Raney Nickel and hydrazine hydrate or by use of iron/acetic acid.
  • Amino substituents may be acylated by use of an acid chloride or an anhydride under appropriate conditions. Equally an amide group may be cleaved to the amino compound by treatment with, for example, dilute aqueous base.
  • amino substituent may also be converted to a dimethylamino substituent by reaction with formic acid and sodium cyanoborohydride. Similarly, reaction of a primary or secondary amino group with another suitable aldehyde under reducing conditions will lead to the corresponding substituted amine.
  • a further aspect of the present invention is intermediate compounds of formulae (Villa) and (VI I lb) defined above, with the exception of the following compounds:
  • Another further aspect of the present invention is intermediate compounds of formulae (X), (XI), (XII), (XIII), (XIV), (XV) and (XVI) as defined above.
  • the compounds of formula (I) and salts thereof have anticancer activity as demonstrated hereinafter by their inhibition of the protein tyrosine kinase c-erbB-2, c-erbB-4 and/or EGF-R enzymes and their effect on selected cell lines whose growth is dependent on c-erbB-2 or EGF-r tyrosine kinase activity.
  • Certain compounds of formula (I) are also demonstrated hereinafter to inhibit lck and/or zap70 protein tyrosine kinase enzymes and are expected to have activity in disease conditions in which T cells are hyperactive.
  • the present invention thus also provides compounds of formula (I) and pharmaceutically acceptable salts or solvates thereof for use in medical therapy, and particularly in the treatment of disorders mediated by aberrant protein tyrosine kinase activity such as human malignancies and the other disorders mentioned above.
  • the compounds of the present invention are especially useful for the treatment of disorders caused by aberrant c-erbB-2 and/or EGF-r and/or lck activity such as breast, ovarian, gastric, pancreatic, non-small cell lung, bladder, head and neck cancers, psoriasis and rheumatoid arthritis.
  • a further aspect of the invention provides a method of treatment of a human or animal subject suffering from a disorder mediated by aberrant protein tyrosine kinase activity, including susceptible malignancies, which comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • a further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in therapy.
  • a further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of cancer and malignant tumours.
  • a further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of psoriasis.
  • a further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of rheumatoid arthritis.
  • the compounds, salts or solvates of the present invention Whilst it is possible for the compounds, salts or solvates of the present invention to be administered as the new chemical, it is preferred to present them in the form of a pharmaceutical formulation.
  • a pharmaceutical formulation comprising at least one compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents or excipients.
  • compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose.
  • a unit may contain for example 0.5mg to 1g, preferably 70mg to 700mg, more preferably 5mg to 100mg of a compound of the formula (I) depending on the condition being treated, the route of administration and the age, weight and condition of the patient.
  • compositions may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route.
  • Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).
  • compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in- water liquid emulsions or water-in-oil liquid emulsions.
  • compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
  • the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).
  • compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • the formulations are preferably applied as a topical ointment or cream.
  • the active ingredient may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
  • compositions adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
  • compositions adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.
  • compositions adapted for rectal administration may be presented as suppositories or as enemas.
  • compositions adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.
  • compositions adapted for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulizers or insufflators.
  • Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.
  • formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
  • the animal requiring treatment with a compound, salt or solvate of the present invention is usually a mammal, such as a human being.
  • a therapeutically effective amount of a compound, salt or solvate of the present invention will depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian
  • an effective amount of a compound of the present invention for the treatment of neoplastic growth, for example colon or breast carcinoma will generally be in the range of 0.1 to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of 1 to 10 mg/kg body weight per day.
  • the actual amount per day would usually be from 70 to 700 mg and this amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same.
  • An effective amount of a salt or solvate of the present invention may be determined as a proportion of the effective amount of the compound ger se. It is envisaged that similar dosages would be appropriate for treatment of the other conditions referred to above.
  • Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one other pharmaceutically active agent.
  • the compound(s) of formula (I) and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately this may occur simultaneously or sequentially in any order.
  • the amounts of the compound(s) of formula (I) and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
  • Analytical thin layer chromatography was used to verify the purity of some intermediates which could not be isolated or which were too unstable for full characterisation, and to follow the progess of reactions. Unless otherwise stated, this was done using silica gel (Merck Silica Gel 60 F254). Unless otherwise stated, column chromatography for the purification of some compounds used Merck Silica gel 60 (Art. 1.09385, 230-400 mesh), and the stated solvent system under pressure.
  • Petrol refers to petroleum ether, either the fraction boiling at 40-60°C, or at 60-80°C.
  • Ether refers to diethylether.
  • DMSO dimethylsulphoxide
  • THF refers to tetrahydrofuran
  • HPLC refers to high pressure liquid chromatography.
  • NMM refers to ⁇ /-methylmorpholine
  • the optionally substituted bicyclic species and the specified amine were mixed in an appropriate solvent (typically acetonitrile unless otherwise specified, although ethanol, 2-propanol or DMSO may also be used), and heated to reflux. When the reaction was complete (as judged by tic), the reaction mixture was allowed to cool. The resulting suspension was diluted, e.g. with acetone, and the solid collected by filtration, washing e.g. with excess acetone, and dried at 60°C in vacuo, giving the product as the hydrochloride salt. If the free base was required (e.g. for further reaction), this was obtained by treatment with a base e.g. triethylamine; purification by chromatography was then performed if required.
  • an appropriate solvent typically acetonitrile unless otherwise specified, although ethanol, 2-propanol or DMSO may also be used
  • a suitable solvent e.g. dichloromethane
  • a sulfide such as the product of general procedure E1
  • a suitable solvent typically methanol/water (2:1), although dichloromethane can be used
  • an oxidizing agent typically oxone, although MCPBA can be used.
  • the resulting mixture was stirred at room temperature until the reaction was complete.
  • the reaction was concentrated to remove any organic solvents, diluted with water, and extracted with an appropriate solvent (e.g. dichloromethane). The organic layer was dried and concentrated to provide the corresponding cyanosulfone.
  • This material may subsequently be carried forward to the appropriately substituted pyridopyrimidine intermediate according to the procedures as described in WO95/19774, J. Med. Chem., 1996, 39, pp 1823-1835, and J. Chem. Soc, Perkin Trans. 1 , 1996, pp 2221-2226.
  • Specific compounds made by such procedures include 6-chloro-pyrido[3,4-d]pyrimidin-4-one and 4,6-dichloro-pyrido[3,4- djpyrimidine.
  • the relevant nitro-substituted 1 H-indazole was treated with a base such as potassium carbonate or sodium hydroxide in a suitable solvent, such as acetone or acetonitrile.
  • a base such as potassium carbonate or sodium hydroxide
  • a suitable solvent such as acetone or acetonitrile.
  • the appropriate aryl halide or heteroaryl halide was added and the reaction mixture heated or stirred at room temperature overnight. Subsequent concentration in vacuo and chromatography on silica gave the desired 1 -substituted nitro-1 H-indazoles. Hydrogenation was carried out by analogy with the preparation of 5-amino-1 -benzyl-1 H-indole described above.
  • Amines prepared by such methods include:- 5-Amino-1 -benzyl-1 H-indazole; m/z (M+1) + 224
  • 4-Benzyloxyaniline is commercially available as the hydrochloride salt; this is treated with aqueous sodium carbonate solution, and the mixture extracted with ethyl acetate; the organic solution is dried (MgSO 4 ) and concentrated to give the free base as a brown solid, used without further purification.
  • Step 1 Preparation of the precursor nitro-compounds 4-Nitrophenol (or an appropriate substituted analogue, such as 3-chloro-4- nitrophenol) was treated with a base such as potassium carbonate or sodium hydroxide in an appropriate solvent, such as acetone or acetonitrile. The appropriate aryl or heteroaryl halide was added and the reaction mixture heated or stirred at room temperature overnight.
  • a base such as potassium carbonate or sodium hydroxide
  • an appropriate solvent such as acetone or acetonitrile.
  • the appropriate aryl or heteroaryl halide was added and the reaction mixture heated or stirred at room temperature overnight.
  • Purification B removal of insoluble material by filtration, followed by concentration of the reaction mixture in vacuo, and chromatography on silica.
  • the precursor nitro compound was reduced by catalytic hydrogenation at atmospheric pressure using 5% Pt/carbon, in a suitable solvent (eg ethanol, THF, or mixtures thereof to promote solubility).
  • a suitable solvent eg ethanol, THF, or mixtures thereof to promote solubility.
  • the mixture was filtered through HarborliteTM, washing with excess solvent, and the resulting solution concentrated in vacuo to give the desired aniline.
  • the anilines were acidified with HCI (e.g. in a solution in dioxane) to give the corresponding hydrochloride salt.
  • Anilines prepared by such methods include:
  • the reaction mixture was allowed to cool, 1 N HCI (50ml) added and stirred at room temperature for 15 minutes.
  • the reaction was filtered and the residue washed with dioxane (20ml) and 2N HCI (20ml).
  • the combined filtrate and washings were stirred at room temperature for a further hour.
  • the dioxane was removed under vacuum, the reaction diluted with water and the solid which precipitated was collected by filtration, and washed with water, iso- hexane and acetone. This precipitate was converted to the free base by partitioning into a mixture of triethylamine, ethyl acetate and water.
  • the organic phase was washed with water, dried (magnesium sulphate) and the solvent removed under vacuum.
  • 6-lodo-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-quinazolin-4yl)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-3- chlorophenyl)amine and 4-chloro-6-iodo-quinazoline.
  • 6-lodo-(4-(3-fluorobenzyloxy)-3-fluorophenyl)-quinazolin-4yl)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-3- fluorophenyl)amine and 4-chloro-6-iodo-quinazoline.
  • 6-lodo-(4-(3-fluorobenzyloxy)-3-methoxyphenyl)-quinazolin-4yl)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-3- methoxyphenyl)amine and 4-chloro-6-iodo-quinazoline.
  • 6-lodo-(4-(3-bromobenzyloxy)-phenyl)-quinazolin-4-yl)amine Prepared according to Procedure A from (4-(3-bromobenzyloxy)-phenyl)amine and 4-chloro-6-iodo-quinazoline.
  • 1 H NMR (DMSO-d6) 9.84 (s, 1 H); 8.98 (s, 1H); 8.57 (s, 1H); 8.13 (m, 2H); 7.71 (d, 2H); 7.56 (d, 2H); 7.50 (m, 1 H); 7.41 (m, 1 H); 7.08 (d, 2H); 5.17 (s, 2H).
  • 6-lodo-(4-(3-trifluoromethylbenzyloxy)-phenyl)-quinazolin-4-yl)amine Prepared according to Procedure A from (4-(3-trifluoromethylbenzyloxy)-phenyl)amine and 4-chloro-6-iodo-quinazoline.
  • ⁇ NMR (DMSO-d6) 9.2 (bs, 1 H); 8.91 (s, 1H); 8.37 (d, 1 H); 7.89-7.72 (m, 8H); 7.19 (d, 2H); 5.30 (s, 2H).
  • 6-lodo-(4-benzyloxy-3-trifluoromethyl-phenyl)-quinazolin-4-yl)amine The mixture of 4-chloro-6-iodo-quinazoline (366mg, 1.26 mmol) and 4-0-benzyl-3- trifluoroaniline (405mg, 1.26 mmol) in isopropanol (12ml) was heated to reflux for 3.5 hours. Filtered, washed with isopropanol and dried. 535mg yellow solid was afforded, (yield: 76%). ESI-MS m/z 522 (M+H) + .
  • the cooled reaction mixture was extracted with water (100 ml) and ethyl acetate (100 ml). The organic phase was washed with brine (100 ml). The aqueous layers were combined and washed with additional ethyl acetate (100 ml). The organic layers were combined, dried with MgSO 4 , filtered and concentrated to a residue. The residue was chromatographed on silica gel with a methanol-chloroform mixture. Fractions were collected, combined, and concentrated. The resultant solid was suspended in dichloromethane (10 ml) and diethyl ether was added facilitate precipitation. The solid was filtered and dried under vacuum at room temperature to yield a yellowish solid 287 mg (59%).
  • the cooled reaction mixture was extracted with water (100 ml) and ethyl acetate (100 ml). The organic phase was washed with brine (100 ml). The aqueous layers were combined and washed with additional ethyl acetate (100 ml). The organic layers were combined, dried with MgSO 4 , filtered and concentrated to a residue. The residue was chromatographed on silica gel with a methanol-chloroform mixture. Fractions were collected, combined, and concentrated. The resultant solid was suspended in dichloromethane (10 ml) and diethyl ether was added to facilitate precipitation. The solid was filtered and dried under vacuum at room temperature to yield a yellow solid 287 mg (59%).
  • 6-lodo-(4-(3-fluorobenzyloxy)-3-fluorophenyl)-quinazolin-4yl)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-3-fluorophenyl)- amine and 4-chloro-6-iodoquinazoline.
  • 6-lodo-(4-(3-bromobenzyloxy)-phenyl)-quinazolin-4-yl)amine Prepared according to Procedure A from (4-(3-bromobenzyloxy)-phenyl)-amine and 4-chloro-6-iodoquinazoline.
  • 1 H NMR (DMSO-d6) 9.84 (s, 1 H); 8.98 (s, 1H); 8.57 (s, 1H); 8.13 (m, 2H); 7.71 (d, 2H); 7.56 (d, 2H); 7.50 (m, 1H); 7.41 (m, 1 H); 7.08 (d, 2H); 5.17 (s, 2H).
  • 6-lodo-(4-(3-trifluoromethylbenzyloxy)-phenyl)-quinazolin-4-yl)amine Prepared according to Procedure A from (4-(3-trifluoromethylbenzyloxy)-phenyl)- amine and 4-chloro-6-iodoquinazoline.
  • 1 H NMR (DMSO-d6) 9.2 (bs, 1 H); 8.91 (s, 1H); 8.37 (d, 1 H); 7.89-7.72 (m, 8H); 7.19 (d, 2H); 5.30 (s, 2H).
  • the reaction mixture was then filtered through Harborlite ® and the filtrate was concentrated.
  • the product was purified on Bond ElutTM cartridge, eluting sequentially with dichloromethane, chloroform, diethyl ether and ethyl acetate.
  • the ketal (0.385g , 0.824 mmol) was stirred at room temperature in a mixture of THF (10ml) and 1 N HCI (10ml) for 2 hr.
  • the suspension was basified with 2N NaOH (5ml) and the THF was removed.
  • the aqueous suspension was filtered and washed with water to give the product as a yellow solid (0.346g);m/z 424.
  • N- ⁇ 4-[(3-fluorobenzyl)oxy]phenyl ⁇ -6-[5-( ⁇ [2-(methanesulphonyl)ethyl]amino ⁇ methyl)- 2-furyl]-4-quinazolinamine Prepared according to Procedure D from 5-(4- ⁇ 4-(3-fluorobenzyloxy)anilino ⁇ -6- quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl-ethylamine (1 equiv).
  • N- ⁇ 4-[(3-fluorobenzyl)oxy]-3-methoxyphenyl ⁇ -6-[5-( ⁇ [2- (methanesulphonyl)ethyl]amino ⁇ methyl)-2-furyl]-4-quinazolinamine Prepared according to Procedure D from 5-(4- ⁇ 3-methoxy-4-(3- fluorobenzyloxy)anilino ⁇ -6-quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2- methanesulphonyl-ethylamine (1 equiv).
  • N-[4-(benzyloxy)phenyl]-7-methoxy-6-[5-( ⁇ [2- (methanesulphonyl)ethyl]amino ⁇ methyl)-2-furyl]-4-quinazolinamine Prepared in a similar manner to Procedure D from 5-(4-(4-benzyloxy- phenylamino)-7-methoxy-quinazolin-6-yl)-furan-2-carbaldehyde hydrochloride(78 mg, 0.16 mmol), 2-methanesulphonylethylamine(33 mg, 0.27 mmol), acetic acid(15 mg, 0.25 mmol) and triethylamine(18 mg, 0.18 mmol) in 3 ml of 1 ,2- dichloroethane added to sodium triacetoxyborohydride(102 mg, 0.48 mmol) portionwise over a two day period.
  • reaction mixture was stirred four days and then partitioned between 10 ml of 0.5M NaHCO 3 solution and 50 ml of ethyl acetate.
  • the organic solution was dried with Na 2 SO 4 and concentrated in vacuo.
  • the residue was chromatographed on silica gel with methanol/methylene chloride(1 :49 to 2:48). The resulting solid was crystallized from a small volume of ethyl acetate, suspended in ether and filtered to give 43 mg of product as a pale yellow solid.
  • N- ⁇ 4-r(3-fluorobenzyl)oxy]-3-methoxyphenyl ⁇ -6-[2-( ⁇ [2- (methanesulphonyl)ethyl]amino ⁇ methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine Prepared according to Procedure F from 6-iodo-(4-(3-fluorobenzyloxy)-3- methoxypheny)quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N-bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N- (methanesulphonylethyl)-aminomethylthioamide (1 equiv).
  • N- ⁇ 4-[(3-fluorobenzyl)oxy]phenyl ⁇ -6-[2-( ⁇ [2-(methanesulphonyl)ethyl]amino ⁇ methyl)- 1,3-thiazol-4-yl]-4-quinazolinamine Prepared according to Procedure F from 6-iodo-(4-(3-fluorobenzyloxy)- phenyl)- quinazoIin-4-ylamine and (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N- bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv).
  • N-(1 -benzyl-1 H-indazol-5-yl)-7-methoxy-6-[5-( ⁇ [2- (methanesulphonyl)ethyl]amino ⁇ methyl)-2-furyl]-4-quinazolinamine Prepared according to Procedure D from 5-(4- ⁇ 4-(1 -benzyl-1 H-indazol-5-yl)-7- methoxy-6-quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2- methanesulphonyl-ethylamine (1 equiv).
  • N- ⁇ 4-[(3-bromobenzyl)oxy]phenyl ⁇ -6-[5-( ⁇ [2-(methanesulphonyl)ethyl]amino ⁇ methyl)- 2-furyl]-4-quinazolinamine Prepared according to Procedure D from 5-(4- ⁇ 3-bromo-4-benzyloxyanilino ⁇ -6- quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl-ethylamine (1 equiv).
  • 6-[2-( ⁇ [2-(methanesulphonyl)ethyl]amino ⁇ methyl)-1 ,3-thiazol-4-yl]-N-[4- ⁇ benzenesulphonyl)phenyl]-4-quinazolinamine Prepared according to Procedure F from 6-iodo-(4-(benzenesulphonyl)-phenyl)- quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N- bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv).
  • 6-[2-( ⁇ [2-(methanesulphonyl)ethyl]amino ⁇ methyl)-1 ,3-thiazol-4-yl]-N-(4- ⁇ [3- (trifluoromethyl)benzyl]oxy ⁇ phenyl)-4-quinazolinamine Prepared according to Procedure F from 6-iodo-(4-(3-trifluoromethylbenzyloxy)- phenyl)quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N- bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv).
  • N- ⁇ 3-fluoro-4-[(3-fluorobenzyl)oxy]phenyl ⁇ -6-[2-( ⁇ [2- (methanesulphonyl)ethyl]amino ⁇ methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine Prepared according to Procedure F from 6-iodo-4-(1 -benzyl-1 H-indazol-5-yl)- quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N- bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv).
  • N- ⁇ 3-Chloro-4-f(3-fluorobenzyl)oxy]phenyl ⁇ -6-[5-( ⁇ [2- (methanesulphonyl)ethyl]amino ⁇ methyl)-2-furyl]-4-quinazolinamine Prepared according to Procedure D from 5-(4- ⁇ 3-chloro-4-(3-fluorobenzyloxy)- anilino ⁇ -6-quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl- ethylamine (1 equiv).
  • the reaction mixture was quenched with methanol (3 ml) and poured into a separatory funnel containing aqueous saturated sodium hydrogen carbonate (100 ml) and ethyl acetate (100 ml). The mixture was extracted. The organic layer was washed with water. The organic layer was dried over magnesium sulfate, filtered, and concentrated. The residue was treated with ethyl acetate/hexanes and collected by filtration (0.083 g, 61% yield).

Abstract

Substituted heteroaromatic compounds of formula (I), wherein X is N or CH; Y is CR1 and V is N; or Y is N and V is CR1; or Y is CR1 and V is CR2; or Y is CR2 and V is CR1; R1 represents a group CH¿3?SO2CH2CH2NHCH2-Ar-, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C1-4alkyl or C1-4alkoxy groups; R?2¿ is selected from the group comprising hydrogen, halo, hydroxy, C¿1-4?alkyl, C1-4alkoxy, C1-4alkylamino and di[C1-4alkyl]amino; U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by an R?3¿ group and optionally substituted by at least one independently selected R4 group; R3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl, or R3 represents trihalomethylbenzyl or trihalomethylbenzyloxy; or R3 represents a group of formula (a) wherein each R5 is independently selected from halogen, C¿1-4?alkyl, C1-4alkoxy; and n is 0 to 3; each R?4¿ is independently hydroxy, halogen, C¿1-4?alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, amino, C1-4alkylamino, di[C1-4alkyl]amino, C1-4alkylthio, C1-4alkylsulphinyl, C1-4alkylsulphonyl, C1-4alkylcarbonyl, carboxy, carbamoyl, C1-4alkoxycarbonyl, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-di(C1-4alkyl)carbamoyl, cyano, nitro and trifluoromethyl; and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.

Description

BICYCLIC HETEROAROMAΗC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
The present invention relates to a series of substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to quinoline, quinazoline, pyridopyridine and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
Protein tyrosine kinases catalyse the phosphorylation of specific tyrosyl residues in various proteins involved in the regulation of cell growth and differentiation (A.F. Wilks, Progress in Growth Factor Research, 1990, 2, 97-111 ; S.A. Courtneidge, Dev. Supp.l, 1993, 57-64; J.A. Cooper, Semin. Cell Biol., 1994, 5(6), 377-387; R.F. Paulson, Semin. Immunol., 1995, 7(4), 267-277; A.C. Chan, Curr. Opin. Immunol., 1996, 8(3), 394-401). Protein tyrosine kinases can be broadly classified as receptor (e.g. EGFr, c-erbB-2, c-met, tie-2, PDGFr, FGFr) or non-receptor (e.g. c-src, lck, zap70) kinases. Inappropriate or uncontrolled activation of many of these kinase, i.e. aberrant protein tyrosine kinase activity, for example by over-expression or mutation, has been shown to result in uncontrolled cell growth.
Aberrant activity of protein tyrosine kinases, such as c-erbB-2, c-src, c-met, EGFr and PDGFr have been implicated in human malignancies. Elevated EGFr activity has, for example, been implicated in non-small cell lung, bladder and head and neck cancers, and increased c-erbB-2 activity in breast, ovarian, gastric and pancreatic cancers. Inhibition of protein tyrosine kinases should therefore provide a treatment for tumours such as those outlined above.
Aberrant protein tyrosine kinase activity has also been implicated in a variety of other disorders: psoriasis, (Dvir et al, J. Cell. Biol; 1991 , 113, 857-865), fibrosis, atherosclerosis, restenosis, (Buchdunger et al, Proc.Natl.Acad.Sci. USA; 1991 , 92, 2258-2262), auto-immune disease, allergy, asthma, transplantation rejection
(Klausner and Samelson, Cell; 1991 , 64, 875-878), inflammation (Berkois, Blood; 1992, 79(9), 2446-2454), thrombosis (Salari et al, FEBS; 1990, 263(1), 104-108) and nervous system diseases (Ohmichi et al, Biochemistry, 1992, 31_, 4034-4039). Inhibitors of the specific protein tyrosine kinases involved in these diseases eg PDGF-R in restenosis and EGF-R in psoriasis, should lead to novel therapies for such disorders. P56lck and zap 70 are indicated in disease conditions in which T cells are hyperactive e.g. rheumatoid arthritis, autoimmune disease, allergy, asthma and graft rejection. The process of angiogenesis has been associated with a number of disease states (e.g. tumourogenesis, psoriasis, rheumatoid arthritis) and this has been shown to be controlled through the action of a number of receptor tyrosine kinases (L.K. Shawver, DDT, 1997, 2(2), 50-63).
It is therefore a general object of the present invention to provide compounds suitable for the treatment of disorders mediated by protein tyrosine kinase activity, and in particular treatment of the above mentioned disorders.
In addition to the treatment of tumours, the present invention envisages that other disorders mediated by protein tyrosine kinase activity may be treated effectively by inhibition, including preferential inhibition, of the appropriate protein tyrosine kinase activity.
Broad spectrum inhibition of protein tyrosine kinase may not always provide optimal treatment of, for example tumours, and could in certain cases even be detrimental to subjects since protein tyrosine kinases provide an essential role in the normal regulation of cell growth.
It is another object of the present invention to provide compounds which preferentially inhibit protein tyrosine kinases, such as EGFr, c-erbB-2, c-erbB-4, c- met, tie-2, PDGFr, c-src, lck, Zap70, and fyn. There is also perceived to be a benefit in the preferential inhibition involving small groups of protein tyrosine kinases, for example groups including two or more of c-erbB-2, c-erbB-4, EGF-R, lck and zap70.
A further object of the present invention is to provide compounds useful in the treatment of protein tyrosine kinase related diseases which minimise undesirable side-effects in the recipient.
The present invention relates to heterocyclic compounds which may be used to treat disorders mediated by protein tyrosine kinases and in particular have anti-cancer properties. More particularly, the compounds of the present invention are potent inhibitors of protein tyrosine kinases such as such as EGFr, c-erbB-2, c-erbB-4, c- met, tie-2, PDGFr, c-src, lck, Zap70, and fyn, thereby allowing clinical management of particular diseased tissues.
The present invention envisages, in particular, the treatment of human malignancies, for example breast, non-small cell lung, ovary, stomach, and pancreatic tumours, especially those driven by EGF-R or erbB-2, using the compounds of the present invention. For example, the invention includes compounds which are highly active against the c-erbB-2 protein tyrosine kinase often in preference to the EGF receptor kinase hence allowing treatment of c-erbB-2 driven tumours. However, the invention also includes compounds which are highly active against both c-erbB-2 and EGF-R receptor kinases hence allowing treatment of a broader range of tumours.
The present invention also includes compounds which are active against lck and/or zap70 receptor kinases; these may also be active against c-erbB-2 and/or EGF-R receptor kinases. The compounds may be selective towards lck and/or zap70 in comparison to c-erbB-2 and/or EGF-R.
More particularly, the present invention envisages that disorders mediated by protein tyrosine kinase activity may be treated effectively by inhibition of the appropriate protein tyrosine kinase activity in a relatively selective manner, thereby minimising potential side effects.
Accordingly, the present invention provides a compound of formula (I)
Figure imgf000005_0001
or a salt or solvate thereof;
wherein X is N or CH;
Y is CR1 and V is N; or Y is N and V is CR1; or Y is CR1 and V is CR2; or Y is CR2 and V is CR1;
R1 represents a group CH3SO2CH2CH2NHCH2-Ar-, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C^ alkyl or C^ alkoxy groups;
R2 is selected from the group comprising hydrogen, halo, hydroxy, C alkyl, C^ alkoxy, C^ alkylamino and di[ClJ} alkyljamino;
U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1 H-indazolyl, 2,3-dihydro-1 H-indazolyl, 1 H-benzimidazolyl, 2,3-dihydro- 1 H-benzimidazolyl or 1 H-benzotriazolyl group, substituted by an R3 group and optionally substituted by at least one independently selected R4 group;
R3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl;
or R3 represents trihalomethylbenzyl or trihalomethylbenzyloxy;
or R3 represents a group of formula
Figure imgf000006_0001
wherein each R5 is independently selected from halogen, C,^ alkyl and C1J( alkoxy; and n is 0 to 3;
each R4 is independently hydroxy, halogen, C^ alkyl, C2J, alkenyl, C2^. alkynyl, C^ alkoxy, amino, C1J} alkylamino, di[C^ alkyljamino, C alkylthio, C^ alkylsulphinyl, CM alkylsulphonyl, C^ alkylcarbonyl, carboxy, carbamoyl, C^ alkoxycarbonyl, C^ alkanoylamino, N-(C1J, alkyl)carbamoyl, N,N-di(C1J, alkyl)carbamoyl, cyano, nitro and trifluoromethyl; with the proviso that the following compounds are excluded:
(1-Benzyl-1H-indazol-5-yl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2- yl)-pyrido[3,4-d]pyrimidin-4-yl-amine;
(4-Benzyloxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2-yl)- pyrido[3,4-d]pyrimidin-4-yl-amine;
(1-Benzyl-1H-indazol-5-yl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2- yl)-quinazolin-4-yl-amine;
(1-Benzyl-1 H-indazol-5-yl)-(7-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2- yl)-quinazolin-4-yl-amine;
(1-Benzyl-1 H-indazol-5-yl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-1- methyl-pyrrol-2-yl)-quinazolin-4-yl-amine; and their hydrochloride salts.
Solvates of the compounds of formula (I) are also included within the scope of the present invention.
The definitions for X, Y and V thus give rise to a number of possible basic ring systems for the compounds of formula (I). In particular the compounds may contain the following basic ring systems:
Figure imgf000007_0001
it will be seen that for compounds containing the basic ring system (1) the group R1 may be at the 6- or 7-position; the compounds in which R1 is in the 7-position are of particular interest in the context of lck and/or zap70 activity. It will be seen that for compounds containing the basic ring system (2) the group R1 may be at the 6- or 7-position; the compounds in which R1 is in the 6-position are of particular interest in the context of c-erbB-2 activity whereas the compounds in which R1 is in the 7-position are of particular interest in the context of lck and/or zap70 activity.
Ring systems (1), (2), (5) and (6) are preferred; ring systems (2) and (6) are more preferred.
Ring system (1) is also more preferred.
Alkyl groups containing three or more carbon atoms may be straight, branched or cyclised; preferably they are straight or branched. References to a specific alkyl group such as "butyl" is intended to refer to the straight chain (n-) isomer only. References to other generic terms such as alkoxy, alkylamino etc. are to be interpreted analogously.
Suitable values for the various groups listed above within the definitions for R\ R2,
R4 and R5 are as follows: halo is, for example, fluoro, chloro, bromo or iodo; preferably it is fluoro, chloro or bromo, more preferably fluoro or chloro;
C^ alkyl is, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl; preferably it is methyl, ethyl, propyl, isopropyl or butyl, more preferably methyl; C2.4 alkenyl is, for example, ethenyl, prop-1-enyl or prop-2-enyl; preferably it is ethenyl;
C2_4 alkynyl is, for example, ethynyl, prop-1-ynyl or prop-2-ynyl; preferably it is ethynyl;
C1J( alkoxy is, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy; preferably it is methoxy, ethoxy, propoxy, isopropoxy or butoxy; more preferably it is methoxy;
C^ alkylamino is, for example, methylamino, ethylamino or propylamino; preferably it is methylamino; di[C1w, alkyljamino is, for example, dimethylamino, diethylamino, N-methyl-N- ethylamino or dipropylamino; preferably it is dimethylamino; C^ alkylthio is, for example, methylthio, ethylthio, propylthio or isopropylthio, preferably methylthio;
C1J} alkylsulphinyl is, for example, methylsulphinyl, ethylsulphinyl, propylsulphinyl or isopropylsulphinyl, preferably methylsulphinyl; C1J} alkylsulphonyl is, for example, methanesulphonyl, ethylsulphonyl, propylsulphonyl or isopropylsulphonyl, preferably methanesulphonyl;
C alkylcarbonyl is, for example methylcarbonyl, ethylcarbonyl or propylcarbonyl;
C^ alkoxycarbonyl is, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl or tert-butoxycarbonyl; C^ alkanoylamino (where the number of carbon atoms includes the CO functionality) is, for example, formamido, acetamido, propionamido or butyramido;
N-(C1J| alkyl)carbamoyl is, for example, N-methylcarbamoyl or N-ethylcarbamoyl;
N,N-di(CM alkyl)carbamoyl is, for example, N,N-dimethylcarbamoyl, N-methyl-N- ethylcarbamoyl or N,N-diethylcarbamoyl.
In an especially preferred embodiment X is N, Y is CR1 and V is CR2 (ring system (2) above).
In a further especially preferred embodiment X is N, Y is CR2 and V is CR1 (ring system (2) above).
In a further especially preferred embodiment X is N, Y is CR1 and V is N (ring system (6) above).
In a preferred embodiment R2 represents hydrogen or C^ alkoxy.
In a more preferred embodiment R2 represents hydrogen or methoxy.
In a further preferred embodiment R2 represents halo; more preferred R2 is fluoro.
In a preferred embodiment the group Ar is substituted by one halo, C^ alkyl or C^ alkoxy group.
In a more preferred embodiment the group Ar is substituted by a C^ alkyl group. In a further more preferred embodiment the group Ar does not carry any optional substituents.
In a further more preferred embodiment Ar represents furan, phenyl or thiazole, each of which may optionally be substituted as indicated above.
In a further more preferred embodiment Ar represents furan or thiazole, each of which may optionally be substituted as indicated above.
In a most preferred embodiment Ar represents unsubstituted furan or thiazole.
The side chain CH3SO2CH2CH2NHCH2 may be linked to any suitable position of the group Ar. Similarly, the group R1 may be linked to the carbon atom carrying it from any suitable position of the group Ar.
In a preferred embodiment, when Ar represents furan the side chain CHgSOjCHjCHgNHCHj is in the 4-position of the furan ring and the link to the carbon atom carrying the group R1 is from the 2-position of the furan ring.
In another preferred embodiment, when Ar represents furan the side chain
CH3SO2CH2CH2NHCH2 is in the 3-position of the furan ring and the link to the carbon atom carrying the group R1 is from the 2-position of the furan ring.
In a most preferred embodiment, when Ar represents furan the side chain CH3SO2CH2CH2NHCH2 is in the 5-position of the furan ring and the link to the carbon atom carrying the group R1 is from the 2-position of the furan ring.
In a further most preferred embodiment, when Ar represents thiazole the side chain CH3SO2CH2CH2NHCH2 is in the 2-position of the thiazole ring and the link to the carbon atom carrying the group R1 is from the 4-position of the thiazole ring.
The R3 and R4 groups may be bound to the ring system U by either a carbon atom or a heteroatom of the ring system. The ring system itself may be bound to the bridging NH group by a carbon atom or a heteroatom but is preferably bound by a carbon atom. The R3 and R4 groups may be bound to either ring when U represents a bicyclic ring system, but these groups are preferably bound to the ring which is not bound to the bridging NH group in such a case.
In a preferred embodiment U represents a phenyl, indolyl, or 1 H-indazolyl group substituted by an R3 group and optionally substituted by at least one independently selected R4 group.
In a more preferred embodiment U represents a phenyl or 1 H-indazolyl group substituted by an R3 group and optionally substituted by at least one independently selected R4 group.
In a more preferred embodiment, where U represents a phenyl group the group R3 is in the para- position relative to the bond from U to the linking NH group.
In a further more preferred embodiment, where U represents a I H-indazolyl group the group R3 is in the 1-position of the indazolyl group.
In a preferred embodiment R3 represents benzyl, pyridylmethyl, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl.
In a further preferred embodiment R3 represents trihalomethylbenzyloxy.
In a further preferred embodiment R3 represents a group of formula
Figure imgf000011_0001
, wherein Hal is Br or Cl, particularly Cl, more especially wherein the Hal substituent is in the position marked with a star in the ring as shown.
In a more preferred embodiment R3 represents benzyloxy, fluorobenzyloxy (especially 3-fluorobenzyloxy), benzyl, phenoxy and benzenesulphonyl. In a further more preferred embodiment R3 represents bromobenzyloxy (especially 3-bromobenzyloxy) and trifluoromethylbenzyloxy.
In a further preferred embodiment the ring U is not substituted by an R4 group; in an especially preferred embodiment U is phenyl or indazolyl unsubstituted by an R4 group.
In a further preferred embodiment the ring U is substituted by an R4 group selected from halo or CM alkoxy; especially chloro, fluoro or methoxy.
In a more preferred embodiment the ring U is substituted by an R4 group wherein R4 represents halo, especially 3-fluoro.
In an especially preferred embodiment U together with R4 represents methoxyphenyl, fluorophenyl, trifluoromethylphenyl or chlorophenyl.
In a more especially preferred embodiment U together with R4 represents methoxyphenyl or fluorophenyl.
In an especially preferred embodiment the group U together with the substituent(s) R3 and R4 represents benzyloxyphenyl, (fluorobenzyloxy)phenyl, (benzenesulphonyl)phenyl, benzylindazolyl or phenoxyphenyl.
In a more especially preferred embodiment the group U together with the substituent(s) R3 and R4 represents benzyloxyphenyl, (3-fluorobenzyloxy)phenyl, (benzenesulphonyl)phenyl or benzylindazolyl.
In another more especially preferred embodiment the group U together with the substituent(s) R3 and R4 represents (3-bromobenzyloxy)phenyl, (3- trifiuoromethylbenzyloxy)phenyl, or (3-fluorobenzyloxy)-3-methoxyphenyl.
In another more especially preferred embodiment the group U together with the substituent(s) R3 and R4 represents 3-fluorobenzyloxy-3-chlorophenyl, benzyloxy-3- chlorophenyl, benzyloxy-3-trifluoromethylphenyl, (benzyloxy)-3-fluorophenyl, (3- fluorobenzyloxy)- 3-fluorophenyl or (3-fluorobenzyl)indazolyl. In a most especially preferred embodiment the group U together with the substituent(s) R3 and R4 represents benzyloxyphenyl or (3-fluorobenzyloxy)phenyl.
In a preferred embodiment there is provided a compound of formula (I) or a salt or solvate thereof wherein X is N; V is CR2, wherein R2 is hydrogen, halo (especially fluoro) or C^ alkoxy (especially methoxy); Y is CR1 wherein R1 is as defined above in which Ar is unsubstituted phenyl, furan or thiazole; U is phenyl or indazole; R3 is benzyl, fluorobenzyl, benzyloxy, fluorobenzyloxy, bromobenzyloxy, trifluoromethylbenzyloxy, phenoxy or benzenesulphonyl; and R4 is not present or is halo (especially chloro or fluoro), or methoxy.
In a most preferred embodiment there is provided a compound of formula (I) or a salt or solvate thereof wherein X is N; V is CR2, wherein R2 is hydrogen, halo (especially fluoro) or C^ alkoxy (especially methoxy); Y is CR1 wherein R1 is as defined above in which Ar is unsubstituted furan or thiazole; U is phenyl; R3 is benzyloxy, fluorobenzyloxy or benzenesulphonyl; and R4 is not present or is halo (especially chloro or fluoro), or methoxy.
In a most preferred embodiment there is provided a compound of formula (I) or a salt or solvate thereof wherein X is N; V is CR2, wherein R2 is hydrogen, halo (especially fluoro) or C1J( alkoxy (especially methoxy); Y is CR1 wherein R1 is as defined above in which Ar is unsubstituted furan or thiazole; U is indazole; R3 is benzyl or fluorobenzyl; and R4 is not present.
In a further more preferred embodiment there is provided a compound of formula (I) or a salt or solvate thereof wherein X is N; Y is CR2, wherein R2 is hydrogen, halo (especially fluoro) or C alkoxy (especially methoxy); V is CR1 wherein R1 is as defined above in which Ar is unsubstituted phenyl, furan or thiazole; U is phenyl or indazole; R3 is benzyl, fluorobenzyl, benzyloxy, fluorobenzyloxy, bromobenzyloxy, trifluoromethylbenzyloxy, phenoxy or benzenesulphonyl; and R4 is not present or is halo (especially chloro or fluoro), or methoxy.
In a further most preferred embodiment there is provided a compound of formula (I) or a salt or solvate thereof wherein X is N; Y is CR2, wherein R2 is hydrogen, halo (especially fluoro) or C^ alkoxy (especially methoxy); V is CR1 wherein R1 is as defined above in which Ar is unsubstituted furan or thiazole; U is phenyl; R3 is benzyloxy, fluorobenzyloxy or benzenesulphonyl; and R4 is not present or is halo (especially chloro or fluoro), or methoxy.
In a further most preferred embodiment there is provided a compound of formula (I) or a salt or solvate thereof wherein X is N; Y is CR2, wherein R2 is hydrogen, halo (especially fluoro) or C^ alkoxy (especially methoxy); V is CR1 wherein R1 is as defined above in which Ar is unsubstituted furan or thiazole; U is indazole; R3 is benzyl or fluorobenzyl; and R4 is not present.
In a most especially preferred embodiment there is provided a compound of formula(l) or a salt or solvate thereof wherein X is N, Y is CR2, wherein R2 is hydrogen, halo (especially fluoro) or C^ alkoxy (especially methoxy); V is CR1 wherein R1 is as defined above in which Ar is unsubstituted furan or thiazole; U is phenyl; R3 is phenoxy; and R4 is not present.
In another more preferred embodiment there is provided a compound of formula (I) or a salt or solvate thereof wherein X is N; V is N; Y is CR1 wherein R1 is as defined above in which Ar is unsubstituted phenyl, furan or thiazole; U is phenyl or indazole; R3 is benzyl, fluorobenzyl, benzyloxy, fluorobenzyloxy, bromobenzyloxy, trifluoromethylbenzyloxy, phenoxy or benzenesulphonyl; and R4 is not present or is halo (especially chloro or fluoro), or methoxy.
In another most preferred embodiment there is provided a compound of formula (I) or a salt or solvate thereof wherein X is N; V is N, Y is CR1 wherein R1 is as defined above in which Ar is unsubstituted furan or thiazole; U is phenyl; R3 is benzyloxy, fluorobenzyloxy or benzenesulphonyl; and R4 is not present or is halo (especially chloro or fluoro), or methoxy.
In another most preferred embodiment there is provided a compound of formula (I) or a salt or solvate thereof wherein X is N; V is N, Y is CR1 wherein R1 is as defined above in which Ar is unsubstituted furan or thiazole; U is indazole; R3 is benzyl or fluorobenzyl; and R4 is not present. In yet another preferred embodiment there is provided a compound of formula (I) or a salt or solvate thereof wherein X is CH; Y is CR2, wherein R2 is hydrogen, halo (especially fluoro) or C1J} alkoxy (especially methoxy); V is CR1 wherein R1 is as defined above in which Ar is unsubstituted phenyl, furan or thiazole; U is phenyl or indazole; R3 is benzyl, fluorobenzyl, benzyloxy, fluorobenzyloxy, bromobenzyloxy, trifluoromethylbenzyloxy, phenoxy or benzenesulphonyl; and R4 is not present or is halo (especially chloro or fluoro), or methoxy.
In yet another most preferred embodiment there is provided a compound of formula (I) or a salt or solvate thereof wherein X is CH; Y is CR2, wherein R2 is hydrogen, halo (especially fluoro) or CM alkoxy (especially methoxy); V is CR1 wherein R1 is as defined above in which Ar is unsubstituted furan or thiazole; U is phenyl; R3 is benzyloxy, fluorobenzyloxy, phenoxy or benzenesulphonyl; and R4 is not present or is halo (especially chloro or fluoro), or methoxy.
In yet another most preferred embodiment there is provided a compound of formula (I) or a salt or solvate thereof wherein X is CH; Y is CR2, wherein R2 is hydrogen, halo (especially fluoro) or C1J( alkoxy (especially methoxy); V is CR1 wherein R1 is as defined above in which Ar is unsubstituted furan or thiazole; U is indazole; R3 is benzyl or fluorobenzyl; and R4 is not present.
In a most especially preferred embodiment there is provided a compound of formula(l) or a salt or solvate thereof wherein X is CH, Y is CR2, wherein R2 is hydrogen, halo (especially fluoro) or C^ alkoxy (especially methoxy); V is CR1 wherein R1 is as defined above in which Ar is unsubstituted furan or thiazole; U is phenyl; R3 is phenoxy; and R4 is not present.
Preferred compounds of the present invention include:
4-(4-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-furan- 2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-Benzenesulphonyl-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-
2-yl)-pyrido[3,4-djpyrimidin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-Benzyloxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2-yl)- quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)- furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)-methyl)-thiazol-4-yl)- quinazolin-4-yl)-amine;
N-{4-[(3-Fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-
2-furyl]-4-quinazolinamine;
N-{4-[(3-Fluorobenzyl)oxy]-3-methoxyphenyl}-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-[4-(Benzyloxy)phenylj-7-methoxy-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
N-[4-(Benzyloxy)phenyl]-6-[4-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4- quinazolinamine;
N-{4-[(3-Fluorobenzyl)oxy]-3-methoxyphenyl}-6-[2-({[2- (methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-{4-[(3-Bromobenzyl)oxy]phenyl}-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-
1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-{4-[(3-Fluorobenzyl)oxy]phenyl}-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-
1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-(Benzyloxy)-3-fluorophenyl]-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-
1,3-thiazol-4-ylj-4-quinazolinamine;
N-(1-Benzyl-1H-indazol-5-yl)-7-methoxy-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
6-[5-({[2-(Methanesulphonyl)ethyl]amino}methyl)-2-furyl]-N-(4-{[3- (trifluoromethyl)benzyl]oxy}phenyl)-4-quinazolinamine;
N-{3-Fluoro-4-[(3-fluorobenzyl)oxyjphenyl}-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
N-{4-[(3-Bromobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-
2-furyl]-4-quinazolinamine; N-[4-(Benzyloxy)phenylj-6-[3-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4- quinazolinamine;
N-[1 -(3-Fluorobenzyl)-1 H-indazol-5-yl]-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine; 6-[5-({[2-(Methanesulphonyl)ethyl]amino}methyl)-2-furyl]-N-[4-
(benzenesulphonyl)phenyl]-4-quinazolinamine;
6-[2-({[2-(Methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-N-[4-
(benzenesulphonyl)phenyl]-4-quinazolinamine;
6-[2-({[2-(Methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-N-(4-{[3- (trifluoromethyl)benzyl]oxy}phenyl)-4-quinazolinamine
N-{3-Fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-(1-Benzyl-1 H-indazoI-5-yl)-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-1 ,3- thiazol-4-yl]-4-quinazolinamine; N-(3-Fluoro-4-benzyloxyphenyl)-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-
1,3-thiazol-4-yl]-4-quinazolinamine;
N-(3-Chloro-4-benzyloxyphenyl)-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-
1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
6-[5-({[2-(Methanesulphonyl)ethyl]amino}methyl)-2-furyl]-7-methoxy-N-(4- benzenesulphonyl)phenyl-4-quinazolinamine;
N-[4-(Benzyloxy)phenyl]-7-fluoro-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-(1-Benzyl-1 H-indazol-5-yl)-7-fluoro-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl) -2-furyl]-4-quinazolinamine;
N-[4-(Benzenesulphonyl)phenyl]-7-fluoro-6-[5-({[2-
(methanesulphonyl)ethyljamino} methyl)-2-furyl]-4-quinazolinamine;
N-(3-Trifluoromethyl-4-benzyioxyphenyl)-6-[5-({[2- (methanesulphonyl)ethyljamino}methyl)-4-furyl]-4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts thereof.
Other preferred compounds of the present invention include: (4-Phenoxyphenyl)-(7- (2-(2-methanesulphonyl)ethylaminomethyl)thiazol-4-yl)- quinolin-4-yl)amine; (4-Phenoxyphenyl)-(7- (4-(2-methanesulphonyl)ethylaminomethyl)thiazol-5-yl)- quinolin-4-yl)amine;
(4-Phenoxyphenyl)-(7-(5-(2-(methanesulphonyl)ethylaminomethyl)furan-2-yl)- quinolin-4-yl)amine; and salts or solvates thereof, particularly pharmaceutically acceptable salts thereof.
Other preferred compounds of the present invention include the following (in groups denoted hereafter as Lists 1 to 48):
List 1
(4-Phenoxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine;
(1-Benzyl-1 H-indazol-5-yl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2- yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-(4-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)-furan-
2-yl)-pyrido[3,4-djpyrimidin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine;
List 2 (1-Benzyl-1H-indazol-5-yl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4- yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-Phenoxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine;
List 3 (1-Benzyl-1 H-indazol-5-yl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5- yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-5-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-5-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-5-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-Phenoxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine;
List 4
(1-Benzyl-1 H-indazol-5-yl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2- yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-Benzenesulphonyl-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine;
List 5
(1-Benzyl-1 H-indazol-5-yl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2- yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-(4-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-pyrido[3,4-djpyrimidin-4-yl)-amine; (4-Benzenesulphonyl-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine;
List 6
(1 -Benzyl-1 H-indazol-5-yl)-(6-(3-((2-methanesulphonyl-ethylamino)methyl)-phenyl)- pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-(4-Fluorobenzyloxy)-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)-methyl)- phenyl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- pyrido[3,4-djpyrimidin-4-yl)-amine;
List 7 (1 -Benzyl-1 H-indazol-5-yl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-phenyl)- pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)- phenyl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- pyrido[3,4-d]pyrimidin-4-yI)-amine; (4-Phenoxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- pyrido[3,4-d]pyrimidin-4-yl)-amine;
List 8 (4-(4-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinazolin-4-yl)-amine;
List 9
(1-Benzyl-1 H-indazol-5-yl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2- yl)-quinazolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesuIphonyl-ethylamino)methyl)- furan-2-yl)-quinazolin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-quinazolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)-furan-
2-yl)-quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinazolin-4-yl)-amine;
List 10
(1-Benzyl-1 H-indazol-5-yl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4- yl)-quinazolin-4-yl)-amine; (4-(4-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)- quinazolin-4-yl)-amine;
List 11
(1-Benzyl-1H-indazol-5-yl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5- yl)-quinazolin-4-yl)-amine; (4-(4-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-5-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-5-yl)-quinazolin-4-yl)-amine; (4-Benzenesulphonyl-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-5-yl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- quinazolin-4-yl)-amine;
List 12
(1-Benzyl-1 H-indazol-5-yl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2- yl)-quinazolin-4-yl)-amine; (4-(4-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-quinazolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-2-yl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinazolin-4-yl)-amine;
List 13
(1-Benzyl-1H-indazol-5-yl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2- yl)-quinazolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-quinazolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-2-yl)-quinazolin-4-yl)-amine; (4-Benzyloxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinazolin-4-yl)-amine;
List 14
(1-Benzyl-1H-indazol-5-yl)-(6-(3-((2-methanesulphonyl-ethylamino)methyl)-phenyl)- quinazolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-quinazolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)-methyl)- phenyl)-quinazolin-4-yl)-amine; (4-Benzyloxy-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinazolin-4-yl)-amine;
List 15
(1-Benzyl-1H-indazol-5-yl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-phenyl)- quinazolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-quinazolin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-quinazolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)- phenyl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinazolin-4-yl)-amine;
List 16 (4-(4-Fluorobenzyloxy)-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-quinazolin-4-yl)-amine; (4-Benzenesulphonyl-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan- 2-yl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinazolin-4-yl)-amine;
List 17
(1-Benzyl-1 H-indazol-5-yl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2- yl)-quinazolin-4-yl)-amine; (4-(4-Fluorobenzyloxy)-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-quinazolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)-methyl)-furan- 2-yl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinazolin-4-yl)-amine;
List 18
(1-Benzyl-1H-indazol-5-yl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4- yl)-quinazolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-quinazolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-4-yl)-quinazolin-4-yl)-amine; (4-Benzyloxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)- quinazolin-4-yl)-amine;
List 19
(1-Benzyl-1 H-indazol-5-yl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5- yl)-quinazolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-5-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-5-yl)-quinazolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-5-yl)-quinazolin-4-yl)-amine; (4-Benzyloxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- quinazolin-4-yl)-amine;
List 20
(1-Benzyl-1H-indazol-5-yl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazoI-2- yl)-quinazolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-quinazolin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-quinazolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-2-yl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-phenyI)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinazolin-4-yl)-amine;
List 21 (1 -Benzyl-1 H-indazol-5-yl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2- yl)-quinazolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-quinazolin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-quinazolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-2-yl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinazolin-4-yl)-amine;
List 22 (1 -Benzyl-1 H-indazol-5-yl)-(7-(3-((2-methanesulphonyl-ethylamino)methyl)-phenyl)- quinazolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(7-(3-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(7-(3-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-quinazolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(7-(3-((2-methanesulphonyl-ethylamino)-methyl)- phenyl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(7-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinazolin-4-yl)-amine; (4-Phenoxy-phenyl)-(7-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinazolin-4-yl)-amine;
List 23
(1-Benzyl-1H-indazol-5-yl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-phenyl)- quinazolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-quinazolin-4-yl)-amine; (4-Benzenesulphonyl-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)-methyl)- phenyl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinazolin-4-yl)-amine; (4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinazolin-4-yl)-amine;
List 24
(1 -Benzyl-1 H-indazol-5-yl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2- yl)-pyτido[3,4-djpyridin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-pyrido[3,4-d]pyridin-4-yl)-amine; (4-Benzenesulphonyl-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-
2-yl)-pyrido[3,4-djpyridin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- pyrido[3,4-djpyridin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- pyrido[3,4-d]pyridin-4-yl)-amine;
List 25
(1-Benzyl-1 H-indazol-5-yl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2- yl)-pyrido[3,4-d]pyridin-4-yl)-amine; (4-(4-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)-furan- 2-yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- pyrido[3,4-d]pyridin-4-yl)-amine; List 26
(1-Benzyl-1 H-indazol-5-yl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4- yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-4-yl)-pyrido[3,4-d]pyridin-4-yl)-amine; (4-Benzyloxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)- pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)- pyrido[3,4-d]pyridin-4-yl)-amine;
List 27
(1-Benzyl-1H-indazol-5-yl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5- yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-5-yl)-pyrido[3,4-d]pyridin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-5-yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-5-yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Phenoxy-phenyI)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- pyrido[3,4-d]pyridin-4-yl)-amine;
List 28 (1 -Benzyl-1 H-indazol-5-yl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2- yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-pyrido[3,4-d]pyridin-4-yl)-amine; (4-Benzenesulphonyl-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-2-yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- pyrido[3,4-djpyridin-4-yl)-amine; (4-Phenoxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- pyrido[3,4-djpyridin-4-yl)-amine;
List 29
(1 -Benzyl-1 H-indazol-5-yl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2- yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-(4-FIuorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-pyrido[3,4-d]pyridin-4-yl)-amine; (4-Benzenesulphonyl-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-2-yl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- pyrido[3,4-djpyridin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- pyrido[3,4-d]pyridin-4-yl)-amine;
List 30
(1-Benzyl-1 H-indazol-5-yl)-(6-(3-((2-methanesulphonyl-ethylamino)methyl)-phenyl)- pyrido[3,4-djpyridin-4-yl)-amine; (4-(4-Fluorobenzyloxy)-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-pyrido[3,4-djpyridin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)-methyl)- phenyl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- pyrido[3,4-d]pyridin-4-yl)-amine; List 31
(1-Benzyl-1 H-indazol-5-yl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-phenyl)- pyrido[3,4-d]pyridin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)- phenyl)-pyrido[3,4-d]pyridin-4-yl)-amine; (4-Benzyloxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- pyrido[3,4-d]pyridin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- pyrido[3,4-d]pyridin-4-yl)-amine;
List 32
(4-Phenoxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinolin-4-yl)-amine; (4-Phenoxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinolin-4-yl)-amine; (4-Phenoxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinolin-4-yl)-amine;
List 33
(1-Benzyl-1H-indazol-5-yl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2- yl)-quinolin-4-yl)-amine; (4-(4-Fluorobenzyloxy)-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-quinolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-quinolin-4-yl)-amine; (4-Benzenesulphonyl-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan- 2-yl)-quinolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinolin-4-yl)-amine;
List 34
(1-Benzyl-1 H-indazoI-5-yl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2- yl)-quinolin-4-yl)-amine; (4-(4-Fluorobenzyloxy)-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-quinolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-quinolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)-methyl)-furan- 2-yl)-quinolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinolin-4-yl)-amine;
List 35
(1-Benzyl-1H-indazol-5-yl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4- yl)-quinolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-quinolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-quinolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-4-yl)-quinolin-4-yl)-amine; (4-Benzyloxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)- quinolin-4-yl)-amine;
List 36
(1-Benzyl-1 H-indazol-5-yl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5- yl)-quinolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-5-yl)-quinolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-5-yl)-quinolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-5-yl)-quinolin-4-yl)-amine; (4-Benzyloxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- quinolin-4-yl)-amine;
List 37
(1-Benzyl-1H-indazol-5-yl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2- yl)-quinolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-quinolin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-quinolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-2-yl)-quinolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quino!in-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinolin-4-yl)-amine;
List 38 (1-Benzyl-1H-indazol-5-yl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2- yl)-quinolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-quinolin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)- thiazol-2-yl)-quinolin-4-yi)-amine;
(4-Benzenesulphonyl-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)-methyl)- thiazol-2-yl)-quinolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinolin-4-yl)-amine;
List 39 (1 -Benzyl-1 H-indazol-5-yl)-(7-(3-((2-methanesulphonyl-ethylamino)methyl)-phenyl)- quinolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(7-(3-((2-methanesuIphonyl-ethylamino)methyl)- phenyl)-quinolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(7-(3-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-quinolin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(7-(3-((2-methanesulphonyI-ethylamino)-methyl)- phenyl)-quinolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(7-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinolin-4-yl)-amine; (4-Phenoxy-phenyl)-(7-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinolin-4-yl)-amine;
List 40
(1-Benzyl-1H-indazol-5-yl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-phenyl)- quinolin-4-yl)-amine;
(4-(4-Fluorobenzyloxy)-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-quinolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)- phenyl)-quinolin-4-yl)-amine; (4-Benzenesulphonyl-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)-methyl)- phenyl)-quinolin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinolin-4-yl)-amine; (4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- quinolin-4-yl)-amine;
List 41
(4-Benzyloxy-3-chlorophenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy)-3-chlorophenyl)-(6-(5-((2-methanesulphonyl- ethylamino)methyl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-3-trifluoromethylphenyl)-(6-(5-((2-methanesulphonyl- ethylamino)methyl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-(3-Fluoro-benzyloxy)-3-trifluoromethylphenyl)-(6-(5-((2-methanesulphonyl- ethylamino)methyl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-3-bromophenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-
2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy-3-bromophenyl)-(6-(5-((2-methanesulphonyl- ethylamino)methyl)-furan-2-yl)-pyrido[3,4-djpyrimidin-4-yl)-amine;
(4-Benzyloxy-3-iodophenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2- yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy-3-iodophenyl)-(6-(5-((2-methanesulphonyl- ethylamino)methyl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-Benzyloxy-3-fluorophenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-
2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy-3-fluorophenyl)-(6-(5-((2-methanesulphonyl- ethylamino)methyl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
List 42
(4-Benzyloxy-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-(3-Fluoro-benzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl- ethylamino)methyl)-thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-Benzyloxy-3-trifluoromethylphenyl)-(6-(2-((2-methanesulphonyl- ethylamino)methyl)-thiazol-4-yl)-pyrido[3,4-djpyrimidin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy)-3-trifluoromethylphenyl)-(6-(2-((2-methanesulphonyl- ethylamino)methyl)-thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-Benzyloxy-3-bromophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy-3-bromophenyl)-(6-(2-((2-methanesulphonyl- ethylamino)methyl)-thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-3-iodophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol- 4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy-3-iodophenyl)-(6-(2-((2-methanesulphonyl- ethylamino)methyl)-thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-3-fluorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-(3-Fluoro-benzyloxy-3-fluorophenyl)-(6-(2-((2-methanesulphonyl- ethylamino)methyl)-thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
List 43
(4-Benzyloxy-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-quinazolin-4-yl)-amine
(4-(3-Fluoro-benzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl- ethylamino)methyl)-thiazol-4-yl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-3-trifluoromethylphenyl)-(6-(2-((2-methanesulphonyl- ethylamino)methyl)-thiazol-4-yl)-quinazolin-4-yl)-amine; (4-(3-Fluoro-benzyloxy)-3-trifluoromethylphenyl)-(6-(2-((2-methanesulphonyl- ethylamino)methyl)-thiazol-4-yl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-3-bromophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy-3-bromophenyl)-(6-(2-((2-methanesulphonyl- ethylamino)methyl)-thiazol-4-yl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-3-iodophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)- thiazol-4-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy-3-iodophenyl)-(6-(2-((2-methanesulphonyl- ethylamino)methyl)-thiazol-4-yl)-quinazolin-4-yl)-amine; List 44
(4-(3-Fluoro-benzyloxy)-3-trifluoromethylphenyl)-(6-(5-((2methanesulphonyl- ethylamino)-methyl)-furan-2-yl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-3-bromophenyl)-( 6-(5-((2methanesulphonyl-ethylamino)-methyl)- furan-2-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy-3-bromophenyl)-( 6-(5-((2methanesulphonyl-ethylamino)- methyl)-furan-2-yl)-quinazolin-4-yl)-amine;
(4-Benzyloxy-3-iodophenyl)-( 6-(5-((2methanesulphonyl-ethylamino)-methyl)-furan-2- yl)-quinazolin-4-yl)-amine; (4-(3-Fluoro-benzyloxy-3-iodophenyl)-( 6-(5-((2methanesulphonyl-ethylamino)- methyl)-furan-2-yl)-quinazolin-4-yl)-amine.
List 45 N-[4-(Benzyloxy)-3-chlorophenyl]-7-methoxy-6-[5-({[2- (methanesulphonyl)ethylJamino}methyl)-2-furylj-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-chlorophenyl]-7-methoxy-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-[4-Benzyloxy-3-trifluoromethylphenyl]-7-methoxy-6-[5-({[2- (methanesulphonyl)ethyljamino}methyl)-2-furyl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-trifluoromethylphenylj-7-methoxy-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-[4-Benzyloxy-3-bromophenyl]-7-methoxy-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazoiinamine; N-[4-(3-Fluoro-benzyloxy-3-bromophenyl]-7-methoxy-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-[4-Benzyloxy-3-iodophenyl]-7-methoxy-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy-3-iodophenyl]-7-methoxy-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-[4-Benzyloxy-3-fluorophenyl]-7-methoxy-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy-3-fluorophenyl]-7-methoxy-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-[1-(3-Fluorobenzyl-1 H-indazol-5-yl]-7-methoxy-6-[5-({[2- (methanesulphonyl)ethyljamino}methyl)-2-furyl]-4-quinazolinamine; List 46
N-[4-(Benzyloxy)-3-chlorophenyl]-7-fluoro-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-chlorophenyl]-7-fluoro-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine N-[4-Benzyloxy-3-trifluoromethylphenyl]-7-fluoro-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furylj-4-quinazolinamine N-[4-(3-Fluoro-benzyloxy)-3-trifluoromethylphenyl]-7-fluoro-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine N-[4-Benzyloxy-3-bromophenyl]-7-fluoro-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine N-[4-(3-Fluoro-benzyloxy-3-bromophenyl]-7-fluoro-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine N-[4-Benzyloxy-3-iodophenyl]-7-fluoro-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine N-[4-(3-Fluoro-benzyloxy-3-iodophenyl]-7-fluoro-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine N-[4-Benzyloxy-3-fluorophenyl]-7-fluoro-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine N-[4-(3-Fluoro-benzyloxy-3-fluorophenylj-7-fluoro-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine N-[1 -(3-fiuorobenzyl-1 H-indazol-5-yl]-7-fluoro-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
List 47
N-[4-(benzyloxy)-3-chlorophenyl]-7-methoxy-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[4-(3-Fluoro-benzyloxy)-3-chlorophenylj-7-methoxy-6-[2-({[2- (methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine; N-[4-Benzyloxy-3-trifluoromethylphenylj-7-methoxy-6-[2-({[2- (methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-trifluoromethylphenyl]-7-methoxy-6-[2-({[2- (methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4yl]-4-quinazolinamine; N-[4-Benzyloxy-3-bromophenyl]-7-methoxy-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[4-(3-Fluoro-benzyloxy-3-bromophenyl]-7-methoxy-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine; N-[4-Benzyloxy-3-iodophenyl]-7-methoxy-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-ylj-4-quinazolinamine;
N-[4-(3-Fluoro-benzyloxy-3-iodophenyl]-7-methoxy-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[4-Benzyloxy-3-fluorophenyl]-7-methoxy-6-[2-({[2- (methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[4-(3-Fluoro-benzyloxy-3-fluorophenyl]-7-methoxy-6-[2-({[2-
(methanesuIphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[1 -(3-fluorobenzyl-1 H-indazol-5-yl]-7-methoxy-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
List 48
N-[4-(benzyloxy)-3-chlorophenyl]-7-fluoro-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[4-(3-Fluoro-benzyloxy)-3-chlorophenyI]-7-fluoro-6-[2-({[2- (methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[4-Benzyloxy-3-trifluoromethylphenyl]-7-fluoro-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[4-(3-Fluoro-benzyloxy)-3-trifluoromethylphenyl]-7-fluoro-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine; N-[4-Benzyloxy-3-bromophenyl]-7-fluoro-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[4-(3-Fluoro-benzyloxy-3-bromophenyl]-7-fluoro-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[4-Benzyloxy-3-iodophenylj-7-fluoro-6-[2-({[2- (methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[4-(3-Fluoro-benzyloxy-3-iodophenyl]-7-fluoro-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[4-Benzyloxy-3-fluorophenyl]-7-fluoro-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy-3-fluorophenyl]-7-fluoro-6-[2-({[2- (methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine; N-[1 -(3-fluorobenzyl-1 H-indazol-5-yl]-7-fluoro-6-[2-({[2- (methanesulphonyl)ethyljamino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts or solvates thereof.
Particularly preferred compounds of the present invention include:
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxyphenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2-yl)- quinazolin-4-yl)-amine;
N-{4-[(3-Fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-
2-furyl]-4-quinazolinamine; N-[4-(Benzyloxy)phenyl]-7-methoxy-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
N-(1 -Benzyl-1 H-indazol-5-yl)-7-methoxy-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
N-{3-Fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
N-[1-(3-Fluorobenzyl)-1 H-indazol-5-ylj-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
6-[5-({[2-(Methanesulphonyl)ethyl]amino}methyl)-2-furyl]-N-[4-
(benzenesulphonyl)phenyl]-4-quinazolinamine; N-{3-Fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-(1 -Benzyl-1 H-indazol-5-yl)-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-1 , 3- thiazol-4-yl]-4-quinazolinamine;
N-(3-Fluoro-4-benzyloxyphenyl)-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-4- furyl]-4-quinazolinamine;
N-(3-Chloro-4-benzyloxyphenyl)-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-4- furyl]-4-quinazolinamine;
N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-(1 -Benzyl-1 H-indazol-5-yl)-7-fluoro-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-(3-Trifluoromethyl-4-benzyloxyphenyl)-6-[5-({[2- (methanesulphonyl)ethyljamino}methyl)-4-furylj-4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts or solvates thereof.
Further particularly preferred compounds of the present invention include:
(4-Phenoxyphenyl)-(7- (2-(2-methanesulphonyl)ethylaminomethyl)thiazol-4-yl)- quinolin-4-yl)amine;
(4-Phenoxyphenyl)-(7- (4-(2-methanesulphonyl)ethylaminomethyl)thiazol-5-yl)- quinolin-4-yl)amine;
(4-Phenoxyphenyl)-(7-(5-(2-(methanesulphonyl)ethylaminomethyl)furan-2-yl)- quinolin-4-yl)amine; and salts or solvates thereof, particularly pharmaceutically acceptable salts or solvates thereof.
Other particularly preferred compounds of the present invention include
(4-Phenoxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl )-furan-2-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl )-furan-2-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl )-thiazol-4-yl)- quinazolin-4-yl)-amine; (4-Phenoxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl )-thiazol-5-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl )-thiazol-2-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl )-thiazol-2-yl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(3-((2-methanesulphonyl-ethylamino)methyl )-phenyl)- quinazolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl )-phenyl)- quinazolin-4-yl)-amine; (4-Phenoxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinoiin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-furan-2-yl)- quinolin-4-yl)-amine; (4-Phenoxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(3-((2-methanesulphonyl-ethylamino)methyl)-phenyl)- quinolin-4-yl)-amine; (4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethyIamino)methyl)-phenyl)- quinolin-4-yl)-amine; and salts or solvates thereof, particularly pharmaceutically acceptable salts or solvates thereof.
Other most particularly preferred compounds of the present invention include:
(4-Phenoxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-5-yl)- quinolin-4-yl)-amine; (4-Phenoxy-phenyl)-(7-(4-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinolin-4-yl)-amine;
(4-Phenoxy-phenyl)-(7-(5-((2-methanesulphonyl-ethylamino)methyl)-thiazol-2-yl)- quinolin-4-yl)-amine; and salts or solvates thereof, particularly pharmaceutically acceptable salts or solvates thereof.
Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism). The individual stereoisomers (enantiomers and diastereoisomers) and mixtures of these are included within the scope of the present invention. Likewise, it is understood that compounds of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention.
Salts of the compounds of the present invention may comprise acid addition salts derived from a nitrogen in the compound of formula (I). The therapeutic activity resides in the moiety derived from the compound of the invention as defined herein and the identity of the other component is of less importance although for therapeutic and prophylactic purposes it is, preferably, pharmaceutically acceptable to the patient. Examples of pharmaceutically acceptable acid addition salts include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids, and organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic and methanesulphonic and arylsulphonic, for example p-toluenesulphonic, acids.
According to a further aspect of the present invention there is provided a process for the preparation of a compound of formula (I) as defined above which comprises the steps:
(a) the reaction of a compound of formula (II)
Figure imgf000042_0001
wherein X is as defined above; Y* is CL' and V is N; or Y' is N and V' is CL'; or Y' is CL' and V' is CR2; orY' is CR2 and V' is CL'; wherein R2 is as defined above, and L and L' are suitable leaving groups, with a compound of formula (III)
UNH2 (III) wherein U is as defined above, to prepare a compound of formula (IV)
Figure imgf000043_0001
and subsequently (b) reaction with appropriate reagent(s) to substitute the group R1 by replacement of the leaving group L'; and, if desired, (c) subsequently converting the compound of formula (I) thereby obtained into another compound of formula (I) by means of appropriate reagents.
Alternatively, the compound of formula (II) as defined above is reacted with the appropriate reagents to substitute the group R1 by replacement of the leaving group L' and then the product thereby obtained (of formula (V) below) is reacted with the compound of formula (III) as defined above, followed, if desired, by conversion of the compound of formula (I) thereby obtained into another compound of formula (I).
In a variant of this alternative the compound of formula (V)
Figure imgf000043_0002
wherein X, Y, V, U and L are as defined above, may be prepared by the reaction of a compound of formula (VI)
Figure imgf000043_0003
wherein V and Y' are as defined above, with appropriate reagents to substitute the group R1 for the leaving group L' to prepare a compound of formula (VII)
Figure imgf000044_0001
and subsequent reaction to incorporate the leaving group L. For example, a chloro leaving group can be incorporated by reaction of a corresponding 3,4- dihydropyrimidone with carbon tetrachloride/triphenylphosphine in an appropriate solvent.
The group R1 may, therefore, be substituted onto the basic ring system by replacement of a suitable leaving group. This may, for example, be carried out by reaction of the corresponding aryl or heteroaryl stannane derivative with the corresponding compound of formula (IV) carrying the leaving group L' in the appropriate position on the ring.
According to a further aspect of the present invention there is provided a process for the preparation of a compound of formula (I) as defined above which comprises the steps:
(a) reacting a compound of formula (IV) as defined above with appropriate reagent(s) to prepare a compound of formula (VIII)
Figure imgf000044_0002
wherein X and U are as defined above;
Y" is CT and V" is N; or Y" is N and V" is CT; orY" is CT and V" is CR2; or Y" is CR2 and V" is CT; wherein R2 is as defined above and T is an appropriately functionalised group; and (b) subsequently converting the group T into the group R1 by means of appropriate reagent(s); and, if desired, (c) subsequently converting the compound of formula (I) thereby obtained into another compound of formula (I) by means of appropriate reagents. In one alternative, the group T would represent a group Ar as defined above carrying a formyl group (CHO).
Where T represents a group Ar carrying a formyl group the compound (of formula (Villa)) may be suitably prepared from the corresponding dioxolanyl substituted compound (of formula (Vlllb)), for example by acid hydrolysis. The dioxolanyl substituted compound may be prepared by reaction of a compound of formula (IV) with an appropriate reagent to substitute the relevant leaving group with the substituent carrying the dioxolanyl ring. This reagent could, for example, be an appropriate heteroaryl stannane derivative.
Therefore a suitable process may comprise reaction of a compound of formula (Villa) in which T is a group Ar carrying a formyl substituent (i.e. a -CHO group) with a compound of formula CH3SO2CH2CH2NH2. The reaction preferably involves a reductive amination by means of an appropriate reducing agent, for example sodium triacetoxyborohydride.
Alternatively, another suitable process may comprise oxidation of a compound of formula (VI lie) in which T is a group Ar carrying a substituent of formula
CH3SCH2CH2NHCH2 or CH3SOCH2CH2NHCH2. Suitable methods for the oxidation to the desired compound of formula (I) will be well known to the person skilled in the art but include, for example, reaction with an organic peroxide, such as peracetic acid or metachlorobenzoic acid, or reaction with an inorganic oxidising agent, such as OXONE®. The compound of formula (Vlllc) in which T is a group Ar carrying a substituent of formula CH3SCH2CH2NHCH2 or CH3SOCH2CH2NHCH2 may be prepared by an analogous reaction to that described above, namely reaction of a compound of formula (Villa) in which T is a group Ar carrying a formyl substituent (i.e. a -CHO group) with a compound of formula CH3SCH2CH2NH2or CH3SOCH2CH2NH2 respectively.
Alternatively, an analogous scheme to those described above could be used wherein the substitution of the group R1 onto the basic ring system occurs prior to the coupling reaction with the compound of formula (III). According to a further alternative process the group T is converted into the group R1 by a de novo synthesis of a substituted heterocyclic system using appropriate agents. Such a process would involve standard synthetic methodology known to the person skilled in the art for building up the heterocylic ring system.
For example, T could represent a haloketone group as shown in the compound of formula (IX) in scheme 1 below which, when coupled with an appropriate N- protected thioamide [compound of formula (XI) in scheme 2], would result in the formation of an N-protected amino-substituted thiazole system of formula (X).
Scheme 1 outlines, for example, the synthesis of derivatives carrying a substituted thiazole ring as an R1 substituent:
Figure imgf000047_0001
(Xa) (Xlb)
Figure imgf000047_0002
(I)
Scheme 1
wherein halo is as previously defined (preferably iodo), and P' in the compound of formula (XI) is a suitable protecting group, such as trifluorocarbonyl.
An analogous process may be used to prepare compounds of formula(l) which carry R1 in the 7-position of the basic ring system from a starting compound of formula(IVb)
Figure imgf000048_0001
via intermediates of formulae (Xb) and (Xlb) which are respectively analogous to those of formulae (Xa) and (Xlb).
An appropriately substituted thioamide coupling reagent, suitable for preparation of a thiazole ring system, may be prepared according to Scheme 2:
CK N Oc ,CF,
NH NaHCO, , MeCN TEA or NMM , 0°C reflux \ .N N ,CN TFAA ^s'
(XII) (XIII) (XIV)
Figure imgf000048_0002
(XV) (XVIa)
Scheme 2
Wherein in scheme 2 the trifluorocarbonyl protecting group in the compounds of formula (XIV), (XV) and (XVIa) is equivalent to the group P' in scheme 1.
Alternatively, an analogous scheme to those described above could be used wherein the substitution of the group R1 onto the basic ring system occurs prior to the coupling reaction with the compound of formula(lll). Other substituted thioamides are prepared using analogous processes to that shown above.
In general, the group R2 will be present as a substituent in the basic ring system prior to the introduction of the group R1 or the group NHU. Where R2 is other than hydrogen it may in certain circumstances be necessary to protect the group prior to performing the reaction steps to introduce the R1 and NHU substituents. Particular mention should be made of the situation where R2 is hydroxy; suitable protecting groups to ensure non-interference with the subsequent reaction steps include the 2- methoxyethoxymethyl ether (MEM) group or a bulky silyl protecting group such as tert-butyldiphenylsilyl (TBDPS).
Suitable protecting groups, methods for their introduction and methods for their removal would be well known to the person skilled in the art. For a description of protecting groups and their use see T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", 2nd edn., John Wiley & Sons, New York, 1991.
Suitable leaving groups for L and L' will be well known to those skilled in the art and include, for example, halo such as fluoro, chloro, bromo and iodo; sulphonyloxy groups such as methanesulphonyloxy and toluene-p-sulphonyloxy; alkoxy groups; and triflate.
The coupling reaction referred to above with the compound of formula (III) is conveniently carried out in the presence of a suitable inert solvent, for example a Cι_4 alkanol, such as isopropanol, a halogenated hydrocarbon, an ether, an aromatic hydrocarbon or a dipolar aprotic solvent such as acetone, acetonitrile or DMSO at a non-extreme temperature, for example from 0 to 150°C, suitably 10 to 120°C, preferably 50 to 100°C.
Optionally, the reaction is carried out in the presence of a base. Examples of suitable bases include an organic amine such as triethylamine, or an alkaline earth metal carbonate, hydride or hydroxide, such as sodium or potassium carbonate, hydride or hydroxide. The compound of formula (I) may be obtained from this process in the form of a salt with the acid HL, wherein L is as hereinbefore defined, or as the free base by treating the salt with a base as hereinbefore defined.
The compounds of formulae (II) and (III) as defined above, the reagents to substitute the group R1, and the reagent(s) to convert the group T into the group R1 are either readily available or can be readily synthesised by those skilled in the art using conventional methods of organic synthesis.
As indicated above, the compound of formula (I) prepared may be converted to another compound of formula (I) by chemical transformation of the appropriate substituent or substituents using appropriate chemical methods (see for example, J.March "Advanced Organic Chemistry", Edition III, Wiley Interscience, 1985).
For example, a compound containing an alkylthio group may be oxidised to the corresponding sulphinyl or sulphonyl compound by use of an organic peroxide (e.g. benzoyl peroxide) or suitable inorganic oxidant (eg OXONE ®).
A compound containing a nitro substituent may be reduced to the corresponding amino-compound, e.g. by use of hydrogen and an appropriate catalyst (if there are no other susceptible groups), by use of Raney Nickel and hydrazine hydrate or by use of iron/acetic acid.
Amino substituents may be acylated by use of an acid chloride or an anhydride under appropriate conditions. Equally an amide group may be cleaved to the amino compound by treatment with, for example, dilute aqueous base.
An amino substituent may also be converted to a dimethylamino substituent by reaction with formic acid and sodium cyanoborohydride. Similarly, reaction of a primary or secondary amino group with another suitable aldehyde under reducing conditions will lead to the corresponding substituted amine.
All of the above-mentioned chemical transformations may also be used to convert any relevant intermediate compound to another intermediate compound prior to the final reaction to prepare a compound of formula (I); this would thus include their use to convert one compound of formula (III) to a further compound of formula (III) prior to any subsequent reaction.
Various intermediate compounds used in the above-mentioned processes, including but not limited to certain of the compounds of formulae (II), (III), (IV), (V), (VI), (VII) and (VIII) as illustrated above, are novel and thus represent a further aspect of the present invention.
In particular, a further aspect of the present invention is intermediate compounds of formulae (Villa) and (VI I lb) defined above, with the exception of the following compounds:
(1-Benzyl-1 H-indazol-5-yl)-(6-(5-[1 ,3-dioxolan-2-yl]-furan-2-yI)-pyrido[3,4-d]pyrimidin-
4-yl)-amine;
5-(4-(1-Benzyl-1 H-indazol-5-ylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2- carbaldehyde;
5-(4-(4-Benzyloxy-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2-carbaldehyde;
(4-Benzyloxy-phenyl)-(6-(5-[1 ,3-dioxolan-2-yl]-furan-2-yl)-quinazolin-4-yl)-amine;
5-(4-(4-Benzyloxy-phenylamino)-quinazolin-6-yl)-furan-2-carbaldehyde;
(1-Benzyl-1H-indazol-5-yl)-(6-(5-[1 ,3-dioxolan-2-yl]-furan-2-yl)-quinazolin-4-yl)- amine;
5-(4-(1-Benzyl-1H-indazol-5-ylamino)-quinazolin-6-yl)-furan-2-carbaldehyde;
5-(4-(1-Benzyl-1] -indazol-5-ylamino)-quinazolin-6-yl)-1-methyl-pyrrole-2- carbaldehyde;
(1-Benzyl-1H-indazol-5-yl)-(7-(5-[1 ,3-dioxolan-2-yl]-furan-2-yl)-quinazolin-4-yl)- amine;
5-(4-(1-Benzyl-1H-indazol-5-ylamino)-quinazolin-7-yl)-furan-2-carbaldehyde.
In particular, a yet further aspect of the present invention is intermediate compounds of formula (Vlllc) as defined above; with the proviso that the following compound is excluded:
(4-Benzyloxy-phenyl)-(6-(5-((2-methanesuiphinyl-ethylamino)-methyl)-furan-2-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine.
In particular, another further aspect of the present invention is intermediate compounds of formulae (X), (XI), (XII), (XIII), (XIV), (XV) and (XVI) as defined above. The compounds of formula (I) and salts thereof have anticancer activity as demonstrated hereinafter by their inhibition of the protein tyrosine kinase c-erbB-2, c-erbB-4 and/or EGF-R enzymes and their effect on selected cell lines whose growth is dependent on c-erbB-2 or EGF-r tyrosine kinase activity. Certain compounds of formula (I) are also demonstrated hereinafter to inhibit lck and/or zap70 protein tyrosine kinase enzymes and are expected to have activity in disease conditions in which T cells are hyperactive.
The present invention thus also provides compounds of formula (I) and pharmaceutically acceptable salts or solvates thereof for use in medical therapy, and particularly in the treatment of disorders mediated by aberrant protein tyrosine kinase activity such as human malignancies and the other disorders mentioned above. The compounds of the present invention are especially useful for the treatment of disorders caused by aberrant c-erbB-2 and/or EGF-r and/or lck activity such as breast, ovarian, gastric, pancreatic, non-small cell lung, bladder, head and neck cancers, psoriasis and rheumatoid arthritis.
A further aspect of the invention provides a method of treatment of a human or animal subject suffering from a disorder mediated by aberrant protein tyrosine kinase activity, including susceptible malignancies, which comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
A further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in therapy.
A further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of cancer and malignant tumours.
A further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of psoriasis. A further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of rheumatoid arthritis.
Whilst it is possible for the compounds, salts or solvates of the present invention to be administered as the new chemical, it is preferred to present them in the form of a pharmaceutical formulation.
According to a further feature of the present invention there is provided a pharmaceutical formulation comprising at least one compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents or excipients.
Pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Such a unit may contain for example 0.5mg to 1g, preferably 70mg to 700mg, more preferably 5mg to 100mg of a compound of the formula (I) depending on the condition being treated, the route of administration and the age, weight and condition of the patient.
Pharmaceutical formulations may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).
Pharmaceutical formulations adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in- water liquid emulsions or water-in-oil liquid emulsions.
Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).
Pharmaceutical formulations adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
For treatments of the eye or other external tissues, for example mouth and skin, the formulations are preferably applied as a topical ointment or cream. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
Pharmaceutical formulations adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
Pharmaceutical formulations adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.
Pharmaceutical formulations adapted for rectal administration may be presented as suppositories or as enemas.
Pharmaceutical formulations adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.
Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulizers or insufflators. Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.
It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
The animal requiring treatment with a compound, salt or solvate of the present invention is usually a mammal, such as a human being.
A therapeutically effective amount of a compound, salt or solvate of the present invention will depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian However, an effective amount of a compound of the present invention for the treatment of neoplastic growth, for example colon or breast carcinoma, will generally be in the range of 0.1 to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of 1 to 10 mg/kg body weight per day. Thus, for a 70kg adult mammal, the actual amount per day would usually be from 70 to 700 mg and this amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same. An effective amount of a salt or solvate of the present invention may be determined as a proportion of the effective amount of the compound ger se. It is envisaged that similar dosages would be appropriate for treatment of the other conditions referred to above.
The compounds of the present invention and their salts and solvates may be employed alone or in combination with other therapeutic agents for the treatment of the above-mentioned conditions. In particular, in anti-cancer therapy, combination with other chemotherapeutic, hormonal or antibody agents is envisaged. Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one other pharmaceutically active agent. The compound(s) of formula (I) and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately this may occur simultaneously or sequentially in any order. The amounts of the compound(s) of formula (I) and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
Certain embodiments of the present invention will now be illustrated by way of example only. The physical data given for the compounds exemplified is consistent with the assigned structure of those compounds.
1H NMR spectra were obtained at 500MHz on a Bruker AMX500 spectrophotometer, on a Bruker spectrophotometer at 300MHz, on a Bruker AC250 or Bruker AM250 spectrophotometer at 250MHz and on a Varian Unity Plus NMR spectrophotometer at 300 or 400 MHz. J values are given in Hz. Mass spectra were obtained on one of the following machines: VG Micromass Platform (electrospray positive or negative), HP5989A Engine (thermospray positive) or Finnigan-MAT LCQ (ion trap) mass spectrometer. Analytical thin layer chromatography (tic) was used to verify the purity of some intermediates which could not be isolated or which were too unstable for full characterisation, and to follow the progess of reactions. Unless otherwise stated, this was done using silica gel (Merck Silica Gel 60 F254). Unless otherwise stated, column chromatography for the purification of some compounds used Merck Silica gel 60 (Art. 1.09385, 230-400 mesh), and the stated solvent system under pressure.
Petrol refers to petroleum ether, either the fraction boiling at 40-60°C, or at 60-80°C.
Ether refers to diethylether.
DMSO refers to dimethylsulphoxide.
THF refers to tetrahydrofuran.
HPLC refers to high pressure liquid chromatography.
NMM refers to Λ/-methylmorpholine
Useful preparative techniques are described in WO96/09294, WO97/03069, WO97/13771 , WO95/19774, WO96/40142 and WO97/30034; also described in these publications are appropriate intermediate compounds other than those detailed below.
Preparation processes specified in the prior art or in the experimental details below for compounds with a particular basic ring system (1) to (6) above may be suitably adapted for others of these basic ring systems.
General Procedures
(A) Reaction of an amine with a bicyclic species containing a 4-chloropyrimidine or 4-chloropyridine ring
The optionally substituted bicyclic species and the specified amine were mixed in an appropriate solvent (typically acetonitrile unless otherwise specified, although ethanol, 2-propanol or DMSO may also be used), and heated to reflux. When the reaction was complete (as judged by tic), the reaction mixture was allowed to cool. The resulting suspension was diluted, e.g. with acetone, and the solid collected by filtration, washing e.g. with excess acetone, and dried at 60°C in vacuo, giving the product as the hydrochloride salt. If the free base was required (e.g. for further reaction), this was obtained by treatment with a base e.g. triethylamine; purification by chromatography was then performed if required.
(B) Reaction of a product from Procedure (A) with a heteroaryl tin reagent A stirred mixture of the product from Procedure (A), (containing a suitable leaving group such as chloro, bromo, iodo or triflate), a heteroaryl stannane and a suitable palladium catalyst, such as bis(triphenylphosphine)palladium (II) chloride or 1 ,4-bis(diphenylphosphino)butane palladium (II) chloride (prepared as described in C.E. Housecraft et. al., Inorg. Chem., (1991), 30(1), 125-130), together with other appropriate additives (such as diisopropylethylamine or lithium chloride), were heated at reflux in dry dioxane or another suitable solvent (e.g. DMF) under nitrogen until the reaction was complete. The resulting mixture was generally purified by chromatography on silica.
(C) Removal of a 1 ,3-dioxolan-2-yl protecting group to liberate an aldehyde The compound containing the 1 ,3-dioxolan-2-yl group was suspended in an appropriate solvent, e.g.THF and treated with hydrochloric acid, either as an aqueous solution (e.g. 2N) or as a solution in dioxane (e.g. 4 molar) and stirred at ambient temperature until the reaction was judged complete (e.g. by tic or
LC/MS analysis). Generally the mixture was diluted with water, and the resulting precipitate was collected by filtration, washed with water and dried to give the aldehyde.
(D) Reaction of an aldehyde with an amine by reductive amination
An aldehyde (such as the product of General Procedure C) and the required primary or secondary amine were stirred together in a suitable solvent (such as dichloromethane) containing glacial acetic acid ( 4A molecular sieves may also be present) for ca. 1h. A suitable reducing agent, such as sodium (triacetoxy) borohydride was then added and stirring continued under nitrogen until the reaction was complete (as judged by hplc or tic). The resulting mixture was washed with an aqueous basic solution (e.g. sodium or potassium carbonate) and extracted with a suitable solvent, e.g. dichloromethane. The dried organic phase was evaporated and the residue purified either by column chromatography or by Bond Elut™ cartridge. If desired, the isolated material was then converted into the hydrochloride salt e.g. by treatment with ethereal hydrogen chloride.
(E) Reaction sequence to prepare appropriately substituted thioamides E-1 Reaction of an aminosulfide with chloroacetonitrile To a stirred mixture of an aminosulfide and a suitable base such as sodium bicarbonate or sodium carbonate in an appropriate solvent (typically acetonitrile, although DMF or dioxane can be used) was added chloroacetonitrile dropwise. The resulting mixture was heated to reflux until the reaction was complete. The solid was filtered and the filtrate was concentrated to provide the corresponding aminonitrile.
E-2 Trifluoroacetamide protection of an aminonitrile
A solution of the aminonitrile (such as the product of general procedure A) and an amine base, such as triethylamine or NMM in a suitable solvent (e.g. dichloromethane), was cooled to 0°C and trifluoroacetic anhydride was added dropwise. The resulting mixture was stirred at room temperature until the reaction was complete. Water was added and the mixture was extracted with a suitable solvent (e.g. dichloromethane), the organic layer was dried over anhydrous magnesium sulfate and concentrated. The crude product was purified by column chromatography to provide the corresponding trifluoroacetamide.
E-3 Oxidation of a cyanosulfide
To a stirred solution of a sulfide (such as the product of general procedure E1) in a suitable solvent (typically methanol/water (2:1), although dichloromethane can be used) cooled to 0°C was added an oxidizing agent (typically oxone, although MCPBA can be used). The resulting mixture was stirred at room temperature until the reaction was complete. The reaction was concentrated to remove any organic solvents, diluted with water, and extracted with an appropriate solvent (e.g. dichloromethane). The organic layer was dried and concentrated to provide the corresponding cyanosulfone.
E-4 Preparation of thioamides
To a solution of a cyanosulfone (such as the product of general procedure E-3 ) and an organic base (e.g. triethylamine) in THF was added hydrogen sulfide gas. The resulting mixture was stirred at room temperature until the reaction was complete. The mixture was concentrated and triturated with hexane to provide thioamide.
(F) Reaction sequence to prepare an optionally substituted thiazole F-1 Reaction of a vinylstannane with a product from Procedure (A) A stirred mixture of the optionally substituted bicyclic 4-anilinopyrimidine species, tributyl(1-ethoxyvinyl)stannane (1 to 5 molar equivalents), and a suitable palladium catalyst (0.03 to 0.1 molar equivalents), such as bis(triphenylphosphine) palladium (II) chloride or tetrakis(triphenylphosphine) palladium (0) was heated at reflux in an appropriate solvent (typically acetonitrile, although DMF or dioxane can be used) until the reaction was complete. The resulting mixture was concentrated and generally purified by trituration with diethyl ether to provide the corresponding bicyclic pyrimidine vinyl ether.
F-2 Reaction of a product from Procedure (F-1) with a bromination reagent A bicyclic pyrimidine vinyl ether (such as the product of general procedure F-1) and 1 equivalent of a bromination reagent, such as N-bromosuccinimide or bromine, were stirred at 0°C in a suitable solvent (typically 10% aqueous THF or dichloromethane) until the reaction was complete. The resulting mixture was dried over anhydrous magnesium sulfate and concentrated, or in the case of bromine the solid was filtered, to provide the corresponding α-bromoketone.
F-3 Reaction of a product from procedure (F-2) with a product from Procedure (E-4) A stirred mixture of an α-bromoketone (such as the product of general procedure F- 2) and thioamide from Procedure E-4 in a 1 :1 molar ratio was heated to 70-100°C in an appropriate solvent (typically DMF, although acetonitrile and THF can be used) until the reaction was complete. The resulting mixture was washed with an aqueous basic solution (e.g. sodium carbonate) and extracted with a suitable solvent, e.g. ethyl acetate. The dried organic layer was concentrated and the residue was purified by column chromatography to provide the corresponding trifluoroacetamide aminothiazole.
F-4 Removal of a trifluoroacetamide protecting group to liberate an aminothiazole A mixture of a trifluoroacetamide protected aminothiazole (such as the product of general procedure F-3) in 2M NaOH/methanol (1:1) was stirred at room temperature until the reaction was complete. The mixture was concentrated, poured into water and extracted with an appropriate solvent e.g. 10% MeOH/dichloromethane. The dried organic layer was concentrated, then dissolved in ethyl acetate/MeOH (1:1) and treated with 4M HCI/dioxane. The resulting solid was filtered to provide the corresponding amine hydrochloride salt.
Synthesis of Intermediates Λ/-5-[Λ/-fetY-Butoxycarbonyl)amino]-2-chloropyridine
A stirred solution of 6-chloronicotinic acid (47.3g), diphenylphosphoryl azide (89.6g) and triethylamine (46ml) in t-butanol (240ml) were heated under reflux under nitrogen for 2.5 hours. The solution was cooled and concentrated in vacuo. The syrupy residue was poured into 3 litres of a rapidly stirred solution of 0.33N aqueous sodium carbonate. The precipitate was stirred for one hour and filtered. The solid was washed with water and dried in vacuo at 70°C to give the title compound (62g) as a pale brown solid; m.p. 144-146°C; δH [2H6J-DMSO
8.25(1 H,d), 7.95 (1 H, bd), 7.25 (1 H, d), 6.65(1H, bs), 1.51 (9H,s); m/z (M + 1)+ 229.
This material may subsequently be carried forward to the appropriately substituted pyridopyrimidine intermediate according to the procedures as described in WO95/19774, J. Med. Chem., 1996, 39, pp 1823-1835, and J. Chem. Soc, Perkin Trans. 1 , 1996, pp 2221-2226. Specific compounds made by such procedures include 6-chloro-pyrido[3,4-d]pyrimidin-4-one and 4,6-dichloro-pyrido[3,4- djpyrimidine.
2-Amino-4-fluoro-5-iodo-benzoic acid
To a vigorously stirred solution of dichloromethane (700 ml), methanol (320 ml), and 2-amino-4-fluoro-benzoic acid (33.35 grams, 215 mmoles) was added solid sodium hydrogencarbonate (110 grams, 1.31 moles) followed by portion addition of benzyltrimethyl ammonium dichloroiodate (82.5 grams, 237 mmoles). The mixture was allowed to stir for 48 hours. The mixture was filtered to remove the insolubles. The remaining solid residue was washed with 200 ml of dichloromethane. The filtrate was concentrated and redissolved in a one to one mixture of ethyl acetate (1 litre) and a 0.2 N solution of sodium hydroxide (1 litre), added to a 2 litre separatory funnel and extracted. The organic layer was washed with an additional 200 ml of water. The aqueous layers were combined and acidified with 2N hydrochloric acid. The resulting precipitate was collected by suction filtration, washed with water and dried under vacuum at 60°C to yield 46.5 grams (77%) of the title compound. 1H NMR (400 MHz, DMSO-d6) δ: 8.04(d, 1H), 7.1 (s, broad, 2H), 6.63(d, 1H). ESI-MS m/z 280 (M-1).
4-Fluoro-5-iodo-isatoic anhydride Anhydrous dioxane (0.5 litres), 2-amino-4-fluoro-5-iodo-benzoic acid (46 grams, 164 mmoles), and trichloromethylchloroformate (97.4 grams, 492 mmoles) were added to a one litre one neck flask equipped with a magnetic stir bar and reflux condenser. The solution was placed under anhydrous nitrogen, stirred and heated to reflux for 16 hours. The reaction mixture was allowed to cool and was poured into one litre of hexanes. The solid was collected by suction filtration, washed with an additional 0.5 litres of hexanes, and dried under vacuum at room temperature to yield 45.5 grams (90%) of the title compound. 1H NMR (400 MHz, DMSO-d6) δ: 11.86(s, 1 H), 8.24(d, 1 H), 6.84(d, 1 H). ESI-MS m/z 308 (M+1).
4-Chloro-6-bromoquinazoline and 4-Chloro-6-iodoquinazoline were prepared as described in WO 96/09294.
4-Hydroxy-6-iodo-7-fluoroquinazoline
Dimethylformamide (0.5 litres), 4-fluoro-5-iodo-isatoic anhydride (45 grams, 147 mmoles), and formamidine acetate (45.92 grams, 441 mmoles), were combined in a one litre one-neck flask fitted with a magnetic stir bar. The mixture was placed under anhydrous nitrogen and heated at 110°C for 6 hours. The mixture was allowed to cool, followed by concentrating the reaction mixture to one third its original volume on the rotary evaporator. The resulting mixture was poured onto 3 litres of ice water. The resulting precipitated solid was collected by suction filtration. The solid was washed with an additional one litre of distilled water. The resulting solid was dried under vacuum at 70°C to yield 38.9 grams (91%) of the title compound. 1H NMR (400 MHz, DMSO-d6) δ: 12.43(s, 1 H), 8.46(d, 1H), 8.12(s, 1 H), 7.49(d, 1H). ESI-MS m/z 291(M+1).
4-Chloro-6-iodo-7-fluoro-quinazoline hydrochloride
Thionyl chloride (0.6 litres), 4-hydroxy-6-iodo-7-fluoro-quinazoline (36 grams, 124 mmoles), and dimethylformamide (6 ml) were combined in a one litre one-neck flask fitted with a magnetic stir bar. The mixture was placed under anhydrous nitrogen and heated to a gentle reflux for 24 hours. The mixture was allowed to cool, followed by concentrating the reaction mixture to a thick yellowish residue. To this residue was added dichloromethane (0.1 litre) and toluene (0.1 litre). The mixture was concentrated to dryness. This procedure was repeated two additional times. To the resulting solid was added 0.5 litres of dry dichloromethane and the mixture was stirred for one hour. The mixture was filtered and the remaining solids were washed with minimal dichloromethane. The dichoromethane filtrates were combined, concentrated to a solid, and dried under vacuum at room temperature to yield 28.6 grams (67%) of the title compound. 1H NMR (400 MHz, CDCIg-d,) δ: 9.03(s, 1H), 8.76(d, 1 H), 7.69(d, 1 H). ESI-MS m/z 309(M+1).
2-Bromo-4-(1 ,3-dioxolan-2-yl) thiazole
2-Bromothiazole-4-carbaldehyde (6.56g,34.17mmol) [A . Ung, S.G.Pyne/ Tetrahedron: Asymmetry 9 (1998) 1395-1407jand ethylene glycol (5.72ml, 102.5 mmol) were heated under reflux in toluene (50ml) ,with a Dean and Stark trap fitted, for 18hr. The product was concentrated and purified by column chromatography (15% ethyl acetate /hexane) to give the product as a yellow solid (6.03g); m/z 236,238.
4-(1 ,3-Dioxolan-2-yl)-5-(tributylstannyl)thiazole 2-Bromo-4-(1 ,3-dioxolan-2-yl) thiazole (6.4 g ,27.14 mmol) was stirred at -78° C in dry THF (38ml).1.6M n butyl lithium in hexane (18.6ml, 29.78 mmol) was added dropwise under nitrogen. After 30min at this temperature, tributyl tin chloride (7.35ml,27.14 mmol) was added dropwise. The reaction was allowed to warm to 0° and water (20ml) was added. The product was extracted into ether (3x100ml). The combined organic extracts were dried (MgSO4) and evaporated. The residue was triturated with isohexane (3x100ml) and the mother liquors were decanted, combined and concentrated to give a brown oil (11.88g); m/z 444 - 450.
1-/V-Benzyl-5-nitro-1 H-indazole and 2-Λ/-Benzyl-5-nitro-1 H-indazole
A stirred mixture of 5-nitroindazole (50g), potassium carbonate (46.6g, 1.1 equiv.) and benzyl bromide (57.6g, 1.1 equiv) in Λ/,Λ/-dimethylformamide (500 ml) was heated at 75°C for a period of 4 hours. The reaction was then cooled and water (500ml) was gradually added to precipitate the product which was filtered off and washed with water (50ml) and dried in the air at ambient temperature. The weight of pale yellow solid thus obtained was 72.3g (93%), m.p. 95-97°C; HPLC (Partisil 5, dichloromethane, 4ml/min, 250nm) gave an isomer ratio (1-Λ/-benzyl : 2-Λ/-benzyl) of 63:37 (RT-1Λ/ 3.4min, RT-2/V 6.6min). To a filtered solution of the mixed regioisomers (100g) in acetone (470ml) at room temperature was added, gradually with stirring, water (156ml) and the mixture was stirred for one hour. The resultant yellow crystalline solid was filtered off and dried in the air at ambient temperature to give 36.4g (34%) of material; m.p.124-126°C; HPLC showed an isomer ratio (1-/V- benzyl : 2-Λ/-benzyl) of 96:4; δH (CDCI3) 5.58 (2H,s,CH2), 7.12-7.15(2H) & 7.22- 7.29(3H)-(phenyl), 7.33 (1H,dt, J=1 Hz & 9Hz, H-7), 8.15(1H,dd, J=2Hz & 9Hz,H-6), 8.19(1 H,d,J=1 Hz,H-3), 8.67 (1 H,dd,J=1 Hz & 2Hz, H-4).
Also note the published method in FR 5600, 8 January 1968.
5-Amino-1-/V-benzyl-1 H-indazole 1-Benzyl-5-nitroindazole (400g) was suspended in ethanol (5 litre) and hydrogenated in the presence of 5% platinum on carbon catalyst (20g) operating at 1 bar pressure and 50-60°C. When hydrogen uptake was complete the reactor contents were heated to 70°C, discharged and filtered while still hot and the filtrate concentrated to ~4 litre which caused some crystallisation. Water (4 litre) was then gradually added with stirring and the mixture was stirred at 5°C overnight. The resultant crystals were filtered off and air-dried at ambient temperature to give 305g (86%) of material, m.p.150-152°C; HPLC (Supelcosil ABZ +, gradient 0.05% trifluoroacetic acid in water/0.05% trifluoroacetic acid in acetonitrile, 1.5ml/min, 220nm) showed <1% of the corresponding 2-Λ/-isomer (RT-1Λ/ 6.03min, RT-2Λ/ 5.29min); δH (CDCI3) 3.3-3.8(2H,broad s,NH2), 5.47
(2H,s,CH2), 6.74 (1H,dd,J=2Hz & 9Hz,H-6), 6.87 (1H,dd,J=1Hz & 2Hz,H-4), 7.06- 7.11(3H) & 7.17-7.25 (3H)-(phenyl & H-7), 7.77 (1 H,d,J=1Hz,H-3).
Also note the published method in FR 5600, 8 January 1968.
1 -Benzyl-3-methyl-5-nitro-1 H-indazole
2-Fluoro-5-nitroacetophenone (H. Sato et al, Bioorganic and Medicinal Chemistry Letters, 5(3), 233-236, 1995) (0.24g) was treated with triethylamine (0.73ml)and benzyl hydrazine dihydrochloride (0.255g) in ethanol (20ml) at reflux under N2 for 8 days. The mixture was cooled and the solid 1-benzyl-3-methyl-5-nitroindazole (0.16g) was collected by filtration; m/z (M+1)+ 268.
1 -Benzyl-3-methyl-1 H-indazol-5-ylamine 1-Benzyl-3-methyl-5-nitroindazole (0.15g) in THF (15ml) was treated with platinum on carbon (0.05g, 5%) under an atmosphere of hydrogen at room temperature. When hydrogen uptake was complete, the mixture was filtered and concentrated in vacuo to give the title compound; m/z (M+1)+ 268.
Further amino-indazole intermediates
The relevant nitro-substituted 1 H-indazole was treated with a base such as potassium carbonate or sodium hydroxide in a suitable solvent, such as acetone or acetonitrile. The appropriate aryl halide or heteroaryl halide was added and the reaction mixture heated or stirred at room temperature overnight. Subsequent concentration in vacuo and chromatography on silica gave the desired 1 -substituted nitro-1 H-indazoles. Hydrogenation was carried out by analogy with the preparation of 5-amino-1 -benzyl-1 H-indole described above.
Amines prepared by such methods include:- 5-Amino-1 -benzyl-1 H-indazole; m/z (M+1)+ 224
5-Amino-1-(2-fluorobenzyl)-1 H-indazole; m/z (M+1)+ 242
5-Amino-1-(3-fluorobenzyl)-1 H-indazole; m/z (M+1)+ 242
5-Amino-1-(4-fluorobenzyl)-1 H-indazole; m/z (M+1)+ 242
5-Amino-1-(2-pyridylmethyl)-1 H-indazole; m/z (M+1)+ 225 5-Amino-1-(3-pyridylmethyl)-1 H-indazole; m/z (M+1)+ 225
5-Amino-1-(4-pyridylmethyl)-1 H-indazole; m/z (M+1)+ 225
5-Amino-1-(2,3-difluorobenzyl)-1 H-indazole; m/z (M+1)+ 260
5-Amino-1-(3,5-difluorobenzyl)-1 H-indazole; m/z (M+1)+ 260.
1-Benzenesulphonylindol-5-yl-amine was prepared according to the published method (J. Org. Chem., 55, 1379-90, (1990)).
4-Benzyloxyaniline is commercially available as the hydrochloride salt; this is treated with aqueous sodium carbonate solution, and the mixture extracted with ethyl acetate; the organic solution is dried (MgSO4) and concentrated to give the free base as a brown solid, used without further purification.
Other substituted anilines were in general prepared by analogous methods to those outlined in WO 96/09294 and/or as follows:
Step 1 : Preparation of the precursor nitro-compounds 4-Nitrophenol (or an appropriate substituted analogue, such as 3-chloro-4- nitrophenol) was treated with a base such as potassium carbonate or sodium hydroxide in an appropriate solvent, such as acetone or acetonitrile. The appropriate aryl or heteroaryl halide was added and the reaction mixture heated or stirred at room temperature overnight.
Purification A: Most of the acetonitrile was removed in vacuo, and the residue was partitioned between water and dichloromethane. The aqueous layer was extracted with further dichloromethane (x 2), and the combined dichloromethane layers were concentrated in vacuo.
Purification B: removal of insoluble material by filtration, followed by concentration of the reaction mixture in vacuo, and chromatography on silica.
Step 2: Reduction to the corresponding aniline
The precursor nitro compound was reduced by catalytic hydrogenation at atmospheric pressure using 5% Pt/carbon, in a suitable solvent (eg ethanol, THF, or mixtures thereof to promote solubility). When reduction was complete, the mixture was filtered through Harborlite™, washing with excess solvent, and the resulting solution concentrated in vacuo to give the desired aniline. In some cases, the anilines were acidified with HCI (e.g. in a solution in dioxane) to give the corresponding hydrochloride salt.
Anilines prepared by such methods include:
4-(2-Fluorobenzyloxy)aniline; m/z (M+1)+ 218
4-(3-Fluorobenzyloxy)aniline; m/z (M+1)+ 218
4-(4-Fluorobenzyloxy)aniline; m/z (M+1)+ 218 3-Chloro-4-(2-fluorobenzyloxy)aniline; m/z (M+1)+ 252 3-Chloro-4-(3-fluorobenzyloxy)aniline; m/z (M+1)+ 252 3-Chloro-4-(4-fluorobenzyloxy)aniline; m/z (M+1)+ 252 4-Benzyloxy-3-chloroaniline; m/z (M+1)+ 234 and, in appropriate cases, their hydrochloride salts.
4-Benzenesulphonylaniline was prepared by the published method (Helv. Chim. Acta., 1983, 66(4), p1046.
4-Benzyloxy-3-trifluoromethyl-nitrobenzene 60% NaH dispersion (1.4g, 33.5 mmol) in mineral oil was washed with hexanes and then suspended in DMF (10 ml). To this NaH suspension in DMF, added benzyl alcohol (2.8 ml, 26.3 mmol) with water bath to keep the temperature below 30 °C. The reaction mixture was stirred until the evolution of the hydrogen gas ceased. To a solution of 2-fluoro-5-nitrobenzotrifluoride (5.0g, 23.9 mmol) in DMF (20 ml) was added the benzyl alkoxide solution slowly at 0 °C. Upon the completion of the addition, the ice bath was removed and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into 200ml ice water, stirred until the yellow solid was formed. Filtered and the solid was washed with water and then trituated with pentane. 5.9 g yellow solid was collected ( yield: 83%). ESI-MS m/z 298 (M+H)+
4-Benzyloxy-3-trifluoromethyl-aniline
Raney Ni suspension (about 200 mg Ni) was stirred with methanol. The supernate was decanted. This was repeated twice and then fresh methanol was added. To this suspension of Ni in methanol, was added 2-O-benzyl-5-nitrotrifluoride (375 mg, 1.26 mmol). With the water bath to keep the temperature below 30 °C, the hydrazine hydrate (189 mg, 3.79 mmol) was slowly added. Upon the completion of addition, the reaction mixture was stirred at room temperature for 10 minutes and then 45 °C until evolution of nitrogen gas ceased. Filtered through Celite® and the filtrate was concentrated under reduced pressure. 336mg thick yellow syrup was obtained (yield: 100%). ESI-MS m/z 268 (M+H)+ .
4-(Tributylstannyl)thiazole-2-carbaldehyde
4-Bromo-2-(tributylstannyl)thiazole (T.R. Kelly and F. Lang, Tetrahedron Lett., 36, 9293, (1995)) (15.0g) was dissolved in THF (150ml) under a nitrogen atmosphere, cooled to -85°C and treated with f-BuLi (1.7M, in pentane, 43ml). The mixture was stirred at -85°C for 30min, and then Λ/-formylmorpholine (8.4g) was added by syringe. After further stirring at -85°C for 10min the mixture was allowed to warm to room temperature. Water (200ml) was added and the mixture was extracted with diethyl ether (4 x 100ml). The combined ethereal extracts were washed with water, dried (NaS04), and concentrated in vacuo. Chromatography on silica, eluting with 10%ether//-hexane, gave the title compound as a yellow oil; δH [2H6JDMSO 10.03
(1H,s), 8.29 (1H,s), 1.55(6H,q), 1.21-1.37 (6H,m), 1.09-1.20 (6H,m), 0.85 (9H,t).
(1-Benzyl-1 H-indazol-5-yl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)-amine hydrochloride
Prepared according to Procedure A from 1 -benzyl-1 H-indazol-5-ylamine and 4,6- dichloropyrido[3,4-d]pyrimidine; δH [2H6J-DMSO 9.08 (1 H,s), 8.92 (1 H,s), 8.82 (1 H,s), 8.23 (1 H,d), 8.19 (1 H,s), 7.80 (1 H,d), 7.70 (1H,dd), 7.38-7.22 (5H,m), 5.69 (2H,s); m/z (M + 1)+ 387.
(1 -Benzyl-1 H-indazol-5-yl)-(6-(5-[1 ,3-dioxolan-2-yl]-furan-2-yl)-pyrido[3,4-d]- pyrimidin-4-yl)-amine
(1 -Benzyl-1 H-indazol-5-yl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)-amine (4.28g), 2- (tributylstannyl)-5-(1 ,3-dioxolan-2-yl)-furan (J. Chem Soc, Chem. Commun., (1988), p560) (10g) and 1 ,4-bis(diphenylphosphino)butane palladium (II) chloride (1g) were heated at reflux in dioxane (150ml) for 24 hr (Procedure B). The solvent was removed in vacuo and the residue chromatographed on silica. Subsequent trituration gave the title compound as a yellow solid; δH [2Hβ] -DMSO 10.46 (1 H, s),
9.17 (1 H, s), 8.74 (1H, s), 8.52 (1H, s), 8.23 (1 H, s), 8.18 (1 H, s), 7.80-7.68 (2H, m), 7.41-7.22 (5H, m), 7.17 (1H, d), 6.80 (1 H, d), 6.06 (1H, s), 5.71 (2H, s), 4.20-3.96 (4H, m).
5-(4-(1-Benzyl-1 H-indazol-5-ylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2- carbaldehyde
(1 -Benzyl-1 H-indazol-5-yl)-(6-(5-[1 ,3-dioxolanyl]-furan-2-yl)-pyrido[3,4-d]pyrimidin-4- yl)-amine (3.03g) and 2N HCI (50ml) were stirred in THF (50ml) for 16 hr. The resulting precipitate was filtered and washed with water to give the hydrochloride salt of the product; δH [2H6]DMSO 11.70 (1H,s), 9.74 (1 H,s) 9.30 (1H,s), 9.27 (1 H,s), 8.85 (1H,s), 8.23 (1H,s), 8.18 (1H,s), 7.68-7.87 (3H,m), 7.55 (1H,d), 7.22-7.38 (5H,m), 5.71 (2H,s). Subsequent neutralisation with triethylamine in ethanol/water gave the title compound; δH [2H6] -DMSO 9.64(1 H,s), 9.19 (1H,s), 9.09(1H,s), 8.72(1 H,s), 8.12(2H,m), 7.71(2H,m), 7.63(1 H,dd), 7.43(1 H,d), 7.20(5H,m), 5.62(2H,s).
(4-Benzyloxyphenyl)-(6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine Prepared according to Procedure A from 4-benzyloxyaniline and 4,6-dichloro- pyrido[3,4-d]pyrimidine; δH (CDCI3) 9.11 (1 H,s), 8.78 (1 H,s), 7.75 (1 H,d), 7.56 (2H,dd), 7.40 (5H,m), 7.15 (2H,d), 5.10 (2H,s); m/z (M + 1)+ 409.
5-(4-(4-Benzyloxy-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2-carbaldehyde (4-Benzyloxyphenyl)-(6-chloro-pyrido[3,4-c |pyrimidin-4-yl)-amine (4.0g, H .Ommol), 5-(1 ,3-dioxolan-2-yl)-2-(tributylstannyl)furan ( J. Chem. Soc, Chem. Commun., (1988), 560) (6.0g, 14.0mmol) were reacted together in a procedure analogous to Procedure B above for 20hrs. The reaction mixture was allowed to cool, 1 N HCI (50ml) added and stirred at room temperature for 15 minutes. The reaction was filtered and the residue washed with dioxane (20ml) and 2N HCI (20ml). The combined filtrate and washings were stirred at room temperature for a further hour. The dioxane was removed under vacuum, the reaction diluted with water and the solid which precipitated was collected by filtration, and washed with water, iso- hexane and acetone. This precipitate was converted to the free base by partitioning into a mixture of triethylamine, ethyl acetate and water. The organic phase was washed with water, dried (magnesium sulphate) and the solvent removed under vacuum. The residue was triturated with iso-hexane/ethyl acetate to give the product (2.41 g, 52%) as a yellow solid; δH [2H6] -DMSO 10.60 (1H, b, NH), 9.83
(1H, s, CHO), 9.30 (1 H, s, 2-H), 9.08 (1 H, s, 5-H or 8-H), 8.76 (1H, s, 5-H or 8-H), 7.89 (1 H, d, furan-H), 7.82 (2H, d, 2'-H, 6'-H), 7.65-7.42 (6H, m, 5x Ph-H, furan-H), 7.21 (2H, d, 3'-H, 5'-H), 5.26 (2H, s, OCH2); m/z (M + 1)+ 423.
(4-Benzyloxyphenyl)-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-pyrido[3,4-c/]pyrimidin-4-yl)- amine Reaction of (4-benzyloxyphenyl)-(6-chloro-pyrido[3,4-d]pyrimidin-4-yl)amine (5.44g, 15.0mmol), 5-(1 ,3-dioxolan-2-yl)-2-(tributylstannyl)furan (10.4g, 24.2mmol) and bis(triphenylphosphine)palladium (II) chloride (catalytic amount) in dioxane (150ml) according to Procedure B, followed by purification by silica gel chromatography (eluted with 50-100% EtOAc//-hexane), allowed the isolation of the dioxolane product (3.45g, 7.40mmol, 49%); δH [2H6JDMSO 10.28 (1 H,s), 9.13 (1H,s), 8.69 (1 H,s), 8.61 (1 H,s), 7.71 (2H,d), 7.31-7.52 (5H,m), 7.14 (1H,d), 7.09 (2H,d), 6.77 (1 H,d), 6.03 (1 H,s), 5.15 (2H,s), 3.95-4.19 (4H,m). This could then be converted to 5-(4-(4-Benzyloxy-phenylamino)-pyrido[3,4- d]pyrimidin-6-yl)-furan-2-carbaldehyde (identical to that described above) using Procedure C.
(4-Phenoxyphenyl)-(7-iodoquinolin-4-yl)amine
4-Chloro-7-iodoquinoline (10g, 34mmol) [Semenov, V. P.; Studenikov, A. N.
Synthesis of 7-iodo-4-aminoquinoline derivatives. Khim. Geterotsikl. Soedin. (1980), Issue 7, 972-5] and 4-phenoxyaniline (6.38g, 34mmol) in butanol (75ml) were heated at gentle reflux (120°C) overnight (18 hrs). On cooling the resultant precipitate was collected by filtration and washed with acetonitrile (2x50ml). The resultant solid was suspended in chloroform (500ml) and 2N sodium carbonate solution (300ml) and heated at 75°C for 45 mins. On cooling the resultant precipitate was collected by filtration, washed with water (2x50ml) and dried to yield the product as a pale brown solid. (9.95g, 66%) δH [2H6] DMSO 8.35(3H,m), 8.20(1 H,s), 8.10(1 H,d), 7.85(1 H,s),
7.35(4H,m), 7.15(4H,d), 6.75(1H,d).
(4-Benzyloxyphenyl)-(6-bromoquinazolin-4-yl)-amine hydrochloride 4-Chloro-6-bromoquinazoline (0.25g, I .Ommol) and 4-benzyloxyaniline (0.25g, 1.3mmol) were mixed in 2-propanol (6ml) and heated at reflux for 10 mins (Procedure A). The solution was allowed to cool at room temperature and the 2- propanol removed in vacuo. The resulting solid was triturated with acetone to give the product as a yellow solid (0.39g, 88%); δH [2H6]-DMSO 11.60 (1 H, b, NH), 9.21 (1 H, s, 5-H), 8.86 (1 H, s, 2-H), 8.20 (1 H, d, 7-H), 7.90 (1 H, d, 8-H), 7.65 (2H, d, 2'-H, 6'-H), 7.50-7.25 (5H, m, Ph-H), 7.10 (2H, d, 3'-H, 5'-H), 5.15 (2H, s, CH2); m/z 405/407 (M+).
(4-Benzyloxyphenyl)-(6-iodoquinazolin-4-yl)-amine hydrochloride 4-Chloro-6-iodoquinazoline (8g) was treated with 4-benzyloxyaniline (5.5g) in acetonitrile (500ml) at reflux under N2 for 18 hours. Subsequent cooling and filtration gave the title compound (13.13g); δH [2H6]-DMSO 11.45 (1 H, b, NH), 9.22 (1H, s, 5-H), 8.89 (1H, s, 2-H), 8.36 (1H, d, 7-H), 7.69 (1H, d, 8-H), 7.63 (2H, d, 2'-H, 6'-H), 7.52-7.29 (5H, m, Ph-H), 7.14 (2H, d, 3'-H, 5'-H), 5.18 (2H, s, CH2); m/z (M+1)+ 454. (4-Benzyloxyphenyl)-(6-iodo-7-fluoro-quinazolin-4-yl)-amine hydrochloride Prepared according to Procedure A from 4-chloro-6-iodo-7-fluoro-quinazoline hydrochloride (4.02 grams, 11.65 mmoles), anhydrous dioxane (70 ml), dichloromethane (20 ml) and 4-benzyloxyaniline hydrochloride (2.83 grams, 12 mmoles). The mixture was stirred and heated to 110°C (oil bath temperature) for 16 hours. The mixture was cooled to room temperature and filtered to remove the precipitated solids. The solids were washed with cold anhydrous dioxane (100 ml) followed by cold anhydrous diethyl ether. The yellowish solid was collected and dried under vacuum at room temperature to yield 4.68 grams (79%) of the title compound. δH (400 MHz, DMSO-d6): 11.2(s, 1 H), 9.3(d, 1 H), 8.79(s, 1 H), 7.64(d, 1 H), 7.58(d, 2H), 7.44(d, 2H), 7.38(m, 2H), 7.31(m, 1 H), 7.09(d, 2H), 5.14(s, 2H) ESI-MS m/z 472(M+1).
(1 -Benzyl-1 H-indazol-5-yl)-(6-iodo-7-fluoro-quinazolin-4-yl)-amine hydrochloride Prepared according to Procedure A from 1 -benzyl-1 H-indazol-5-ylamine and 4- chloro-6-iodo-7-fluoroquinazoline. δH (400 MHz, DMSO-d6): 11.55(s, 1 H), 9.41 (d, 1H), 8.8(s, 1 H), 8.18(s, 1 H), 8.05(d, 1 H), 7.78(d, 1H), 7.69(d, 1H), 7.61(m, 1 H), 7.29(m, 2H), 7.23(m, 3H), 5.67(s, 2H). ESI-MS m/z 496(M+1).
(4-Benzenesulphonyl)phenyl-(6-iodo-7-fluoro-quinazolin-4-yl)-amine hydrochloride
Prepared according to Procedure A from 4-(benzenesulphonyl)phenylamine and
4-chloro-6-iodo-7-fluoroquinazoline. 1H NMR (400 MHz, DMSO-d6) δ: 10.89(s, 1H), 9.3(d, 1H), 8.79(s, 1 H), 8.07(d, 2H), 8.0(d, 2H), 7.94(d, 2H), 7.67(m, 2H), 7.61 (m, 2H). ESI-MS m/z 504(M-1).
6-lodo-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-quinazolin-4yl)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-3- chlorophenyl)amine and 4-chloro-6-iodo-quinazoline. 1H NMR (DMSO-d6) 9.83 (s, 1H); 8.92 (s, 1H); 8.58 (s, 1H); 8.09 (d, 1H); 8.00 (d, 1 H); 7.61 (d, 1 H); 7.52 (d, 1 H); 7.44 (m, 1H); 7.20-7.33 (m, 3H); 7.15 (m, 1H); 5.21 (s, 2H); MS m/z 506 (M+1).
6-lodo-(4-(3-fluorobenzyloxy)-3-fluorophenyl)-quinazolin-4yl)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-3- fluorophenyl)amine and 4-chloro-6-iodo-quinazoline. 1H NMR (DMSO-d6) 9.83 (s, 1H); 8.92 (s, 1H); 8.57 (s, 1H); 8.08 (d, 1H); 7.85 (d, 1H); 7.53 (d, 1H); 7.50 (d, 1H); 7.43 (m, 1H); 7.30-7.20 (m, 3H); 7.15 (m, 1H); 5.20 (s, 2H); MS m/z 490 (M+1).
6-lodo-(4-(3-fluorobenzyloxy)-3-methoxyphenyl)-quinazolin-4yl)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-3- methoxyphenyl)amine and 4-chloro-6-iodo-quinazoline. 1H NMR 400 MHz (DMSO- d6) 11.29 (bs, 1H0; 9.14 (s,1 H); 8.87 (s,1 H); 8.32 (d,1H); 7.62 (d,1 H); 7.42 (m,1 H); 7.34 (d,1 H); 7.29-7.22 (m,3H); 7.18-7.08 (m,2H); 5.15 (s,2H); 3.80 (s,3H); MS m/z 502 (M+1)
6-lodo-(4-benzyloxy-3-fluorophenyl)-quinazolin-4-yl)amine
Prepared according to Procedure A from 4-benzyloxy)-3-fluorophenylamine and 4- chloro-6-iodo-quinazoline. 1H NMR (DMSO-d6) 9.82 (s, 1H); 8.93 (s, 1H); 8.57 (s, 1H); 8.09 (d, 1H); 7.84 (d, 1H); 7.51 (m, 2H); 7.44 (d, 2H); 7.37 (m, 2H); 7.33 (m, 1 H); 7.24 (m, 1H); 5.18 (s, 2H); MS m/z 472 (M+1)
6-lodo-(4-(3-bromobenzyloxy)-phenyl)-quinazolin-4-yl)amine Prepared according to Procedure A from (4-(3-bromobenzyloxy)-phenyl)amine and 4-chloro-6-iodo-quinazoline. 1H NMR (DMSO-d6) 9.84 (s, 1 H); 8.98 (s, 1H); 8.57 (s, 1H); 8.13 (m, 2H); 7.71 (d, 2H); 7.56 (d, 2H); 7.50 (m, 1 H); 7.41 (m, 1 H); 7.08 (d, 2H); 5.17 (s, 2H).
6-lodo-(4-(3-fluorobenzyloxy)-phenyl)-quinazolin-4-yl)amine
Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-phenyl)amine and 4- chloro-6-iodo-quinazoline. H NMR (DMSO-d6) 9.77 (s, 1H); 8.92 (s, 1H); 8.50 (s, 1H); 8.06 (d, 1H); 7.66 (d, 2H); 7.50 (d, 1H); 7.42 (m, 1 H); 7.30-7.25 (m, 2H); 7.14 (m, 1H); 7.03 (d, 2H); 5.13 (s, 2H); MS m/z 472 (M+1)
6-lodo-(4-(3-trifluoromethylbenzyloxy)-phenyl)-quinazolin-4-yl)amine Prepared according to Procedure A from (4-(3-trifluoromethylbenzyloxy)- phenyl)amine and 4-chloro-6-iodo-quinazoline. Η NMR (DMSO-d6) 9.2 (bs, 1 H); 8.91 (s, 1H); 8.37 (d, 1 H); 7.89-7.72 (m, 8H); 7.19 (d, 2H); 5.30 (s, 2H). 6-lodo-(4-benzyloxy-3-trifluoromethyl-phenyl)-quinazolin-4-yl)amine The mixture of 4-chloro-6-iodo-quinazoline (366mg, 1.26 mmol) and 4-0-benzyl-3- trifluoroaniline (405mg, 1.26 mmol) in isopropanol (12ml) was heated to reflux for 3.5 hours. Filtered, washed with isopropanol and dried. 535mg yellow solid was afforded, (yield: 76%). ESI-MS m/z 522 (M+H)+.
(4-Benzyloxyphenyl)-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-7-fluoro-quinazolin-4-yl)- amine
Synthesized according to Procedure B from a solution of (4-benzyloxyphenyl)-(6- iodo-7-fluoro-quinazolin-4-yl)-amine hydrochloride (508 mg, 1 mmole), 5-(1 ,3- dioxolan-2-yl)-2-(tributylstannyl)furan (645 mg, 1.5 mmole), diisopropylethyl amine (650 mg, 5 mmole), and dichlorobis(triphenylphosphine) palladium (140 mg, 0.2 mmole) in 6 ml of DMF under nitrogen was stirred at 100°C (oil bath temperature) for 4 hours. The cooled reaction mixture was extracted with water (100 ml) and ethyl acetate (100 ml). The organic phase was washed with brine (100 ml). The aqueous layers were combined and washed with additional ethyl acetate (100 ml). The organic layers were combined, dried with MgSO4, filtered and concentrated to a residue. The residue was chromatographed on silica gel with a methanol-chloroform mixture. Fractions were collected, combined, and concentrated. The resultant solid was suspended in dichloromethane (10 ml) and diethyl ether was added facilitate precipitation. The solid was filtered and dried under vacuum at room temperature to yield a yellowish solid 287 mg (59%). 1H NMR (400 MHz, DMSO-d6) δ: 10.1(s, 1H), 8.85(d, 1 H), 8.45(s, 1 H), 7.6(m, 3H), 7.44(d, 2H), 7.38(m, 2H), 7.31(m, 1H), 7.03(m, 2H), 6.94(m, 1 H), 6.74(d, 1H), 6.01(s, 1H), 5.1(s, 2H), 4.10(m, 2H), 3.96(m, 2H). ESI-MS m/z 482(M-1).
(1 -Benzyl-1 H-indazol-5-yl)-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-7-fluoro- quinazolin-4-yl)-amine Prepared according to Procedure B from (1 -benzyl-1 H-indazol-5-yl)-(6-iodo-7- fluoro-quinazolin-4-yl)-amine hydrochloride and 5-(1 ,3-dioxolan-2-yl)-2- (tributylstannyl)furan. δ Η NMR (400 MHz, DMSO-d6) δ 10.27(s, 1 H), 8.89(d, 1H), 8.46(s, 1H), 8.1(d, 2H), 7.69(d, 1H), 7.61(m, 2H), 7.26(m, 5H), 6.96(m, 1H), 6.74(d, 1H), 6.01 (s, 1H), 5.65(s, 2H), 4.09(m, 2H), 3.96(m, 2H). ESI-MS m/z 506(M-1). (4-Benzenesulphonyl)phenyl-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-7-fluoro- quinazolin-4-yl)-amine
Prepared according to Procedure B from (4-benzenesulphonyl)phenyl-(6-iodo-7- fluoro-quinazolin-4-yl)-amine hydrochloride and 5-(1 ,3-dioxolan-2-yl)-2-
(tributylstannyl)furan. δ1H NMR (400 MHz, DMSO-d6) 10.49(s, 1 H), 8.88(d, 1 H), 8.63(s, 1H), 8.1 (d, 2H), 7.95(m, 4H), 7.65(m, 4H), 6.97(m, 1H), 6.75(d, 1 H), 6.01(s, 1H), 4.09(m, 2H), 3.97(m, 2H). ESI-MS m/z 516(M-1).
(4-Benzyloxyphenyl)-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-quinazolin-4-yl)-amine Prepared according to Procedure B from (4-benzyloxy-phenyl)-(6- bromoquinazolin-4-yl)-amine (1.5g, 3.7mmol) and 5-(1 ,3-dioxolan-2-yl)-2- (tributylstannyl)-furan (1.9g, 4.42mmol) dissolved in dioxan (30ml) and heated at reflux under nitrogen for 6 hr. The solvent was removed from the cooled reaction under vacuum, and the residual oil was triturated with iso-hexane/ethyl acetate to give the product (1.07g, 62%) as a pale yellow solid; δH [2H6]-DMSO 9.96 (1 H, b, NH), 8.80 (1H, s, 5-H), 8.51 (1H, s, 2-H), 8.18 (1H, d, 7-H), 7.80 (1H, d, 8-H), 7.70 (2H, d, 2'-H, 6'-H), 7.58-7.30 (5H, m, 5 x Ph-H), 7.10 (3H, m, 3'-H, 5'-H, furan 3-H), 6.78 (1H, d, furan 4-H), 6.12 (1H, s, CH02), 5.18 (2H, s, PhCH2), 4.22- 3.94 (4H, m, 2 x CH2); m/z 466 (M+1 )+.
(4-Benzyloxy-3-trifluoromethylphenyl)-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)- quinazolin-4-yl)-amine
Prepared according to Procedure B using 6-lodo-(4-benzyloxy-3-trifluoromethyl- phenyl)-quinazolin-4-yl)amine (480 mg, 0.92 mmol), and 5-tributyltin-(1 ,3-dioxolan-2- yl)-furan (731 mg, 1.38 mmol) in dioxane (10ml). The resulting product was a yellow solid (0.47 g, 95.8% yield). ESI-MS m/z 534 (M+H)+ .
5-(4-(4-Benzyloxy-3-trifluoromethylphenylamino)-quinazolin-6-yl)-furan-2- carbaldehyde
Prepared according to Procedure C using (4-Benzyloxy-3-trifiuoromethylphenyl)-(6- (5-(1,3-dioxolan-2-yl)-furan-2-yl)-quinazolin-4-yl)-amine (470mg, 0.88 mmol) solution in THF ( 5 ml) followed by the addition of 2N HCI (20ml) at room temperature. The resulting mixture was stirred for 30 minutes. Water was added (15ml) then filtered. The yellow solid was washed with water and small amount of ether and dried in vacuo (0.39 g, 84% yield). ESI-MS m/z 490 (M+H)+.
(4-Benzyloxyphenyl)-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-7-methoxy-quinazolin-4- yl)-amine
Prepared according to Procedure B from a solution of (4-benzyloxyphenyl)-7- methoxy-6-trifluoromethanesulphonyl-quinazolin-4-yI)-amine (0.30 g, 0.59 mmol), 5-(1 ,3-dioxolan-2-yl)-2-(tributylstannyl)furan (0.37 g, 0.86mmol), lithium chloride (78 mg, 1.8 mmol), and dichloro-bis(triphenylphosphine)palladium (90 mg, 0.13 mmol) in 2 ml of DMF under nitrogen was stirred at 85-90° C for 50 minutes. The cooled reaction mixture was partitioned between 30 ml of water and 40 ml of ethyl acetate. The organic solution was washed with 30 ml of brine, dried with Na2SO4 and concentrated in vacuo. The residue was chromatographed on silica gel with hexanes/ethyl acetate (1 :1 to 0:1). The resulting solution was concentrated to near dryness and the resulting solid suspended in ether and filtered to give 0.232 g of product as a pale yellow solid. 1H NMR (400 MHz, DMSO-d6) δ: 9.90(s, 1 H), 8.71 (s, 1 H), 8.40(s, 1 H), 7.60(d, 2H), 7.44(d, 2H), 7.37(t, 2H), 7.30(t, 1H), 7.24(s, 1 H), 7.00(m, 3H), 6.67(d, 1 H), 5.99(s, 1H), 5.09(s, 2H), 4.10(m, 2H), 4.02(s, 3H), 3.95(m, 2H). ESI-MS m/z 496(M+1).
(4-Benzyloxyphenyl)-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-7-fluoro-quinazolin-4-yl)- amine
Prepared according to Procedure B from a solution of (4-benzyloxyphenyl)-(6- iodo-7-fluoro-quinazolin-4-yl)-amine hydrochloride (508 mg, 1 mmole), 5-(1 ,3- dioxolan-2-yl)-2-(tributylstannyl)furan (645 mg, 1.5 mmole), diisopropylethyl amine (650 mg, 5 mmole), and dichlorobis(triphenylphosphine) palladium (140 mg, 0.2 mmole) in 6 ml of DMF under nitrogen was stirred at 100°C (oil bath temperature) for 4 hours. The cooled reaction mixture was extracted with water (100 ml) and ethyl acetate (100 ml). The organic phase was washed with brine (100 ml). The aqueous layers were combined and washed with additional ethyl acetate (100 ml). The organic layers were combined, dried with MgSO4, filtered and concentrated to a residue. The residue was chromatographed on silica gel with a methanol-chloroform mixture. Fractions were collected, combined, and concentrated. The resultant solid was suspended in dichloromethane (10 ml) and diethyl ether was added to facilitate precipitation. The solid was filtered and dried under vacuum at room temperature to yield a yellow solid 287 mg (59%). 1H NMR (400 MHz, DMSO-d6) δ: 10.1 (s, 1H), 8.85 (d, 1 H), 8.45 (s, 1 H), 7.6 (m, 3H), 7.44 (d, 2H), 7.38 (m, 2H), 7.31 (m, 1H), 7.03 (m, 2H), 6.94 (m, 1H), 6.74 (d, 1H), 6.01 (s, 1H), 5.1 (s, 2H), 4.10 (m, 2H), 3.96 (m, 2H). ESI-MS m/z 482(M-1).
(4-Benzyloxyphenyl)-(6-iodo-7-fluoro-quinazolin-4-yl)-amine hydrochloride Prepared according to Procedure A from 4-chloro-6-iodo-7-fluoro-quinazoline hydrochloride (4.02 grams, 11.65 mmoles), anhydrous dioxane (70 ml), dichloromethane (20 ml), and 4-benzyloxyaniline hydrochloride (2.83 grams, 12 mmoles). The mixture was stirred and heated to 110°C (oil bath temperature) for 16 hours, cooled to room temperature and filtered to remove the precipitated solids. The solids were washed with cold anhydrous dioxane (100 ml) followed by cold anhydrous diethyl ether. The yellowish solid was collected and dried under vacuum at room temperature to yield 4.68 grams (79%) of the title compound. δH NMR (400 MHz, DMSO-d6): 11.2(s, 1 H), 9.3(d, 1 H), 8.79(s, 1 H), 7.64(d, 1H), 7.58(d, 2H), 7.44(d, 2H), 7.38(m, 2H), 7.31 (m, 1H), 7.09(d, 2H), 5.14(s, 2H) ESI-MS m/z 472(M+1).
(1 -Benzyl-1 H-indazol-5-yl)-(6-iodo-7-fluoro-quinazolin-4-yl)-amine hydrochloride Prepared according to Procedure A from 1 -benzyl-1 H-indazol-5-ylamine and 4- chloro-6-iodo-7-fluoroquinazoline. δH NMR (400 MHz, DMSO-d6): 11.55(s, 1 H), 9.41(d, 1H), 8.8(s, 1H), 8.18(s, 1 H), 8.05(d, 1 H), 7.78(d, 1H), 7.69(d, 1H), 7.61 (m, 1H), 7.29(m, 2H), 7.23(m, 3H), 5.67(s, 2H). ESI-MS m/z 496(M+1).
(4-Benzenesulphonyl)phenyl-(6-iodo-7-fluoro-quinazolin-4-yl)-amine hydrochloride
Prepared according to Procedure A from 4-benzenesulphonyl)phenylamine and 4-chloro-6-iodo-7-fluoroquinazoline. δHNMR (400 MHz, DMSO-d6) δ: 10.89(s, 1H), 9.3(d, 1H), 8.79(s, 1 H), 8.07(d, 2H), 8.0(d, 2H), 7.94(d, 2H), 7.67(m, 2H), 7.61 (m, 2H). ESI-MS m/z 504(M-1 ).
6-lodo-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-quinazolin-4yl)amine
Prepared according to Procedure A from 4-(3-fluorobenzyloxy)-3-chlorophenyl)- amine and 4-chloro-6-iodoquinazoline. Η NMR (DMSO-d6) 9.83 (s, 1 H); 8.92 (s, 1H); 8.58 (s, 1 H); 8.09 (d, 1 H); 8.00 (d, 1 H); 7.61 (d, 1 H); 7.52 (d, 1 H); 7.44 (m, 1 H); 7.20-7.33 (m, 3H); 7.15 (m, 1 H); 5.21 (s, 2H); MS m/z 506 (M+1)
6-lodo-(4-(3-fluorobenzyloxy)-3-fluorophenyl)-quinazolin-4yl)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-3-fluorophenyl)- amine and 4-chloro-6-iodoquinazoline. 1H NMR (DMSO-d6) 9.83 (s, 1 H); 8.92 (s, 1 H); 8.57 (s, 1 H); 8.08 (d, 1 H); 7.85 (d, 1 H); 7.53 (d, 1 H); 7.50 (d, 1 H); 7.43 (m, 1 H); 7.30-7.20 (m, 3H); 7.15 (m, 1 H); 5.20 (s, 2H); MS m/z 490 (M+1 )
6-lodo-(4-(3-fluorobenzyloxy)-3-methoxyphenyl)-quinazolin-4yl)amine
Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-3-fluorophenyl)- amine and 4-chloro-6-iodoquinazoline. 1H NMR 400 MHz (DMSO-d6) 11.29 (bs, 1 H0; 9.14 (s,1 H); 8.87 (s,1 H); 8.32 (d,1 H); 7.62 (d,1H); 7.42 (m,1 H); 7.34 (d,1 H); 7.29-7.22 (m,3H); 7.18-7.08 (m,2H); 5.15 (s,2H); 3.80 (s,3H); MS m/z 502 (M+1)
6-lodo-(4-benzyloxy-3-fluorophenyl)-quinazolin-4-yl)amine
Prepared according to Procedure A from (4-benzyloxy-3-fluorophenyl)-amine and 4- chloro-6-iodoquinazoline. 1H NMR (DMSO-d6) 9.82 (s, 1H); 8.93 (s, 1 H); 8.57 (s, 1H); 8.09 (d, 1H); 7.84 (d, 1H); 7.51 (m, 2H); 7.44 (d, 2H); 7.37 (m, 2H); 7.33 (m, 1H); 7.24 (m, 1 H); 5.18 (s, 2H), MS m/z 472 (M+1)
6-lodo-(4-(3-bromobenzyloxy)-phenyl)-quinazolin-4-yl)amine Prepared according to Procedure A from (4-(3-bromobenzyloxy)-phenyl)-amine and 4-chloro-6-iodoquinazoline. 1H NMR (DMSO-d6) 9.84 (s, 1 H); 8.98 (s, 1H); 8.57 (s, 1H); 8.13 (m, 2H); 7.71 (d, 2H); 7.56 (d, 2H); 7.50 (m, 1H); 7.41 (m, 1 H); 7.08 (d, 2H); 5.17 (s, 2H).
6-lodo-(4-(3-fluorobenzyloxy)-phenyl)-quinazolin-4-yl)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-phenyl)-amine and 4-chloro-6-iodoquinazoline. 1H NMR (DMSO-d6) 9.77 (s, 1 H); 8.92 (s, 1 H); 8.50 (s, 1H); 8.06 (d, 1 H); 7.66 (d, 2H); 7.50 (d, 1 H); 7.42 (m, 1H); 7.30-7.25 (m, 2H); 7.14 (m, 1H); 7.03 (d, 2H); 5.13 (s, 2H), MS m/z 472 (M+1)
6-lodo-(4-(3-trifluoromethylbenzyloxy)-phenyl)-quinazolin-4-yl)amine Prepared according to Procedure A from (4-(3-trifluoromethylbenzyloxy)-phenyl)- amine and 4-chloro-6-iodoquinazoline. 1H NMR (DMSO-d6) 9.2 (bs, 1 H); 8.91 (s, 1H); 8.37 (d, 1 H); 7.89-7.72 (m, 8H); 7.19 (d, 2H); 5.30 (s, 2H).
4-(4-(4-Phenoxyphenylamino)-quinolin-7-yl) thiazole-2-carbaldehyde
Prepared according to Procedure B from (4-phenoxyphenyl)-(7-iodoquinolin-4- yl)amine (2g, 4.56mmol), 4-(tributylstannyl)thiazole-2-carbaldehyde (1.84g,4.56mmol) and dichlorobis(triphenylphosphine)palladium (II) (0.74g, 20mol%) heated at reflux overnight (18hrs) in dioxane (50ml). The cooled solution was filtered through a plug of Celite®, concentrated and triturated with iso-hexane (3x20ml). The resultant solid was purified via flash column chromatography on silica gel, eluting with 5% methanol in chloroform. The purified product was isolated as a yellow solid (0.85g, 44%). δH [2H6] DMSO 10.10(1H,s), 9.30(1 ,bs), 8.90(1 Hs), 8.50(2H,s&d),
8.45(1 H,d), 8.20(1H,d), 7.40(5H,bm), 7.10(4H,2d), 6.80(1H,d).
5-(4-(4-Phenoxyphenylamino)-quinolin-7-yl) thiazole-4-carbaldehyde Prepared according to Procedure B from (4-phenoxyphenyl)-(7-iodoquinolin-4- yl)amine (0.876g,2mmol), 4-(1 ,3-dioxolan-2-yl)-5-tributylstannylthiazole (2.1 mmol), bis (triphenylphosphine) palladium (II) chloride (0.105g, 0.15mmol,7.5 mol %) and silver oxide (0.463g, 2mmol) heated under reflux under nitrogen for18 hr. The reaction mixture was then filtered through Harborlite ® and the filtrate was concentrated. The product was purified on Bond Elut™ cartridge, eluting sequentially with dichloromethane, chloroform, diethyl ether and ethyl acetate. The ketal (0.385g , 0.824 mmol) was stirred at room temperature in a mixture of THF (10ml) and 1 N HCI (10ml) for 2 hr. The suspension was basified with 2N NaOH (5ml) and the THF was removed. The aqueous suspension was filtered and washed with water to give the product as a yellow solid (0.346g);m/z 424.
5-(4-(4-Benzyloxy-phenylamino)-quinazolin-6-yl)-furan-2-carbaldehyde Prepared according to Procedure C from 4-(4-benzyloxy-phenylamino)-(6-(5- (1,3-dioxolan-2-yl)-furan-2-yl)-quinazolin-4-yl)-amine (1.0g, 2.1mmol). The precipitate which formed was collected by filtration and washed with acetone, then partitioned between ethyl acetate, triethylamine and water. The organic phase was washed with water, dried (magnesium sulphate) and the solvent was removed under vacuum. Trituration with iso-hexane/ethyl acetate gave the product as an orange solid (610mg, 69%); δH [2H6]-DMSO 10.05 (1 H, b, NH), 9.62 (1 H, s, CHO), 8.95 (1 H, s, 5-H), 8.48 (1 H, s, 2-H), 8.24 (1 H, d, 7-H), 7.80 (1H, d, 8-H), 7.70 (1 H, d, furan 4-H), 7.59 (2H, d, 2'-H, 6'-H), 7.48-7.25 (6H, m, 5 x Ph-H, furan 3-H), 7.02 (2H, m, 3'-H, 5'-H), 5.09 (2H, s, CH2); m/z 422 (M+1)+.
5-(4-(4-Benzyloxy-phenylamino)-7-methoxy-quinazolin-6-yl)-furan-2- carbaldehyde hydrochloride
Prepared according to Procedure C from (4-benzyloxyphenyl)-(6-(5-(1,3- dioxolan-2-yl)-furan-2-yl)-7-methoxy-pyrido[3,4-d]pyrimidin-4-yl)-amine(0.301 g, 0.60 mmol). After stirring 45 minutes, the resulting suspension was filtered and washed with ether to give 0.26 g of product as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ: 11.67(br s, 1H), 9.68(s, 1 H), 9.14(s, 1 H), 8.78(s, 1H), 7.73(d, 1 H), 7.52(d, 2H), 7.44(m, 3H), 7.39(m, 3H), 7.32(m, 1 H), 7.11 (d, 2H), 5.14(s, 2H), 4.12(s, 3H). ESI-MS m/z 452(M+1).
6-(5-(1 ,3-Dioxolan-2-yl)-furan-2-yl)-7-methoxy-quinazolin-4-yl-(4- benzenesulphonyl)phenyl-amine
Prepared according to Procedure B from 4-(4-benzenesulphonyl)phenyl-7- methoxy-quinazolin-4-yl-amine and 5-(1 ,3-dioxolan-2-yl)-2-(tributylstannyl)furan. δ1H NMR (400 MHz, DMSO-d6) 10.36(s, 1 H), 8.74(s, 1H), 8.58(s, 1 H), 8.10(d, 2H), 7.93(m, 4H), 7.62(m, 3H), 7.32(s, 1 H), 7.04(d, 1 H), 6.68(d, 1 H), 5.99(s, 1H), 4.09(m, 2H), 4.04(s, 3H), 3.95(m, 2H). ESI-MS m/z 530(M+1).
5-(4-(4-Phenoxyphenylamino)-quinolin-7-yl)furan-2-carbaldehyde (4-Phenoxyphenyl)-(7-(5-(1 ,3-dioxolan-2-yl)furan-2-yl)-quinolin-4-yl)amine (1.4g) was treated with 1M aqueous hydrochloric acid-tetrahydrofuran (60ml , 1:1) in accordance with procedure C. Addition of 1 M aqueous sodium hydroxide solution to pH 10 followed by extraction with ethyl acetate, drying (magnesium sulfate) and concentration to dryness afforded a yellow solid (1.2g) ; δH [2He] DMSO 9.70 (1 H, s), 9.10 (1H, s), 8.51 (2H, m), 8.35 (1H, s), 8.02 (1 H, d), 7.73 (1H, d), 7.57 (1 H, d), 7.42 (4H, m), 7.22-7.04 (5H, m), 6.88 (1H, d); m/z 407 (M+1)+.
5-(7-Methoxy-4-(4-benzenesulphonyl)phenylamino-quinazolin-6-yl)-furan-2- carbaldehyde hydrochloride Prepared according to Procedure C from 6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-7- methoxy-quinazolin-4-yl-(4-benzenesulphonyl)phenyl-amine . δ1H NMR (400 MHz, DMSO-d6) 11.54(br s, 1 H), 9.68(s, 1 H), 9.13(s, 1 H), 8.83(s, 1 H), 7.95- 8.06(m, 6H), 7.72(d, 1H), 7.68(m, 1 H), 7.62(m, 2H), 7.46(s, 1H), 7.39(d, 1 H), 4.12(s, 3H). ESI-MS m/z 486(M+1).
5-(4-(4-Benzyloxy-phenylamino)-7-fluoro-quinazolin-6-yl)-furan-2- carboxaldehyde hydrochloride
Prepared according to Procedure C from a stirred solution of (4- benzyloxyphenyl)-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-7-fluoro-quinazolin-4-yl)- amine (0.51 grams, 1.1 mmol) in 20 ml of THF was added 5 ml of 1 N HCI. After stirring for 90 minutes, the resultant suspension was filtered and washed with diethyl ether (200 ml) to yield, after drying under vacuum, a yellow solid (0.32 grams, 61% yield). δ1H NMR (400 MHz, DMSO-d6) 11.52(s, 1 H), 9.70(s, 1 H), 9.25(d, 1H),8.76(s, 1H), 7.76(m, 2H), 7.55(d, 2H), 7.45(d, 2H), 7.33(m, 4H), 7.11(d, 2H), 5.14(s, 2H). ESI-MS m/z 440(M+1).
5-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-fluoro-quinazolin-6-yl)-furan-2- carbaldehyde hydrochloride Prepared according to Procedure C from (1 -benzyl-1 H-indazol-5-ylamino)-(6-(5-
(1,3-dioxolan-2-yl)-furan-2-yl)-7-fluoro-quinazolin-4-yl)-amine. δ1H NMR (400
MHz, DMSO-d6) 11.68(s, 1 H),9.71(s, 1 H), 9.28(d, 1 H), 8.74(s, 1 H), 8.12(s, 1 H),
8.02(s, 1H), 7.78(m, 3H), 7.58(m, 2H), 7.3(m, 5H), 5.65(s, 2H). ESI-MS m/z
462(M-1).
5-(4-(4-Benzenesulphonylphenylamino)-7-fluoro-quinazolin-6-yl)-furan-2- carbaldehyde hydrochloride
Prepared according to Procedure C from 6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-7- fluoro-quinazolin-4-yl-(4-benzenesulphonyl)phenyl-amine. 1H NMR (400 MHz, DMSO-d6) δ: 10.96(s, 1H), 9.7(s, 1 H), 9.16(d, 1 H), 8.72(s, 1H), 8.07(d, 2H),
7.96(m, 4H), 7.75(m, 2H), 7.64(m, 3H), 7.29(m, 1H. ESI-MS m/z 472(M-1).
5-(4-(4-Benzyloxy-phenylamino)-quinazolin-6-yl)-furan-2-carbaldehyde hydrochloride Prepared according to Procedure C from 4-(4-benzyloxyphenylamino)-(6-(5-(1 ,3- dioxolan-2-yl)-furan-2-yl)-quinazolin-4-yl)-amine (6.70g, 14.4mmol). The resulting precipitate was collected by filtration and washed with water to give the hydrochloride salt as a yellow solid (6.50g, 14.1 mmol, 98%); δH [2H6]DMSO 12.15 (1 H,s), 9.69 (1 H,s) 9.58 (1 H,s), 8.88 (1 H,s), 8.50 (1 H,dd), 8.02 (1 H,d), 7.77 (1H,d), 7.62-7.74 (3H,m), 7.31-7.52 (5H,m), 7.15 (2H,d), 5.17 (2H,s).
(4-Phenoxyphenyl)-(7-(5-(1 ,3-dioxolan-2-yl)furan-2-yl)-quinolin-4-yl)amine (4-Phenoxyphenyl)-(7-iodo-quinolin-4-yl)amine (2g) was treated with 2- (tributylstannyl)-5-(1 ,3-dioxolan-2-yl)-furan (2.16g) and tetrakis (triphenylphosphine) palladium (0) (0.26g) in dimethylacetamide (20ml) in accordance with Procedure B. Purification via column chromatography, eluting with ethyl acetate, followed by trituration with diethylether afforded a yellow solid (1.4g) ; δH [2He] DMSO 9.10 (1 H, s), 8.45 (2H, m), 8.13 (1 H, s), 7.96 (1 H, d), 7.41 (4H, m), 7.22 (1 H, d), 7.20-7.03 (5H, m), 6.83 (1 H, d), 6.75 (1 H, d), 6.02 (1 H, s), 4.13 (2H, m), 4.01 (2H, m); m/z 451 (M+1)+.
(1 -Benzyl-1 H-indazol-5-yl)-(6-bromoquinazolin-4-yl)-amine Prepared according to Procedure A from 6-bromo-4-chloroquinazoline (5.0g) and 5-amino-1 -benzyl-1 H-indazole (5.0g) in acetonitrile (100ml) at 100°C. The resulting precipitate was treated with triethylamine in ethyl acetate and water to give the title compound as a yellow solid, (7.37g); δH [2Hβ] -DMSO 9.93(1 H,s),
8.82 (1 H,d), 8.52(1H,s), 8.19(1H,s), 8.09(1 H,s), 7.92(1 H,dd), 7.65(3H,m), 7.25(5H,m), 5.62(2H,s).
(1 -Benzyl-1 H-indazol-5-yl)-(6-iodoquinazolin-4-yl)-amine hydrochloride Prepared according to Procedure A from 4-chloro-6-iodoquinazoline (5.8g) was treated with 5-amino-1 -benzyl-1 H-indazole (3.90g) in acetonitrile (500ml) at reflux under N2 for 18 hours. Subsequent cooling and filtration gave the title compound (8.26g); m/z (M+1)+ 478.
(1-Benzyl-1H-indazol-5-yl)-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-quinazolin-4-yl)-amine Prepared according to Procedure B from (1 -benzyl-1 H-indazol-5-yl)-(6- bromoquinazolin-4-yl)-amine (4.3g), 2-(tributylstannyl)-5-(1 ,3-dioxolan-2-yl)-furan (J. Chem. Soc, Chem Commun., (1988), 560) (10g) and 1 ,4-bis(diphenylphosphino) palladium (II) chloride (1g) in dioxane. The solvent was removed in vacuo and the residue chromatographed on silica. Subsequent trituration gave the title compound δH [2H6] -DMSO 10.13 (1 H, s), 8.85 (1 H, s), 8.54 (1H, s), 8.20 (3H, m), 7.80 (3H, m), 7.30 (5H, m), 7.13 (1 H, d), 6.79 (1 H, d), 6.04 (1 H, s), 5.71 (2H, s), 4.15 (4H, m).
(1 -Benzyl-1 H-indazol-5-yl)-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-7-methoxy- quinazolin-4-yl)-amine
Prepared according to Procedure B from (1 -benzyl-1 H-indazol-5-yl)-7-methoxy- 6-trifluoromethanesulphonyl-quinazolin-4-yl)-amine and 2-(tributylstannyl)-5-(1 ,3- dioxolan-2-yl)-furan . 1H NMR (400 MHz, DMSO-d6) δ: 10.07(s, 1 H), 8.75(s, 1 H), 8.42(s, 1 H), 8.09(s, 2H), 7.64(m, 2H), 7.2-7.3(m, 6H), 7.01 (d, 1 H), 6.68(d, 1 H), 5.99(s, 1 H), 5.64(s, 2H), 4.09(m, 2H), 4.03(s, 3H), 3.94(m, 2H). ESI-MS m/z 520(M+1).
5-(4-(1-Benzyl-1 H-indazol-5-ylamino)-quinazolin-6-yl)-furan-2-carbaldehyde hydrochloride Prepared according to Procedure C from (1 -benzyl-1 H-indazol-5-yl)-(6-(5-(1 ,3- dioxolan-2-yl)-furan-2-yl)-quinazolin-4-yl)-amine (2.0g). The resulting precipitate was filtered, washed with water and dried at 60°C in vacuo to give the product as a yellow solid (1.80g, 3.73g, 91%); δH [2H6] -DMSO 12.30 (1 H, s), 9.79 (1 H, s), 9.62
(1H, s), 8.85 (1H, s), 8.62 (1H, m), 8.31 (1H, s), 8.19 (1H, m), 8.10 (1 H, d), 7.90 (2H, m), 7.78 (2H, m), 7.40 (5H, m), 5.80 (2H, s).
5-(4-(1-Benzyl-1H-indazol-5-yl)-7-methoxy-quinazolin-6-yl)-furan-2-carbaldehyde hydrochloride
Prepared according to Procedure C from (1 -benzyl-1 H-indazol-5-yl)-(6-(5-(1 ,3- dioxolan-2-yl)-furan-2-yl)-7-methoxy-quinazoiin-4-yl)-amine. δH NMR (400 MHz, DMSO-d6): 11.94(br s, 1 H), 9.68(s, 1H), 9.20(s, 1 H), 8.79(s, 1 H), 8.19(s, 1H), 7.97(d, 1H), 7.81 (d, 1 H), 7.74(d, 1H), 7.57(m, 1H), 7.44(s, 1H), 7.41 (d, 1H), 7.30(m, 2H), 7.24(m, 3H), 5.68(s, 2H), 4.13(s, 3H). ESI-MS m/z 476(M+1).
7-lodoquinazolin-4-one
7-Amino-quinazolin-4-one (R. Dempsy and E. Skito, Biochemistry, 30, 1991 , 8480) (1.61g) was suspended in 6N HCI (20ml) and cooled in an ice bath. A solution of sodium nitrite (0.75g) in water (10ml) was added dropwise over 15 minutes. After a further 10 minutes, a solution of potassium iodide (1.66g) in water (5ml) was added dropwise. The mixture was warmed to 20°C and after 3 hours partitioned between ethyl acetate and sodium thiosulphate. The organic phase was dried and concentrated in vacuo to give the title compound (0.485g); m/z (M+1+) 271.
4-Chloro-7-iodoquinazoline
7-Iodoquinazolin-4-one (0.46g) was treated with phosphorous oxychloride (5ml) at reflux under nitrogen for 2 hours. The mixture was cooled, evaporated and partitioned between saturated aqueous sodium carbonate and ethyl acetate. The organic phase was dried and concentrated in vacuo to give the title compound
(0.43g); m/z (M+1+) 291.
(1 -Benzyl-1 H-indazol-5-yl)-(7-iodoquinazolin-4-yl)-amine hydrochloride Prepared according to Procedure A from 4-Chloro-7-iodoquinazoline (0.42g) and 1 -benzyl-1 H-indazol-5-ylamine (0.323g) in acetonitrile (20ml) at reflux under nitrogen for 18 hours. The mixture was cooled and filtered to give the title compound (0.57g); m/z (M+1 +) 478.
(1 -Benzyl-1 H-indazol-5-yl)-[7-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)quinazolin-4-yl] amine hydrochloride
Prepared according to Procedure B from (1 -benzyl-1 H-indazol-5-yl)-(7- iodoquinazolin-4-yl)-amine hydrochloride and 5-(1 ,3-dioxolan-2-yl)-2-(tri-n- butylstannyl)furan; tic Rf, 0.25 (100% EtOAc on silica); m/z (M+1+) 490.
5-[4-(1-Benzyl-1 H-indazol-5-ylamino)-quinazolin-7-yl]-furan-2-carbaldehyde Prepared according to Procedure C from (1-benzyl-1 H-indazol-5-yl)-[7-(5-(1 ,3- dioxolan-2-yl)furan-2-yl)quinazolin-4-yl]-amine hydrochloride (0.27g) stirred in THF:2N HCI (2:1 , 15ml) at 20°C for 1 hour. Filtration gave 5-[4-(1 -benzyl-1 H- indazol-5-ylamino)-quinazolin-7-yl]-furan-2-carbaldehyde, which was not further characterised.
(4-Benzyloxy-phenyl)-(6-((5-(2-methylthio-ethylamino)-methyl)-furan-2-yl)- quinazolin-4-yl)-amine dihydrochloride
5-(4-(4-Benzyloxy-phenylamino)-quinazolin-6-yl)-furan-2-carbaldehyde (1 OOmg) and (methylthio)ethylamine (80mg) in dichloromethane (5ml) were reacted together as in Procedure D. Purification using column chromatography, followed by conversion to the hydrochloride salt gave a yellow solid (61 mg). m/z 497 (M+1)+. (6-Chloropyrido[3,4-d]pyrimidin-4-yl)-(4-(4-fluorobenzyloxy)-phenyl)-amine 4,6-Dichloro-pyrido[3,4-d]pyrimidine (1g) and 4-(4-fluorobenzyloxy)aniline (1.08g) in acetonitrile (70ml) were reacted together as in Procedure A. The product was collected by filtration as a yellow solid (1.83g); m/z 381 (M+1)+.
(6-(5-(1 ,3-Dioxolan-2-yl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-(4-(4- fluorobenzyloxy)-phenyl)-amine
(6-Chloropyrido[3,4-d]pyrimidin-4-yl)-(4-(4-fluorobenzyloxy)-phenyl)-amine (1.82g) and 5-(1 ,3-dioxolan-2-yl)-2-(tributylstannyl)-furan (3.75g) in dioxan (40ml) were reacted together as in Procedure B. The mixture was evaporated and the residue suspended in dichloromethane. This was then filtered through celite and the solvent evaporated. The gummy residue was then triturated with hexane giving a beige solid
(1.21g); m/z 485 (M+1)\
5-(4-(4-(4-Fluorobenzyloxy)-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2- carbaldehyde
(6-(5-(1,3-Dioxolan-2-yl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-(4-(4- fluorobenzyloxy)-phenyl)-amine (500mg) was treated with acid as in Procedure C. The product was collected by filtration as a red solid (330mg); m/z 441 (M+1)+.
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(5-(2-(methylthio)-ethylaminomethyl)-furan-2- yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine
5-(4-(4-(4-Fluorobenzyloxy)-phenyl)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2- carbaldehyde (110mg) and (methylthio)ethylamine (0.06ml) in dichloromethane (5ml) were reacted together as in Procedure D. Purification using a Bond Elut™ cartridge gave a yellow oil (52mg); m/z 516 (M+1)+.
(6-Chloropyrido[3,4-d]pyrimidin-4-yl)-(4-(3-fluorobenzyloxy)-phenyl)-amine 4,6-Dichloro-pyrido[3,4-d]pyrimidine (1g) and 4-(3-fluorobenzyloxy)aniline (1.08g) in acetonitrile (70ml) were reacted together as in Procedure A. The product was collected by filtration as a yellow solid (1.86g); m/z 381 (M+1)+.
(6-(5-(1 ,3-Dioxolan-2-yl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-(4-(3- fluorobenzyloxy)-phenyl)-amine (6-Chloropyrido[3,4-d]pyrimidin-4-yl)-(4-(3-fluorobenzyloxy)-phenyl)-amine (1.85g) and 5-(1 ,3-dioxolan-2-yl)-2-(tributylstannyl)-furan (3.82g) in dioxan (40ml) were reacted together as in Procedure B. The mixture was evaporated and the residue suspended in dichloromethane. This was then filtered through Celite® and the solvent evaporated. The gummy residue was then triturated with hexane giving a beige solid (1.74g); m/z 485 (M+1)+.
5-(4-(4-(3-Fluorobenzyloxy)-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-3- carbaldehyde (6-Chloropyrido[3,4-d]pyrimidin-4-yl)-(4-(3-fluorobenzyloxy)-phenyl)-amine (1g) and 5-(tributylstannyl)-furan-3-carbaldehyde (J.Org.Chem. (1992), 57(11), 3126-31) (1.84g) in dioxan (35ml) were reacted together as in Procedure B. The solvent was evaporated and the residue suspended in dichloromethane. The mixture was filtered through Celite® and then evaporated. The residue was triturated with hexane giving a beige solid (1 g); m/z 441 (M+1 )+.
5-(4-(4-(3-Fluorobenzyloxy)-phenylamino)-pyrido[3,4-d1pyrimidin-6-yl)-furan-2- carbaldehyde
(6-(5-(1 ,3-Dioxolan-2-yl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-(4-(3- fluorobenzyloxy)-phenyl)-amine (500mg) was treated with acid as in Procedure C. The product was collected by filtration as a beige solid (251mg); m/z 441 (M+1)+.
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-(2-(methylthio)-ethylaminomethyl)-furan-2- yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine (5-(4-(4-(3-Fluorobenzyloxy)-phenyl)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2- carbaldehyde (125mg) and (methylthio)ethylamine (0.08ml) in dichloromethane (5ml) were reacted together as in Procedure D. Purification using a Bond Elut™ cartridge gave a yellow oil (80mg); m/z 516 (M+1)+.
(4-Benzenesulphonyl-phenyl)-(6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine
Prepared according to Procedure A from 4-benzenesulphonylaniline (Helv. Chim. Acta., 1983, 66 (4), 1046) and 4,6-dichloropyrido[3,4-cf]pyrimidine; δH [2H6]-DMSO 9.09 (1H,s), 8.80-8.88 (2H,m), 8.19 (2H,d), 7.94-8.09 (4H,m), 7.53-7.20 (3H,m); m/z (M + 1)+ 397. (4-Benzenesulphonyl-phenyl)-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-pyrido[3,4- d]pyrimidin-4-yl)-amine
(4-Benzenesulphonyl-phenyl)-(6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine (3.67g) and 5-(1 ,3-dioxolan-2-yl)-2-(tributylstannyl)-furan (6.9g) were reacted together in dioxan (100ml) as in Procedure B. Purification by column chromatography gave a cream solid (2.59g); δH [2H6]DMSO 10.6 (1 H,s) 9.26 (1 H,s) 8.82 (1 H,s) 8.78 (1H,s) 8.25 (2H,d) 8.0-8.3 (4H,d+m) 7.65-7.8 (3H,m) 7.21 (1 H,d) 6.82 (1H,d) 6.09 (1 H,s) 4.0-4.2 (4H,m); m/z 501 (M+1)+.
5-(4-(4-Benzenesulphonyl-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl)furan-2- carbaldehyde hydrochloride
(4-Benzenesulphonyl-phenyl)-(6-(5-(1 ,3-dioxolan-2-yl)-furan-2-yl)-pyrido[3,4- d]pyrimidin-4-yl)-amine (2.59g) was treated with acid in tetrahydrofuran (70ml) as in Procedure C. The compound was obtained as a yellow solid after filtration (1.57g); δH [2H6]DMSO 9.7 (1 H,s) 9.26 (1 H,s) 9.11 (1 H,s) 8.82 (1 H,s) 8.19 (1 H,s) 8.15 (1 H,s) 7.95-8.03 (4H,m) 7.75 (1H,d) 7.58-7.7 (3H,m) 7.49 (1H,s); m/z 457 (M+1)+.
(4-Benzenesulphonyl-phenyl)-(6-(5-((2-methylthio-ethylamino)-methyl)-furan-2- yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine dihydrochloride 5-(4-((4-Benzenesulphonyl-phenyl)amino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2- carbaldehyde (250mg) and (methylthio)ethylamine (185mg)) in dichloromethane (5ml) were reacted together as in Procedure D. Purification using a Bond Elut™ cartridge, gave a yellow solid (245mg), 70mg of which was converted to the hydrochloride salt, ( yellow solid ,68mg); m/z 532 (M+1)+.
(4-Benzyloxy-phenyl)-(6-(3-(1 ,3-dioxolan-2-yl)-phenyl)-pyrido[3,4-d]pyrimidin-4- yl)-amine
(4-Benzyloxy-phenyl)-(6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine (1.4g) and 3-(1 ,3- dioxolan-2-yl)-phenyl-tributylstannane (3.08g) [A.Lee and W-C.Dai, Tetrahedron (1997), 53(3), 859-868] in dioxan (30ml) were reacted together as in Procedure B. The mixture was evaporated and the residue suspended in dichloromethane. This was then filtered through celite and the solvent evaporated. The gummy residue was then triturated with hexane giving a beige solid . This material was further purified by column chromatography, giving a brown foam (252mg); m/z 477 (M+1)+. 3-(4-((4-Benzyloxy-phenyl)-amino)-pyrido[3,4-d]pyrimidin-6-yl)-benzaldehyde (4-(4-Benzyloxy-phenyl)-6-(3-(1 ,3-dioxolan-2-yl)-phenyl)-pyrido[3,4-d]pyrimidin-4-yl)- amine (250mg) was treated with acid as in Procedure C. The product was isolated by filtration as a brown solid (115mg); m/z 433 (M+1)+.
4-(4-(4-Benzyloxy-phenyl)-amino)-quinazolin-6-yl)-thiazol-2-carbaldehyde (4-Benzyloxy-phenyl)-(6-iodo-quinazolin-4-yl)-amine (2g) and 4-(tributylstannyl)- thiazol-2-carbaldehyde (3.28g) in dioxan (25ml) were reacted together as in Procedure B. The mixture was evaporated and the residue purified using column chromatography, giving a yellow solid (849mg); m/z 439 (M+1)+.
Other suitable intermediates prepared by analogous methods to those described above are:
(4-Benzyloxy-3-chlorophenyl)-6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-(3-Fluoro-benzyloxy)-3-chlorophenyl)-6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-3-trifluoromethylphenyl)-6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy)-3-trifluoromethylphenyl)-6-chloro-pyrido[3,4-d]pyrimidin-4- yl)-amine;
(4-Benzyloxy-3-bromophenyl)-6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-(3-Fluoro-benzyloxy-3-bromophenyl)-6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-3-iodophenyl)-6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy-3-iodophenyl)-6-(chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-3-fluorophenyl)-6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluoro-benzyloxy-3-fluorophenyl)-6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine; 5-((4-Benzyloxy-3-chlorophenylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2- carbaldehyde;
5-((4-(3-Fluoro-benzyloxy)-3-chlorophenylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2- carbaldehyde;
5-((4-Benzyloxy-3-trifluoromethylphenylamino)-pyrido[3,4-d] 6-yl)-furan-2- carbaldehyde;
5-((4-(3-Fluoro-benzyloxy)-3-trifluoromethylphenylamino)-pyrido[3,4-d]pyrimidin-6- yl)-furan-2-carbaldehyde;
5-((4-Benzyloxy-3-bromophenylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2- carbaldehyde; 5-((4-(3-Fluoro-benzyloxy-3-bromophenylamino)-pyrido[3,4-d] 6-yl)-furan-2- carbaldehyde;
5-((4-Benzyloxy-3-iodophenylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2- carbaldehyde; 5-((4-(3-Fluoro-benzyloxy-3-iodophenylamino)-pyrido[3,4-d] 6-yl)-furan-2- carbaldehyde;
5-((4-Benzyloxy-3-fluorophenylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2- carboxaldehyde;
5-((4-(3-Fluoro-benzyloxy-3-fluorophenylamino)-pyrido[3,4-d] 6-yl)-furan-2- carbaldehyde;
N-[4-(benzyloxy)-3-chlorophenyl]-7-fluoro-6-chloro-4-quinazolinamine;
N-[4-(3-Fluoro-benzyloxy)-3-chlorophenyl]-7-fluoro-6-chloro-4-quinazolinamine
N-[4-Benzyloxy-3-trifluoromethylphenyl]-7-fluoro-6-chloro-4-quinazolinamine
N-[4-(3-Fluoro-benzyloxy)-3-trifluoromethylphenyl]-7-fluoro-6-chloro-4- quinazolinamine;
N-[4-Benzyloxy-3-bromophenyI]-7-fluoro-6-chloro-4-quinazolinamine;
N-[4-(3-Fluoro-benzyloxy-3-bromophenyl]-7-fluoro-6-chloro-4-quinazolinamine;
N-[4-Benzyloxy-3-iodophenyl]-7-fluoro-6-chloro-4-quinazolinamine;
N-[4-(3-Fluoro-benzyloxy-3-iodophenyl]-7-fluoro-6-chloro-4-quinazolinamine; N-[4-Benzyloxy-3-fluorophenyl]-7-fluoro-6-chloro-4-quinazolinamine;
N-[4-(3-Fluoro-benzyloxy-3-fluorophenyl]-7-fluoro-6-chloro-4-quinazolinamine;
N-[1-(3-fluorobenzyl-1 H-indazol-5-yl]-7-fluoro-6-chloro-4-quinazolinamine;
5-(4-[4-(Benzyloxy)-3-chlorophenylamino]-7-fluoro-quinazolin-6-yl)-furan-2- carbaldehyde; 5-(4-[4-(3-Fiuoro-benzyloxy)-3-chlorophenyl]-7-fluoro-quinazolin-6-yl)-furan-2- carbaldehyde;
5-(4-[4-Benzyloxy-3-trifluoromethylphenyl]-7-fluoro-quinazolin-6-yl)-furan-2- carbaldehyde;
5-(4-[4-(3-Fluoro-benzyloxy)-3-trifluoromethylphenyl]-7-fluoro-quinazolin-6-yl)-furan- 2-carbaldehyde;
5-(4-[4-Benzyloxy-3-bromophenyl]-7-fluoro-quinazolin-6-yl)-furan-2-carbaldehyde;
5-(4-[4-(3-Fluoro-benzyloxy-3-bromophenyl]-7-fluoro-quinazolin-6-yl)-furan-2- carbaldehyde;
5-(4-[4-Benzyloxy-3-iodophenyl]-7-fluoro-quinazolin-6-yl)-furan-2-carbaldehyde; 5-[4-(3-Fluoro-benzyloxy-3-iodophenyl]-7-fluoro-quinazolin-6-yl)-furan-2- carbaldehyde;
5-[4-Benzyloxy-3-fluorophenyl]-7-fluoro-quinazolin-6-yl)-furan-2-carbaldehyde
5-(4-(3-Fluoro-benzyloxy-3-fluorophenyl]-7-fluoro-quinazolin-6-yl)-furan-2- carbaldehyde;
5-(4-[1-(3-Fluorobenzyl-1 H-indazol-5-ylamino]-7-fluoro-quinazolin-6-yl)-furan-2- carbaldehyde;
Examples Example 1
Figure imgf000089_0001
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine dihydrochloride
(4-(4-Fluorobenzyloxy)-phenyl)-(6-(5-(2-(methylthio)-ethylaminomethyl)-furan-2-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine (52mg) in methanol (9ml) and water (3ml) was treated with Oxone™ (99mg) at room temperature for 2 days. The mixture was then partitioned between aqueous sodium carbonate solution and dichloromethane. The dried organic phase was evaporated and the residue purified by Bond Elut™ cartridge, followed by conversion to the hydrochloride salt, giving a yellow solid (31 mg); δH [2H6]DMSO 9.9 (1 H,bs) 9.25 (1H,s) 8.8 (1 H,s) 7.9 (2H,d) 7.5-7.6 (2H,m) 7.1-7.3 (5H,m) 6.9 (1H,d) 5.2 (2H,s) 4.5 (2H,s) 3.6-3.8 (4H,m) 3.2 (3H,s); m/z 548 (M+1)+.
Example 2
Figure imgf000089_0002
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine dihydrochloride (4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-(2-(methylthio)-ethylaminomethyl)-furan-2-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine (80mg) in methanol (9ml) and water (3ml) was treated with Oxone™ (153mg) at room temperature for 2 days. The mixture was then partitioned between aqueous sodium carbonate solution and dichloromethane. The dried organic phase was evaporated and the residue purified by Bond Elut™ cartridge, followed by conversion to the hydrochloride salt, giving a yellow solid (69mg); δH [2H6]DMSO 9.8 (1H,bs) 9.4 (1H,s) 9.3 (1H,s) 8.7 (1H,s) 7.8 (2H,d) 7.3-7.4 (2H,m) 7.0-7.3 (5H,m) 6.8 (1 H,d) 5.3 (2H,s) 4.4 (2H,s) 3.5-3.7 (4H,m) 3.1 (3H,s); m/z 548 (M+1)+.
Example 3
Figure imgf000090_0001
(4-Benzenesulphonyl-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)- furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine dihydrochloride (4-Benzenesulphonyl-phenyl)-(6-(5-((2-methylthio-ethylamino)-methyl)-furan-2-yl)- pyrido[3,4-d]pyrimidin-4-yl)-amine (162mg) in methanol (20ml) and water (10ml) was treated with Oxone™ (345mg) at room temperature for 18h. The mixture was then evaporated and the residue purified by Bond Elut™ cartridge, followed by conversion to the hydrochloride salt, giving a yellow solid (55mg); δH [2H6]DMSO 9.8 (1H,bs) 9.3 (1H,s) 9.2 (1 H,s) 8.8 (1 H,s) 8.3 (2H,d) 7.9-8.0 (4H,m) 7.6-7.7 (3H,m) 7.2 (1H,d) 6.8 (1H,d) 4.4 (2H,s) 3.3-3.7 (4H,m) 3.1 (3H,s); m/z 564 (M+1)+.
Example 4
Figure imgf000090_0002
(4-Benzyloxy-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- pyrido[3,4-d]pyrimidin-4-yl)-amine dihydrochloride. 3-((4-(4-Benzyloxy-phenyl)-amino)-pyrido[3,4-d]pyrimidin-6-yl)-benzaldehyde (106mg) and 2-methanesulphonyl-ethylamine (111mg) in dichloromethane (5ml) were reacted together as in Procedure D. Purification using column chromatography, followed by conversion to the hydrochloride salt, gave a yellow solid (66mg); δH [2H6]DMSO 9.6 (2H,bs) 9.3 (1H,s) 9.2 (1H,s) 8.65 (1 H,s) 8.55 (1H,s) 8.3 (1 H,m) 7.7- 7.8 (2H,m) 7.6 (2H,m) 7.25-7.45 (4H,m) 7.0 (2H,d) 5.1 (2H,s) 4.3 (2H,s) 3.2-3.8 (4H,m) 3.1 (3H,s). m/z 540 (M+1)+.
Example 5
Figure imgf000091_0001
(4-Benzyloxyphenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2-yl)- quinazolin-4-yl)-amine dihydrochloride
5-((4-(4-Benzyloxyphenyl)-amino)-quinazolin-6-yl)-furan-2-carbaldehyde (200mg) and 2-methanesulphonyl-ethylamine (215mg) in dichloromethane (10ml) were reacted together as in Procedure D. Purification using column chromatography, followed by conversion to the hydrochloride salt, gave a yellow solid (121 mg); δH [2H6]DMSO 9.7 (1 H,s) 8.9 (1 H,s) 8.4 (1 H,d) 8.0 (1 H,d) 7.75 (2H,d) 7.3-7.5 (7H,m) 7.1 (2H,d) 6.85 (1H,d) 5.2 (2H,s) 4.4 (2H,s) 3.2-3.7 (4H,m) 3.1 (3H,s); m/z 529(M+1)+.
Example 6
Figure imgf000091_0002
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)- furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine dihydrochloride 5-(4-(4-(3-Fluorobenzyloxy)-phenyl)-pyrido[3,4-d]pyrimidin-6-yl)-furan-3- carbaldehyde (300mg) and 2-methanesulphonyl-ethylamine (335mg) in dichloromethane (15ml) were reacted together as in Procedure D. Purification using a Bond Elut™ cartridge, followed by conversion to the hydrochloride salt, gave a yellow solid (110mg); δH [ H6]DMSO 9.8 (2H,br) 9.3 (1 H,s) 9.0 (1 H,s) 8.8 (1H,s) 8.2 (1H,s) 8.0 (1H,s) 7.1-7.8 (7H,m) 7.0 (1H,s) 5.2 (2H,s) 4.1-4.3 (4H,brm) 3.3-3.5 (2H,bs) (hidden under H2O peak) 3.2 (3H,s); m/z 548(M+1)+.
Example 7
Figure imgf000092_0001
(4-Benzyloxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)-methyl)-thiazol-4- yl)-quinazolin-4-yl)-amine dihydrochloride
4-(4-(4-Benzyloxy-phenyl)-amino)-quinazolin-6-yl)-thiazol-2-carbaldehyde (70mg) and 2-methanesulphonyl-ethylamine (79mg) in dichloromethane (10ml) were reacted together as in Procedure D. Purification using a Bond Elut™ cartridge , followed by conversion to the hydrochloride salt, gave a yellow solid (59mg); δH [2H6]DMSO 12.3 (1H,s) 10.0 (1H,s) 8.95 (1 H,s) 8.8 (1H,s) 8.75 (1 H,d) 7.4-7.6 (6H,m) 7.2 (2H,d) 5.25 (2H,s) 4.8 (2H,s) 3.6-3.8 (4H,m) 3.2 (3H,s); m/z 546(M+1)+.
Example 8
Figure imgf000092_0002
N-{4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)- 2-furyl]-4-quinazolinamine Prepared according to Procedure D from 5-(4-{4-(3-fluorobenzyloxy)anilino}-6- quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl-ethylamine (1 equiv). 1H NMR 400 MHz (DMSO-d6) 9.40 (s,1H); 8.67 (s,1H); 8.30 (d,1H); 7.86 (d,1H); 7.75 (d,2H); 7.43 (m,1H); 7.30-7.21 (m,3H); 7.15 (m,1H); 7.07 (d,2H); 6.80 (d,1H); 5.15 (s,2H); 4.40 (s,2H); 3.65 (m,2H); 3.40 (m,2H); 3.11 (s,3H); MS m/z 547 (M+1). Example 9
Figure imgf000093_0001
N-{4-[(3-fluorobenzyl)oxy]-3-methoxyphenyl}-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine Prepared according to Procedure D from 5-(4-{3-methoxy-4-(3- fluorobenzyloxy)anilino}-6-quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2- methanesulphonyl-ethylamine (1 equiv). 1H NMR 400 MHz (DMSO-d6) 9.22 (s,1H); 8.78 (s,1 H); 8.31 (d,1H); 7.88 (d,1 H); 7.50-7.08 (m,8H); 6.84 (d,1 H); 5.13 (s,2H); 4.42 (s,2H); 3.80 (s,3H); 3.60 (m,2H); 3.40 (m, 2H, obscured by water peak); 3.10 (s,3H); MS m/z 577 (M+1).
Example 10
Figure imgf000093_0002
N-[4-(benzyloxy)phenyl]-7-methoxy-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine Prepared in a similar manner to Procedure D from 5-(4-(4-benzyloxy- phenylamino)-7-methoxy-quinazolin-6-yl)-furan-2-carbaldehyde hydrochloride(78 mg, 0.16 mmol), 2-methanesulphonylethylamine(33 mg, 0.27 mmol), acetic acid(15 mg, 0.25 mmol) and triethylamine(18 mg, 0.18 mmol) in 3 ml of 1 ,2- dichloroethane added to sodium triacetoxyborohydride(102 mg, 0.48 mmol) portionwise over a two day period. The reaction mixture was stirred four days and then partitioned between 10 ml of 0.5M NaHCO3 solution and 50 ml of ethyl acetate. The organic solution was dried with Na2SO4 and concentrated in vacuo. The residue was chromatographed on silica gel with methanol/methylene chloride(1 :49 to 2:48). The resulting solid was crystallized from a small volume of ethyl acetate, suspended in ether and filtered to give 43 mg of product as a pale yellow solid. δ1H NMR (400 MHz, DMSO-d6) 9.78(s, 1 H), 8.73(s, 1 H), 8.42(s, 1H), 6.64(d, 2H), 7.47(m, 2H), 7.40(m, 2H), 7.33(m, 1H), 7.25(s, 1 H), 7.04(d, 2H), 6.98(d, 1H), 6.46(d, 1H), 5.12(s, 2H), 4.04(s, 3H), 3.86(s, 2H), 3.28(t, 2H), 3.01 (s, 3H), 2.99(t, 2H). ESI-MS m/z 559(M+1 ).
Example 11
Figure imgf000094_0001
N-[4-(benzyloxy)phenyl]-6-[4-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4- quinazolinamine
Prepared according to Procedure D from 5-(4-{4-benzyloxyanilino}-6-quinazolinyl)- furan-3-carbaldehyde (0.6 equiv) and 2-methanesulphonyl-ethylamine (1 equiv).
1HNMR 400MHz, dδDMSO 9.51 (bs,2H), 9.11 (s, 1H), 8.79 (s,1H), 8.29 (d, 1H), 8.06 (s, 1H), 7.90 (d, 1H), 7.60 (d, 2H), 7.5-7.3 (m, 5H), 7.11 (d, 2H), 5.14 (s, 2H), 4.14 ( bs, 2H), 3.6-3.5 (m, 3H), 3.12 (s, 3H); MS m/z 529 (M+1).
Example 12
Figure imgf000094_0002
N-{4-r(3-fluorobenzyl)oxy]-3-methoxyphenyl}-6-[2-({[2- (methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine Prepared according to Procedure F from 6-iodo-(4-(3-fluorobenzyloxy)-3- methoxypheny)quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N-bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N- (methanesulphonylethyl)-aminomethylthioamide (1 equiv).1H NMR 400 MHz (CD3OD) 9.40 (s, 1H); 8.79 (s, 1 H); 8.76 (d, 1H); 8.38 (s, 1H); 7.89 (d, 1H); 7.50 (s, 1H); 7.40 (t, 1 H); 7.34 (m, 1H); 7.27 (d, 1H); 7.22 (d, 1H); 7.08 (d, 1 H); 7.03 (t, 1 H); 5.19 (s, 2H); 4.81 (s, 2H); 3.85 (m, 2H); 3.75 (m, 2H); 3.10 (s, 3H); MS m/z 594 (M+1)+, 592 (m-1)-.
Example 13
Figure imgf000095_0001
N-{4-[(3-bromobenzyl)oxy]phenyl}-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)- 1 ,3-thiazol-4-yl]-4-quinazolinamine.
Prepared according to Procedure F from 6-iodo-(4-(3-bromobenzyloxy)- phenyl)quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N- bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv). 1H NMR 400 MHz (CD3OD) 9.40 (s, 1 H); 8.78 (d, 1H); 8.74 (d, 1 H); 8.34 (s, 1H); 7.88 (d, 1H); 7.65 (d, 2H); 7.62 (s, 1H); 7.48 (d, 1H); 7.30 (d, 1H); 7.30 (m, 1H); 7.12 (d, 2H); 5.16 (s, 2H); 4.80 (s, 2H); 3.85 (m, 2H); 3.75 (m, 2H); 3.10 (s, 3H); MS m/z 624, 626 (M+1)+, 622, 624 (m-1)".
Example 14
Figure imgf000095_0002
N-{4-[(3-fluorobenzyl)oxy]phenyl}-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)- 1,3-thiazol-4-yl]-4-quinazolinamine Prepared according to Procedure F from 6-iodo-(4-(3-fluorobenzyloxy)- phenyl)- quinazoIin-4-ylamine and (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N- bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv). 1H NMR 400 MHz (CD3OD) 9.44 (s, 1 H); 8.79 (s, 1H); 8.76 (d, 1H); 8.37 (s, 1H); 7.90 (d, 1H); 7.74 (d, 1H); 7.53 (d, 1H); 7.46 (d, 2H); 7.38 (m, 2H); 7.32 (d, 1 H); 7.24 (d, 1H); 5.21 (s, 2H); 4.82 (s, 2H); 3.85 (m, 2H); 3.77 (m, 2H); 3.11 (s, 3H); MS m/z 564 (M+1)\ 562 (m-1)-. Example 15
Figure imgf000096_0001
N-[4-(benzyloxy)-3-fluorophenyl]-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-
1 ,3-thiazol-4-yl]-4-quinazolinamine
Prepared according to Procedure F from 6-iodo-(4-benzyloxy)-3- fluorophenyl)quinazolin-4-ylamine and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N- bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv). 1H NMR 400 MHz (CD3OD) 9.41 (s, 1 H); 8.77 (d, 1H); 8.75 (s, 1H); 8.36 (s, 1H); 7.90 (d, 1H); 7.71 (d, 2H); 7.60 (m, 1 H); 7.40 (m, 1 H); 7.23 (m, 1H); 7.11 (d, 2H); 7.03 (m, 1H); 5.17 (s, 2H); 4.81 (s, 2H); 3.85 (m, 2H); 3.76 (m, 2H); 3.10 (s, 3H); MS m/z 564 (M+1)+, 562 (m-1)'.
Example 16
Figure imgf000096_0002
N-(1 -benzyl-1 H-indazol-5-yl)-7-methoxy-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine Prepared according to Procedure D from 5-(4-{4-(1 -benzyl-1 H-indazol-5-yl)-7- methoxy-6-quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2- methanesulphonyl-ethylamine (1 equiv). δ 1H NMR (400 MHz, DMSO-d6) 9.94(s, 1H), 8.76(s, 1H), 8.43(s, 1H), 8.13(d, 1H), 8.12(s, 1 H), 7.70(d, 1 H), 7.66(m, 1 H), 7.31 (m, 2H), 7.25(m, 4H), 7.00(d, 1H), 6.46(d, 1H), 5.67(s, 2H), 4.05(s, 3H), 3.85(s, 2H), 3.27(t, 2H), 3.00(s, 3H), 2.98(t, 2H); ESI-MS m/z 583(M+1). Example 17
Figure imgf000097_0001
6-r5-({r2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-N-(4-{[3-(trifluoromethyl) benzyl]oxy}phenyl)-4-quinazolinamine
Prepared according to Procedure D from 5-(4-{4-(3-trifluoromethylbenzyloxy)anilino}- 6-quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl- ethylamine (1 equiv).1H NMR 300 MHz (DMSO-d6) 11.63 (bs, 1 H); 9.88 (bs, 1 H); 9.59 (bs, 1 H); 8.88 (s, 1H); 8.43 (d, 1H); 7.97 (d, 1 H); 7.90-7.67 (m, 6H); 7.34 (d, 1H); 7.19 ( d, 2H); 6.89 (d, 1H); 5.30 (s, 2H); 4.45 (s, 2H); 3. 78 (m, 2H); 3.45 (m, 2H, obscured by water peak); 3.19 (s, 3H); MS m/z 597 (M+1).
Example 18
Figure imgf000097_0002
N-{3-fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
Prepared according to Procedure D from 5-(4-{3-fluoro-4-(3-fluorobenzyloxy)anilino}- 6-quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl- ethylamine (1 equiv). 1H NMR 400 MHz (DMSO-d6) 9.61 (bs, 2H); 9.28 (bs, 1H); 8.80 (s, 1H); 8.34 (d, 1H); 7.87 (m, 2H); 7.59 (d, 1 H); 7.44 (m, 1H); 7.2 - 7.38 (m, 4H); 7.18 (m, 1H); 6.83 (s, 1H); 5.25 (s, 2H); 4.42 (s, 2H); 3.60 (m, 2H); 3.45 (m, 2H, obscured by water peak); 3.16 (s, 3H); MS m/z 565 (M+1).
Example 19
Figure imgf000098_0001
N-{4-[(3-bromobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)- 2-furyl]-4-quinazolinamine Prepared according to Procedure D from 5-(4-{3-bromo-4-benzyloxyanilino}-6- quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl-ethylamine (1 equiv). 1H NMR 400 MHz (DMSO-d6) 11.78 (bs, 1H); 9.65 (bs, 1H); 9.39 (bs, 1H); 8.78 (s, 1 H); 8.37 (d, 1 H); 7.90 (d, 1H); 7.66 (m, 3H); 7.53 (d, 1H); 7.42 (d, 1 H); 7.38 (m, 1H); 7.22 (s, 1H); 7.18 (d, 2); 6.82 (d, 1H); 5.18 (s, 2H); 4.41 (s, 2H); 3.62 (m, 2H); 3.44 (m, 2H, obscured by water peak); 3.10 (s, 3H); MS m/z 606, 608 (M+1).
Example 20
Figure imgf000098_0002
N-[4-(benzyloxy)phenyl]-6-[3-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4- quinazolinamine
Prepared according to Procedure D from 5-(4-(4-benzyloxyanilino)-6-quinazolinyl)- furan-2-carbaIdehyde (0.6 equiv) and 2-methanesulphonyl-ethylamine(1 equiv). 1HNMR 400MHz,( d6DMSO) 9.46(brs,1H), 8.94 (s,1H), 8.7 (s,1H), 8.16 (d,1H), 7.96 (s,1H), 7.88 (d,1H), 7.67 (d,2H), 7.5-7.2 (m,5H), 7.07 (d,2H), 6.93 (s,1H), 5.12 (s, 2H), 4.38 (brs,2H), 3.59 (m,2H), 3.46 (brs,2H), 3.09 (s,3H); MS m/z 529 (M+1)
Example 21
Figure imgf000098_0003
N-[1 -(3-fluorobenzyl)-1 H-indazol-5-yl]-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine Prepared according to Procedure F from 6-iodo-(4-(3-fluorobenzyl)-1H-indazol-5- yl)quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N- bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv). 1H NMR (d4 MeOH) d 9.44 (s, 1 H), 8.76 (m, 2H), 8.36 (s, 1 H), 8.18 (s, 1 H), 8.15, (s, 1H), 7.92 (d, 1 H), 7.75 (m, 2H), 7.34 (m, 1 H), 7.04 (m, 2H), 6.92 (d, 1H), 5.71 (s, 2H), 4.80 (s, 2H), 3.82 (m, 2H), 3.74 (m, 2H), 3.08 (s, 3H); MS m/z 588 (M+H+)
Example 22
Figure imgf000099_0001
6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl1-N-r4-
(benzenesulphonyl)phenyl]-4-quinazolinamine
Prepared according to Procedure D from 5-(4-{4-(benzenesulphonyl)phenyl}-6- quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl-ethylamine (1 equiv). 1H NMR (DMSO-d6) 10.27 (s, 1H), 8.78 (s, 1 H), 8.65 (s, 1 H), 8.18-8.22 (m, 3H), 7.97-8.01 (m, 4H), 7.86 (d, 1H), 7.62-7.72 (m, 3H), 7.10 (d, 1 H), 6.51 (d, 1H), 3.84 (s, 1H), 3.28 (t, 2H), 3.03 (s, 3H), 2.99 (t, 2H); m/z (M+1)+ 563.
Example 23
Figure imgf000099_0002
6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-N-[4- {benzenesulphonyl)phenyl]-4-quinazolinamine Prepared according to Procedure F from 6-iodo-(4-(benzenesulphonyl)-phenyl)- quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N- bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv). 1H NMR 400 MHz (DMSO-d6) 9.80 (s, 1H); 8.87 (s, 1H); 8.65 (s, 1H); 8.64 (s, 1 H); 8.17 (s, 1H); 8.03 (s, 1 H); 7.98 (m, 2H); 7.66 (m, 5H); 4.73 (s, 2H); 3.68 (m, 2H); 3.55 (m, 2H); 3.12 (s, 3H); MS m/z 580 (M+1) \ 578 (m-1)".
Example 24
Figure imgf000100_0001
6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-N-(4-{[3- (trifluoromethyl)benzyl]oxy}phenyl)-4-quinazolinamine Prepared according to Procedure F from 6-iodo-(4-(3-trifluoromethylbenzyloxy)- phenyl)quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N- bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv). 1H NMR 400 MHz (CD3OD) 9.40 (s, 1 H); 8.75 (d, 1H); 8.73 (s, 1 H); 8.35 (s, 1H); 7.89 (d, 1H); 7.77 (s, 1H); 7.73 (m, 1 H); 7.61 (m, 3H); 7.52 (m, ΪH); 7.14 (d, 2H); 5.24 (s, 2H); 4.82 (s, 2H); 3.85 (m, 2H); 3.76 (m, 2H); 3.10 (s, 3H); MS m/z 614 (M+1)+, 612 (m-1)".
Example 25
Figure imgf000100_0002
N-{3-fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[2-({[2- (methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine Prepared according to Procedure F from 6-iodo-4-(1 -benzyl-1 H-indazol-5-yl)- quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N- bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv). 1H NMR 400 MHz (CD3OD) 9.28 (s, 1 H); 8.78 (s, 1 H); 8.74 (d, 1 H); 8.31 (s, 1H); 7.90 (d, 1H); 7.74 (d, 1 H); 7.63 (m, 1 H); 7.54 (m, 1 H); 7.49 (m, 1 H); 7.37 (m, 1H); 7.25 (m, 2H); 7.05 (m, 1 H); 5.24 (s, 2H); 4.77 (s, 2H); 3.81 (m, 2H); 3.72 (m, 2H); 3.10 (s, 3H); MS m/z 582 (M+1)*, 580 (m-1)' Example 26
Figure imgf000101_0001
N-(1 -benzyl-1 H-indazol-5-yl)-6-r2-({[2-(methanesulphonyl)ethyl]amino)methyl)-1 ,3- thiazol-4-yl]-4-quinazolinamine
Prepared according to Procedure F from 6-iodo-4-(1 -benzyl-1 H-indazol-5-yl)- quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N- bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl)- aminomethylthioamide (1 equiv). δ 1H NMR (d4 MeOH) 9.37 (s, 1 H), 8.74 (m, 2H), 8.33 (s, 1H), 8.17 (s, 1 H), 8.14, (s, 1H), 7.90 (d, 1H), 7.70 (m, 2H), 7.22 (m, 5H), 5.69 (s, 2H), 4.78 (s, 2H), 3.81 (m, 2H), 3.74 (m, 2H), 3.09 (s, 3H); MS m/z 570 (M+H+).
Example 27
Figure imgf000101_0002
N-(3-Fluoro-4-benzyloxyphenyl)-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-4- furyl]-4-quinazolinamine
Prepared according to Procedure D from 5-(4-{3-fluoro-4-benzyloxyanilino}-6- quinazolinyI)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl-ethyiamine (1 equiv). 1H NMR 400 MHz (DMSO-d6) 8.83 (s,1H); 8.35 (d,1H); 7.89 (d,1H); 7.83 (d,1H); 7.59 (d,1H); 7.48-7.31 (m,7H); 7.26 (s,1H); 6.83 (d,1H); 5.21 (s,2H); 4.42 (s,2H); 3.60 (m,2H); 3.44 (m, 2H, obscured by water peak); 3.12 (s,3H); MS m/z 547 (M+H+).
Example 28
Figure imgf000102_0001
N-(3-Chloro-4-benzyloxyphenyl)-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-4- furyl]-4-quinazolinamine
Prepared according to Procedure D from 5-(4-{3-chloro-4-benzyloxyanilino}-6- quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl-ethylamine (1 equiv). 1H NMR 400 MHz (DMSO-d6) 9.71 (bs, 2H); 9.45 (bs, 1 H); 8.86 (s, 1H); 8.36 (d, 1H); 7.98 (d, 1H); 7.90 (d, 1H); 7.74 (d, 1H); 7.49-7.44 (m, 2H); 7.40 (m,
2H); 7.35-7.30 (m, 2H); 7.28 (d, 1 H); 6.83 (d, 1 H); 5.25 (s, 2H); 4.42 (s, 2H); 3.62 (m, 2H); 3.44 (m, 2H); 3.12 (s, 3H); MS m/z 563 (M+H+).
Example 29
Figure imgf000102_0002
N-{3-Chloro-4-f(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine Prepared according to Procedure D from 5-(4-{3-chloro-4-(3-fluorobenzyloxy)- anilino}-6-quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl- ethylamine (1 equiv). 1H NMR 400 MHz (DMSO-d6) 9.60 (bs, 1H); 9.32 (bs, 1 H); 8.82 (bs, 1H); 8.34 (d, 1 H); 8.0 (s, 1 H); 7.88 (d, 1 H); 7.74 (d, 1H); 7.45 (m, 1 H); 7.34- 7.23 (m, 4H); 7.17 (m, 1 H); 6.83 (d, 1 H); 5.27 (s, 2H); 4.42 (s, 2H); 3.59 (m, 2H); 3.40 (m, 2H, obscured by waterpeak); 3.12 (s, 3H); MS m/z 581 (M+H+). Example 30
Figure imgf000103_0001
(4-Phenoxyphenyl)-(7- (2-(2-methanesulphonyl)ethylaminomethyl)thiazol-4-yl)- quinolin-4-yl)amine
A suspension of (4-(4-(4-phenoxy)anilino)-quinolin-7-yl)thiazole-2-carbaldehyde (0.05g, 0.14mmol), sodium triacetoxyborohydride (0.12g, 0.56mmol), methanesulphonylethylamine (0.15g, 1.2mmol) and powdered 3 A molecular sieves in dichloromethane (6ml) and glacial acetic acid (1ml) was stirred at room temperature (21 °C) overnight (18hrs) according to Procedure D. The crude reaction mixture was filtered through a SPE column (SCX resin, 5g, 25ml), sequentially washed with methanol (2x10ml) and 10% ammonia in methanol (3x10ml) and the product isolated as a pale yellow gum. Trituration with water (5ml) and drying of the resultant solid over phosphorus pentoxide at 60°C under vacuum for 5hrs yielded the purified product as a pale yellow solid (0.031g, 49%); δH [2H6] DMSO 8.80(1 H,s),
8.25(3H,m), 8.10(1H,s), 7.90(1H,d), 7.20(4H,2d), 6.85(5H,m), 6.60(1 H,d), 3.95(2H,d), 2.90(7H,m); m/z 531 (M+1)+.
Example 31
Figure imgf000103_0002
(4-Phenoxyphenyl)-(7- (4-(2-methanesulphonyl)ethylaminomethyl)thiazol-5-yl)- quinolin-4-yl)amine
4-(4-Phenoxyanilino) 7-(4-formyl thiazol-5-yl) quinoline(50mg, 0.118 mmol), methanesulphonylethylamine (50mg) and molecular seives (4A, 2 large spatula tips) were stirred in a mixture of dichloromethane (6ml) and acetic acid (1ml) at room temperature for 2hr (Procedure D). Sodium triacetoxyborohydride (0.12g, 0.567mmol) was then added and the reaction was stirred at room temp for 18hr. The reaction mixture was added to a 5g SCX cartridge and washed with methanol, the product was eluted with 10% methanolic ammonia. The product was triturated with water to give a beige solid (39.7mg); δH [ H6] DMSO 9.32 (1H,s), 9.22 (1H,s), 8.64 (2H, m), 8.19 (1 H, s), 7.87 (1H,d), 7.56 (4H, m), 7.27 (6H, m), 7.02 (1H, d), 4.07 (2H, s), 3.42 (2H,t), 3.14 (5H,m);m/z 531 .
Example 32
Figure imgf000104_0001
(4-Phenoxyphenyl)-(7-(5-(2-(methanesulphonyl)ethylaminomethyl)furan-2-yl)- quinolin-4-yl)amine
5-(4-(4-phenoxyphenylamino)-quinolin-7-yl)furan-2-carbaldehyde (0.05g) was reacted with 2-(methanesulphonyl)ethylamine (0.075g) according to procedure D. Acidification with acetic acid (0.5ml) followed by purification using a ion-exchange (SCX) Bond Elut™ cartridge, eluting with methanol-ammonia (9:1), concentration and trituration with diethylether afforded an off-white solid; δH [2HQ] DMSO 8.44 (1H, d), 8.41 (1H, d), 8.11 (1H, s), 7.85 (1H, d), 7.44-7.35 (4H, m), 7.18-7.03 (6H, m), 6.79 (1H, d), 6.47 (1H, d), 3.82 (2H, s), 3.01 (2H, t); m/z 514 (M+1)+.
Example 33
Figure imgf000104_0002
6-[5-({[2-(Methanesulphonyl)ethyl]amino}methyl)-2-furyl]-7-methoxy-N-(4- benzenesulphonyl)phenyl-4-quinazolinamine
Prepared according to Procedure D from 5-(7-methoxy-4-(4- benzenesulphonyl)phenylamino-quinazolin-6-yl)furan-2-carbaldehyde hydrochloride (0.6 equiv) and 2-methanesulphonyl (1 equiv). δ1H NMR (400 MHz, DMSO-d6) 10.23 (s, 1H), 8.76(s, 1 H), 8.59 (s, 1 H), 8.14 (d, 2H), 7.96 (m, 4H), 7.59-7.71 (m, 3H), 7.33 (s, 1H), 7.03 (d, 1H), 6.47 (d, 1H), 4.06 (s, 3H), 3.86 (s, 2H), 3.27 (t, 2H), 3.00 (s, 3H), 2.98 (t, 2H). ESI-MS m/z 593(M+1).
Example 34
Figure imgf000105_0001
N-[4-(Benzyloxy)phenyl]-7-fluoro-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine Prepared according to Procedure D from a mixture of 5-(4-(4-benzyloxy- phenylamino)-7-fluoro-quinazolin-6-yl)-furan-2-carbaldehyde hydrochloride (0.13 grams) in 1 ,2-dichloroethane (3 ml), diisopropylethylamine (65 mg), acetic acid (45 mg), 2-methanesulphonylethylamine (0.125 grams), and sodium triacetoxyborohydride (0.27 grams). The mixture was stirred for 18 hours. The reaction mixture was quenched with methanol (3 ml) and poured into a separatory funnel containing aqueous saturated sodium hydrogen carbonate (100 ml) and ethyl acetate (100 ml). The mixture was extracted. The organic layer was washed with water. The organic layer was dried over magnesium sulfate, filtered, and concentrated. The residue was treated with ethyl acetate/hexanes and collected by filtration (0.083 g, 61% yield). δ1H NMR (400 MHz, DMSO-d6) 9.98(s, 1H), 8.83(d, 1 H), 8.44(s, 1H), 7.58(m, 3H), 7.44(m, 2H), 7.37(m, 2H), 7.31(m, 1 H), 7.03(d, 1 H), 6.91(m, 1 H), 6.5(d, 1H), 5.1(s, 2H), 3.84(s, 1H), 3.25(m, 2H), 2.99(s, 3H), 2.96(m, 2H). ESI-MS m/z 545(M-1).
Example 35
Figure imgf000105_0002
N-(1 -Benzyl-1 H-indazol-5-yl)-7-fluoro-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl) -2-furyl]-4-quinazolinamine Prepared according to Procedure D from 5-(4-(1 -Benzyl-1 H-indazol-5-ylamino)- 7-fluoro-quinazolin-6-yl)-furan-2-carbaldehyde (0.6 equiv) and 2- methanesulphonyl-ethylamine (1 equiv). δ 1H NMR (400 MHz, DMSO-d6) 10.16(s, 1 H), 8.91(d, 1H), 8.46(s, 1 H), 8.11(s, 2H), 7.65(m, 3H), 7.26(m, 5H), 6.93(m, 1H), 6.54(d, 2H), 5.65(s, 2H), 3.89(s, 2H), 3.28(m, 2H), 2.99(m, 5H). ESI-MS m/z 569(M-1).
Example 36
Figure imgf000106_0001
N-[4-(Phenylsulphonyl)phenyl]-7-fluoro-6-[5-({[2-(methanesulphonyl)ethyl]amino} methyl)-2-furyl]-4-quinazolinamine
Prepared according to Procedure D from 5-(4-(4-Phenylsulphonylphenylamino)- 7-fluoro-quinazolin-6-yl)-furan-2-carbaldehyde (0.6 equiv) and 2- methanesulphonyl-ethylamine (1 equiv). Η NMR (400 MHz, DMSO-d6) δ: 10.38(s, 1H), 8.87(d, 1H), 8.62(s, 1H), 8.11(d, 2H), 7.95(m, 4H), 7.63(m, 4H), 6.94(m, 1H), 6.51 (d, 1H), 3.84(s, 2H), 3.25(m, 2H), 2.98(s, 3H), 2.95(m, 2H). ESI-MS m/z 579(M-1).
Example 37
Figure imgf000106_0002
N-(3-Trifluoromethyl-4-benzyloxyphenyl)-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-4-furyl]-4-quinazolinamine The mixture of 5-(4-(4-benzyloxy-3-trifluoromethylphenylamino)-quinazolin-6-yl)- furan-2-carbaldehyde (211mg, 0.40 mmol), 2-methanesulphonyl-ethylamine (99mg, 2.0 mmol), acetic acid (0.5 ml) in dichloromethane (15 ml) was stirred at room temperature for 1.5 hours then was heated to reflux for 1 hour. The mixture was cooled to 0 °C with ice bath. Sodium cyanoborohydride (50mg, 0.8 mmol) was added at 0°C. The reaction mixture then was stirred at room temperature for 1 hour. Diluted with ethyl acetate (50 ml), then quenched with saturated sodium bicarbonate solution slowly. Extracted with ethyl acetate and the combined organic extracts were washed with brine, dried over MgSO4 and concentrated in vacuo. Purification of the resulting residue was accomplished using flash chromatography on silica gel with 2% methanol in ethyl acetate which afforded a yellow solid (0.10 g, 43% yield). H1 NMR (400 MHz, DMSO).δ10.0 (s, 1H), 8.7 (s, 1H), 8.5 (s,1H), 8.1 (d, 1H), 8.1 (s, 2H), 7.8 (d, 1H), 7.4 (m, 5H), 7.3 (m,1 H), 7.0 (d, 1 H), 6.5 (d,1H), 5.3 (s,2H), 3.8 (s,2H), 3.2 (m, 2H), 3.0 (s, 3H), 2.9 (m, 2H). ESI-MS m/z 597 (M+H)+.
Further Examples
The compounds in Lists 1 to 48 above and their hydrochloride salts, if appropriate, are prepared by analogous techniques using the appropriate starting materials.
Biological Data
Compounds of the present invention were tested for protein tyrosine kinase inhibitory activity in substrate phosphorylation assays and cell proliferation assays.
Substrate Phosphorylation Assay
The substrate phosphorylation assays use baculovirus expressed, recombinant constructs of the intracellular domains of c-erbB-2 and c-erbB-4 that are constitutively active and EGFr isolated from solubilised A431 cell membranes. The method measures the ability of the isolated enzymes to catalyse the transfer of the g-phosphate from ATP onto tyrosine residues in a biotinylated synthetic peptide (Biotin-GluGluGluGluTyrPheGluLeuVal). Substrate phosphorylation was detected following either of the following two procedures: a.) c-ErbB-2, c-ErbB4 or EGFr were incubated for 30 minutes, at room temperature, with 10mM MnCl2, 10mM ATP, 5 mM peptide, and test compound (diluted from a 5mM stock in DMSO, final DMSO concentration is 2%) in 40mM HEPES buffer, pH 7.4. The reaction was stopped by the addition of EDTA (final concentration 0.15mM) and a sample was transferred to a streptavidin-coated 96-well plate. The plate was washed and the level of phosphotyrosine on the peptide was determined using a Europium-labelled antiphosphotyrosine antibody and quantified with a time-resolved fluorescence technique, b.) ErbB2 was incubated for 50 minutes at room temperature with 15 mM MnCI2, 2 mM ATP, 0.25 mCi [γ- P] ATP/well, 5 mM peptide substrate, and test compound (diluted from a 10mM stock in DMSO, final DMSO concentration is 2%) in 50 mM MOPS pH 7.2. The reaction was terminated by the addition of 200 ml of PBS containing 2.5 mg/ml streptavidin-coated SPA beads (Amersham Inc.), 50 mM ATP, 10 mM EDTA and 0.1%TX-100. The microtitre plates were sealed and SPA beads were allowed to settle for at least six hours. The SPA signal was measured using a Packard Topcount 96-well plate scintillation counter (Packard Instrument Co., Meriden, CT).
The results are shown in Tables 1A (examples 1 to 7) and 1B (examples 8 to 29 and 33 to 37) as the IC50 values.
Table 1A
Figure imgf000108_0001
Table 1B
Figure imgf000109_0001
Figure imgf000109_0002
Compounds of the present invention were tested for lck and ZAP-70 inhibitory activity in substrate phosphorylation assays.
Lck and ZAP-70 enzymes are both expressed in Sf-9 insect cells. Lysates were prepared and the 100 OOOg supernatants were stored at -80 ° C. Lck was assayed in Hepes buffer (pH 7.4) containing ATP (50 μM), MgCl2 (10mM) and
Biotin-EEEEYFELV (200nM). ZAP-70 was assayed in Hepes buffer (pH 7.4) containing ATP (5uM), MgCI2 (10mM) and Biotin-EELQDDYEDMMEENL
(200nM). The reaction was stopped by the addition of EDTA (final concentration 25mM) and samples transferred to streptavidin coated microtitre 96-well plates. Following binding and washing the level of phosphotyrosine peptide was determined using a Europium-labelled (chelate) antiphosphotyrosine antibody. The plate was washed and enhancement solution (Wallac, DELFIA reagent) was added and the level of phosphotyrosine quantified using a time-resolved fluorescence technique. The results are shown in Table 1C as the IC50 values.
Table 1C
Figure imgf000110_0001
Figure imgf000110_0002
Cellular assays: Methylene Blue Growth Inhibition Assay
Human breast (BT474), head and neck (HN5) and gastric tumor (N87) cell lines were cultured in low glucose DMEM (Life Technologies 12320-032) containing 10% fetal bovine serum (FBS) at 37°C in a humidified 10% C02, 90% air incubator. The SV40 transformed human mammary epithelial cell line HB4a was transfected with either human H-ras cDNA (HB4a r4.2) or the human c-erbB2 cDNA (HB4a c5.2). The HB4a clones were cultured in RPMI containing 10% FBS, insulin (5 μg/ml), hydrocortisone (5 μg/ml), supplemented with the selection agent hygromycin B (50μg/ml). Cells were harvested using trypsin/EDTA, counted using a haemocytometer, and plated in 100 ml of the appropriate media, at the following densities, in a 96-well tissue culture plate (Falcon 3075): BT474 10,000 cells/well, HN5 3,000 cells/well, N87 10,000 cells/well, HB4a c5.2 3,000 cells/well, HB4a r4.2 3,000 cells/well. The next day, compounds were diluted in DMEM containing 100 mg/ml gentamicin, at twice the final required concentration, from 10mM stock solutions in DMSO. 100ml/well of these dilutions were added to the 100ml of media currently on the cell plates. Medium containing 0.6% DMSO was added to control wells. Compounds diluted in DMEM were added to all cell lines, including the HB4a r4.2 and HB4a c5.2 cell lines. The final concentration of DMSO in all wells was 0.3%. Cells were incubated at 37°C, 10% CO2 for 3 days. Medium was removed by aspiration. Cell biomass was estimated by staining cells with 100μl per well methylene blue (Sigma M9140, 0.5% in 50:50 ethanol: water), and incubation at room temperature for at least 30 minutes. Stain was removed, and the plates rinsed under a gentle stream of water, and air-dried. To release stain from the cells 100μl of solubilization solution was added (1% N-lauroyl sarcosine, Sodium salt, Sigma L5125, in PBS), and plates were shaken gently for about 30 minutes. Optical density at 620 nM was measured on a microplate reader. Percent inhibition of cell growth was calculated relative to vehicle treated control wells. Concentration of compound that inhibits 50% of cell growth (IC50) was interpolated using nonlinear regression (Levenberg-Marquardt) and the equation, y = Vmax *(1-(x/(K+x))) + Y2, where "K" was equal to the IC50.
Table 2 illustrates the inhibitory activity of compounds of the present invention as IC50 values in μM against a range of tumor cell lines. Table 2
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000113_0002
Liver S-9 homogenates (5 mg/mL protein concentration) from prepared pooled male Sprague Dawley rat livers and pooled human livers (XenoTech, LLC, Kansas City, KS) were incubated in 96-well polypropylene plates with representative examples selected from examples 1 to 40 (10 μM) in a total volume of 0.5 mL. Stock solutions of these compounds were prepared in DMSO at a concentration of 1 mM to maintain a <1% final DMSO concentration for each reaction. Enzymatic incubations contained cofactors (5.71 mM NADPH, 7.14 mM glucose-6-phosphate, 7.14 mM UDPGA, 47.1mM potassium chloride, and 11.4 mM magnesium chloride in 0.1 M potassium phosphate buffer, pH 7.4). Control samples were aspirated from the reaction samples at time zero and placed immediately into 2 volumes of ice-chilled acetonitrile. Sample reaction plates were incubated for 60 min in a shaker incubator maintained at 37°C supplied with O2. Reactions were terminated by addition of 2 volumes of ice-chilled acetonitrile. All samples were vortexed and centrifuged at 2000 x g for 10 min. The supernatant was removed and analyzed by LC-MS. The metabolite identification work was done by using reversed-phase HPLC coupled with ion-trap mass spectroscopy. For example:
Figure imgf000114_0001
Example 5, m/z 529 N-dealkylated, m/z 423
N-[4-(Benzyloxy)phenyl]-6-[4-(aminomethyl)-2-furyl]-4-quinazolinamine
Figure imgf000114_0002
Prepared according to Procedure D and identified as a major metabolite of N-[4- (benzyloxy)phenyl]-6-[4-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4- quinazolinamine in 1HNMR 300MHz, CDCI3 8.69(s,1H), 8.11 (s,1 H), 8.02 (d, 1H), 7.88 (d, 1H), 7.61 (d,2H), 7.5-7.2 (m,7H), 7.05 (d,2H), 6.83 (s,1 H), 5.10 (s,2H), 3.82 (s,2H) ; MS m/z 423 (M+1).
Thus, particular compounds of interest as metabolites (either as isolated compounds or compounds in vivo) are compounds of formula (XVII):
Figure imgf000114_0003
in which Ar, Y, V, X and U are as defined above; all possible preferments for these groups as defined above are applicable.
Compounds of formula (XII) of special interest include:
4-(4-Fluorobenzyloxy)-phenyl)-(6-(5-(aminomethyl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-
4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-(aminomethyl)-furan-2-yl)-pyrido[3,4- d]pyrimidin-4-yl)-amine; (4-Benzenesulphonyl-phenyl)-(6-(5-(aminomethyl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-
4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(3-(aminomethyl)phenyl-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(5-(aminomethyl)-furan-2-yl)-quinazolin-4-yl)-amine;
(4-(3-Fluorobenzyloxy-phenyl)-(6-(4-(aminomethyl)-furan-2-yl)-pyrido[3,4-d]pyrimidin- 4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(2-(aminomethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine;
N-{4-[(3-Fluorobenzyl)oxy]phenyl}-6-[5-(aminomethyl)-2-furyl]-4-quinazolinamine;
N-{4-[(3-Fluorobenzyl)oxy]-3-methoxyphenyl}-6-[5-(aminomethyl)-2-furyl]-4- quinazolinamine; N-[4-(Benzyloxy)phenyl]-7-methoxy-6-[5-(aminomethyl)-2-furyl]-4-quinazolinamine;
N-[4-(Benzyloxy)phenyl]-6-[4-(aminomethyl)-2-furyl]-4-quinazolinamine;
N-{4-[(3-Fluorobenzyl)oxy]-3-methoxyphenyl}-6-[2-(aminomethyl)-1 ,3-thiazol-4-yl]-4- quinazolinamine;
N-{4-[(3-Bromobenzyl)oxy]phenyl}-6-[2-(aminomethyl)-1 ,3-thiazol-4-yl]-4- quinazolinamine;
N-{4-[(3-Fluorobenzyl)oxy]phenyl}-6-[2-(aminomethyl)-1 ,3-thiazol-4-yl]-4- quinazolinamine;
N-[4-(Benzyloxy)-3-fluorophenyl]-6-[2-(aminomethyl)-1 ,3-thiazol-4-yl]-4- quinazolinamine; N-(1 -Benzyl-1 H-indazol-5-yl)-7-methoxy-6-[5-(aminomethyl)-2-furyl]-4- quinazolinamine;
6-[5-(aminomethyl)-2-furyl]-N-(4-{[3-(trifluoromethyl)benzyl]oxy}phenyl)-4- quinazolinamine;
N-{3-Fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-(aminomethyl)-2-furyl]-4- quinazolinamine; N-{4-[(3-Bromobenzyl)oxy]phenyl}-6-[5-(aminomethyl)-2-furyl]-4-quinazolinamine;
N-[4-(Benzyloxy)phenyl]-6-[3-(aminomethyl)-2-furyl]-4-quinazolinamine;
N-[1 -(3-Fluorobenzyl)-1 H-indazol-5-yl]-6-[2-(aminomethyl)-1 ,3-thiazol-4-yl]-4- quinazolinamine; 6-[5-(Aminomethyl)-2-furyl]-N-[4-(benzenesulphonyl)phenyl]-4-quinazolinamine;
6-[2-(Aminomethyl)-1 ,3-thiazol-4-yl]-N-[4-(benzenesulphonyl)phenyl]-4- quinazolinamine;
6-[2-(Aminomethyl)-1,3-thiazol-4-yl]-N-(4-{[3-(trifluoromethyl)benzyl]oxy}phenyl)-4- quinazolinamine N-{3-Fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[2-(aminomethyl)-1 ,3-thiazol-4-yl]-4- quinazolinamine;
N-(1 -Benzyl-1 H-indazol-5-yl)-6-[2-(aminomethyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-(3-Fluoro-4-benzyloxyphenyl)-6-[2-(aminomethyl)-1 ,3-thiazol-4-yl]-4- quinazolinamine; N-(3-Chloro-4-benzyloxyphenyl)-6-[2-(aminomethyl)-1 ,3-thiazol-4-yl]-4- quinazolinamine;
N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-(aminomethyl)-2-furyl]-4- quinazolinamine;
(4-Phenoxyphenyl)-(7- (2-(aminomethyl)-thiazol-4-yl)-quinolin-4-yl)amine; (4-Phenoxyphenyl)-(7- (4-(aminomethyl)-thiazol-5-yl)-quinolin-4-yl)amine;
(4-Phenoxyphenyl)-(7-(5-(aminomethyl)-furan-2-yl)-quinolin-4-yl)amine;
6-[5-(Aminomethyl)-2-furyl]-7-methoxy-N-(4-phenylsulphonyl)phenyl-4- quinazolihamine;
N-[4-(Benzyloxy)phenyl]-7-fluoro-6-[5-(aminomethyl)-2-furyl]-4-quinazolinamine; N-(1 -Benzyl-1 H-indazol-5-yl)-7-fluoro-6-[5-(aminomethyl)-2-furyI]-4- quinazoiinamine;
N-[4-(Benzenesulphonyl)phenyl]-7-fluoro-6-[5-(aminomethyl)-2-furyl]-4- quinazolinamine; N-(3-Trifluoromethyl-4-benzyloxyphenyl)-6-[5-(aminomethyl)-4-furyl]-4- quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts thereof.

Claims

Claims
A compound of formula (I)
Figure imgf000117_0001
or a salt or solvate thereof;
wherein X is N or CH;
Y is CR1 and V is N; or Y is N and V is CR1; or Y is CR1 and V is CR2; or Y is CR2 and V is CR1;
R1 represents a group CH3SO2CH2CH2NHCH2-Ar-, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C^ alkyl or C^ alkoxy groups;
R2 is selected from the group comprising hydrogen, halo, hydroxy, C^ alkyl, C1J} alkoxy, C^ alkylamino and di[C alkyl]amino;
U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1 H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro- 1 H-benzimidazolyl or 1 H-benzotriazolyl group, substituted by an R3 group and optionally substituted by at least one independently selected R4 group;
R3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl;
or R3 represents trihalomethylbenzyl or trihalomethylbenzyloxy; or R3 represents a group of formula
Figure imgf000118_0001
wherein each R5 is independently selected from halogen, C^ alkyl and C^ alkoxy; and n is 0 to 3;
each R4 is independently hydroxy, halogen, C1w, alkyl, C^ alkenyl, C2 , alkynyl, C^ alkoxy, amino, C^ alkylamino, di[C^ aikyl]amino, C^ alkylthio, C^ alkylsulphinyl, C alkylsulphonyl, C1J} alkylcarbonyl, carboxy, carbamoyl, C,^ alkoxycarbonyl, C^ alkanoylamino, N-(C^ alkyl)carbamoyl, N,N-di(C alkyl)carbamoyl, cyano, nitro and trifluoromethyl;
with the proviso that the following compounds are excluded:
(1-Benzyl-1H-indazol-5-yl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2- yl)-pyrido[3,4-d]pyrimidin-4-yl-amine;
(4-Benzyloxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2-yl)- pyrido[3,4-d]pyrimidin-4-yl-amine;
(1-Benzyl-1 H-indazol-5-yl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2- yl)-quinazolin-4-yl-amine; (1-BenzyI-1iH-indazol-5-yl)-(7-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2- yl)-quinazolin-4-yl-amine;
(1-Benzyl-1H-indazol-5-yl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-1- methyl-pyrrol-2-yl)-quinazolin-4-yl-amine; and their hydrochloride salts.
2. A compound as claimed in claim 1 wherein R2 is hydrogen or C^ alkoxy; or R2 is halo.
3. A compound as claimed in claims 1 or claim 2 wherein the group Ar represents unsubstituted furan or thiazole.
4. A compound as claimed in any one of claims 1 to 3 wherein U represents a phenyl or 1H-indazolyl group substituted by an R3 group and optionally substituted by at least one independently selected R4 group.
5.5 5. A compound as claimed in any one of claims 1 to 4 wherein R3 represents benzyl, pyridylmethyl, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl; or R3 represents trihalomethylbenzyloxy.
6. A compound as claimed in claims 1 to 5 wherein U is substituted by an R4 10 group selected from halo or C ╬╣_4 alkoxy; or wherein U is not substituted by an R4 group.
7. A compound of formula (I) or a salt or solvate thereof as claimed in any one of claims 1 to 6 wherein X is N; V is CR2, wherein R2 is hydrogen, halo (especially
15 fluoro) or C1 , alkoxy (especially methoxy); Y is CR1 wherein R1 is as defined above in which Ar is unsubstituted phenyl, furan or thiazole; U is phenyl or indazole; R3 is benzyl, fluorobenzyl, benzyloxy, fluorobenzyloxy, bromobenzyloxy, trifluoromethylbenzyloxy, phenoxy or benzenesulphonyl; and R4 is not present or is halo (especially chloro or fluoro), or methoxy.
20
8. A compound of formula (I) or a salt or solvate thereof as claimed in any one of claims 1 to 6 wherein X is N; Y is CR2, wherein R2 is hydrogen, halo (especially fluoro) or CM alkoxy (especially methoxy); V is CR1 wherein R1 is as defined above in which Ar is unsubstituted phenyl, furan or thiazole; U is phenyl or indazole; R3 is
25 benzyl, fluorobenzyl, benzyloxy, fluorobenzyloxy, bromobenzyloxy, trifluoromethylbenzyloxy, phenoxy or benzenesulphonyl; and R4 is not present or is halo (especially chloro or fluoro), or methoxy.
9. A compound of formula (I) or a salt or solvate thereof as claimed in any one of 30 claims 1 to 6 wherein X is N; V is N; Y is CR1 wherein R1 is as defined above in which Ar is unsubstituted phenyl, furan or thiazole; U is phenyl or indazole; R3 is benzyl, fluorobenzyl, benzyloxy, fluorobenzyloxy, bromobenzyloxy, trifluoromethylbenzyloxy, phenoxy or benzenesulphonyl; and R4 is not present or is halo (especially chloro or fluoro), or methoxy. 35
10. A compound of formula (I) or a salt or solvate thereof as claimed in any one of claims 1 to 6 wherein X is CH; Y is CR2, wherein R2 is hydrogen, halo (especially fluoro) or C1w, alkoxy (especially methoxy); V is CR1 wherein R1 is as defined above in which Ar is unsubstituted phenyl, furan or thiazole; U is phenyl or indazole R3 is benzyl, fluorobenzyl, benzyloxy, fluorobenzyloxy, bromobenzyloxy, trifluoromethylbenzyloxy, phenoxy or benzenesulphonyl; and R4 is not present or is halo (especially chloro or fluoro), or methoxy.
11. A compound as claimed in claim 1 selected from: 4-(4-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)-furan-
2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzenesulphonyl-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan- 2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(3-((2-methanesulphonyl-ethylamino)-methyl)-phenyl)- pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2-yl)- quinazolin-4-yl)-amine; (4-(3-Fluorobenzyloxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl)- furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxy-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)-methyl)-thiazol-4-yl)- quinazolin-4-yl)-amine;
N-{4-[(3-Fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)- 2-furyl]-4-quinazolinamine;
N-{4-[(3-Fluorobenzyl)oxy]-3-methoxyphenyl}-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
N-[4-(Benzyloxy)phenyl]-7-methoxy-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-[4-(Benzyloxy)phenyl]-6-[4-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4- quinazolinamine;
N-{4-[(3-Fluorobenzyl)oxy]-3-methoxyphenyl}-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-{4-[(3-Bromobenzyl)oxy]phenyl}-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)- 1 ,3-thiazol-4-y!]-4-quinazolinamine; N-{4-[(3-Fluorobenzyl)oxy]phenyl}-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-
1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-[4-(Benzyloxy)-3-fluorophenyJ]-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-
1,3-thiazol-4-yl]-4-quinazolinamine; N-(1 -Benzyl-1 H-indazol-5-yl)-7-methoxy-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
6-[5-({[2-(Methanesulphonyl)ethyl]amino}methyl)-2-furyl]-N-(4-{[3-
(trifluoromethyl)benzyl]oxy}phenyl)-4-quinazolinamine;
N-{3-Fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
N-{4-[(3-Bromobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-
2-furyl]-4-quinazolinamine;
N-[4-(Benzyloxy)phenyl]-6-[3-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4- quinazolinamine; N-[1-(3-Fluorobenzyl)-1 H-indazol-5-yl]-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine;
6-[5-({[2-(Methanesulphonyl)ethyl]amino}methyl)-2-furyl]-N-[4-
(benzenesulphonyl)phenyl]-4-quinazolinamine;
6-[2-({[2-(Methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-N-[4- (benzenesulphonyl)phenyl]-4-quinazolinamine;
6-[2-({[2-(Methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-N-(4-{[3-
(trifluoromethyl)benzyl]oxy}phenyl)-4-quinazolinamine
N-{3-Fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[2-({[2-
(methanesulphonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine; N-(1 -Benzyl-1 H-indazol-5-yl)-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-1 ,3- thiazol-4-yl]-4-quinazolinamine;
N-(3-Fluoro-4-benzyloxyphenyl)-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)-
1,3-thiazol-4-yl]-4-quinazolinamine;
N-(3-Chloro-4-benzyloxyphenyl)-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl)- 1 ,3-thiazol-4-yl]-4-quinazolinamine;
N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
6-[5-({[2-(Methanesulphonyl)ethyl]amino}methyl)-2-furyl]-7-methoxy-N-(4- benzenesulphonyl)phenyl-4-quinazolinamine; N-[4-(Benzyloxy)phenyl]-7-fluoro-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
N-(1 -Benzyl-1 H-indazol-5-yl)-7-fluoro-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl) -2-furyl]-4-quinazolinamine;
N-[4-(Benzenesulphonyl)phenyl]-7-fluoro-6-[5-({[2-
(methanesulphonyl)ethyl]amino} methyl)-2-furyl]-4-quinazolinamine;
N-(3-Trifluoromethyl-4-benzyloxyphenyl)-6-[5-({[2-
(methanesulphonyl)ethyl]amino}methyl)-4-furyl]-4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts thereof.
12. A compound as claimed in claim 11 selected from:
(4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl)- furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(4-Benzyloxyphenyl)-(6-(5-((2-methanesulphonyl-ethylamino)-methyl)-furan-2-yl)- quinazolin-4-yl)-amine;
N-{4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2- furyl]-4-quinazolinamine;
N-[4-(benzyloxy)phenyl]-7-methoxy-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2- furyl]-4-quinazolinamine; N-(1 -benzyl-1 H-indazol-5-yl)-7-methoxy-6-[5-({[2-
(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
N-{3-fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-
(methylsϋlfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
N-[1-(3-fluorobenzyl)-1H-indazol-5-yl]-6-[2-({[2-(methylsulfonyl)ethyl]amino}methyl)- 1 ,3-thiazol-4-yl]-4-quinazolinamine;
6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furylj-N-[4-(phenylsulfonyl)phenyl]-4- quinazolinamine;
N-{3-fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[2-({[2-
(methylsulfonyl)ethyl]amino}methyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine; N-(1-benzyl-1 H-indazol-5-yl)-6-[2-({[2-(methylsulfonyl)ethyl]amino}methyl)-1 ,3- thiazol-4-yl]-4-quinazolinamine;
N-(3-fluoro-4-benzyloxyphenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-4-furyl]-
4-quinazolinamine;
N-(3-Chloro-4-benzyloxyphenyl)-6-[2-({[2-(methylsulfonyl)ethyl]amino}methyl)-4- furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-(1-Benzyl-1 H-indazol-5-yl)-7-fluoro-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2- furyl]-4-quinazolinamine; N-(3-trifluoromethyl-4-benzyloxyphenyl)-6-[5-({[2-
(methylsulfonyl)ethyl]amino}methyl)-4-furyl]-4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts thereof.
13. A compound as claimed in claim 1 selected from: (4-Phenoxyphenyl)-(7- (2-(2-methanesulphonyl)ethylaminomethyl)thiazol-4-yl)- quinolin-4-yl)amine;
(4-Phenoxyphenyl)-(7- (4-(2-methanesulphonyl)ethylaminomethyl)thiazol-5-yl)- quinolin-4-yl)amine;
(4-Phenoxyphenyl)-(7-(5-(2-(methanesulphonyl)ethylaminomethyl)furan-2-yl)- quinolin-4-yl)amine; and salts or solvates thereof, particularly pharmaceutically acceptable salts thereof.
14. A process for the preparation of a compound of formula (I) as defined in claim 1 which comprises the steps:
(a) the reaction of a compound of formula (II)
Figure imgf000123_0001
wherein X is as defined above;
Y' is CL' and V is N; or Y' is N and V' is CL'; or Y' is CL' and V is CR2; or Y' is CR2 and V is CL'; wherein R2 is as defined above, and L and L' are suitable leaving groups, with a compound of formula (III) UNH2 (III) wherein U is as defined above, to prepare a compound of formula (IV)
Figure imgf000124_0001
and subsequently (b) reaction with appropriate reagent(s) to substitute the group R1 by replacement of the leaving group L'; and, if desired, (c) subsequently converting the compound of formula (I) thereby obtained into another compound of formula (I) by means of appropriate reagents.
15. A process for the preparation of a compound of formula (I) as defined in claim 1 which comprises the steps:
(a) reacting a compound of formula (IV) as defined above with appropriate reagent(s) to prepare a compound of formula (VIII)
Figure imgf000124_0002
wherein X and U are as defined in claim 1 ;
Y" is CT and V" is N; or Y" is N and V" is CT; or Y" is CT and V is CR2; or Y" is CR2 and V" is CT; wherein R2 is as defined claim 1 and T is an appropriately functionalised group; and (b) subsequently converting the group T into the group R1 by means of appropriate reagent(s); and, if desired, (c) subsequently converting the compound of formula (I) thereby obtained into another compound of formula (I) by means of appropriate reagents.
16. A pharmaceutical formulation comprising at least one compound of formula (I) as claimed in any one of claims 1 to 13 or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents or excipients.
17. A pharmaceutical formulation as claimed in claim 16 in unit dosage form and containing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in an amount of from 70 to 700mg.
18. A compound of formula (I) as claimed in any one of claims 1 to 13 or a pharmaceutically acceptable salt or solvate thereof for use in therapy.
19. The use of a compound of formula (I) as claimed in any one of claims 1 to 13 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for the treatment of a disorder mediated by abberant protein tyrosine kinase activity.
20. The use as claimed in claim 19 in the preparation of a medicament for the treatment of cancer and malignant tumours.
21. The use as claimed in claim 19 in the preparation of a medicament for the treatment of psoriasis.
22. The use as claimed in claim 19 in the preparation of a medicament for the treatment of rheumatiod arthritis.
23. A method of treatment of a human or animal subject suffering from a disorder mediated by abberant protein tyrosine kinase activity which comprises administering to said subject an effective amount of a compound of formula (I) as claimed in any one of claims 1 to 13 or a pharmaceutically acceptable salt or solvate thereof.
24. A method of treatment of a human or animal subject suffering from cancer or malignant tumours which comprises administering to said subject an effective amount of a compound of formula (I) as claimed in any one of claims 1 to 13 or a pharmaceutically acceptable salt or solvate thereof.
25. A method of treatment of a human or animal subject suffering from psoriasis which comprises administering to said subject an effective amount of a compound of formula (I) as claimed in any one of claims 1 to 13 or a pharmaceutically acceptable salt or solvate thereof.
26. A method of treatment of a human or animal subject suffering from rheumatoid arthritis which comprises administering to said subject an effective amount of a compound of formula (I) as claimed in any one of claims 1 to 13 or a pharmaceutically acceptable salt or solvate thereof.
PCT/EP1999/000048 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors WO1999035146A1 (en)

Priority Applications (41)

Application Number Priority Date Filing Date Title
SK1050-2000A SK285405B6 (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds, method for producing the same, pharmaceutical composition containing them and their use
EP99902522A EP1047694B1 (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
IL13704199A IL137041A0 (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
UA2000074012A UA66827C2 (en) 1998-01-12 1999-01-08 Dicyclic heteroaromatic compounds as inhibitors of albuminous tyrosine kinase
HU0100941A HU227593B1 (en) 1998-01-12 1999-01-08 Quinoline, quinazoline and pyrido-pyrimidine derivatives raning protein tyrosyne kinase inhibitor activity,process for their preparation and pharmaceutical compositions thereof
US09/582,746 US6727256B1 (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
JP2000527545A JP3390741B2 (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
CA002317589A CA2317589C (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
DK04076762T DK1454907T3 (en) 1998-01-12 1999-01-08 Quninazoline and pyridopyrmidine derivatives
MEP-2000-448A ME00757B (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
DE69918528T DE69918528T2 (en) 1998-01-12 1999-01-08 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
DK99902522T DK1047694T3 (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
DE122008000048C DE122008000048I1 (en) 1998-01-12 1999-01-08 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
KR1020007007635A KR100569776B1 (en) 1998-01-12 1999-01-08 Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors
BRPI9906904-0A BR9906904B1 (en) 1998-01-12 1999-01-08 heteroaromatic bicyclic compound as a protein tyrosine kinase inhibitor, pharmaceutical formulation comprising the same, and its use.
APAP/P/2000/001861A AP1446A (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
NZ505456A NZ505456A (en) 1998-01-12 1999-01-08 Quinazoline and pyridopyrimidine derivatives and pharmaceuticals thereof, useful as protein tyrosine kinase inhibitors
EA200000637A EA002455B1 (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
SI9930663T SI1047694T1 (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AT99902522T ATE270670T1 (en) 1998-01-12 1999-01-08 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
EEP200000411A EE04616B1 (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU22783/99A AU749549C (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
IL137041A IL137041A (en) 1998-01-12 2000-06-27 6 - (substituted furyl) quinazolin - 4 - aniline derivative, its preparation and protein tyrosine kinase inhibiting compositions containing it
IS5549A IS2276B (en) 1998-01-12 2000-06-27 Bicyclic heteroaromatic compounds inhibited by tyrosine kinase protein
NO20003561A NO316176B1 (en) 1998-01-12 2000-07-11 Bicyclic heteroaromatic compounds such as protein tyrosine kinase inhibitors, use and preparation thereof, as well as pharmaceutical formulation
HR20000469A HRP20000469B1 (en) 1998-01-12 2000-07-12 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HK01102589A HK1031883A1 (en) 1998-01-12 2001-04-11 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
US10/071,358 US6713485B2 (en) 1998-01-12 2002-02-08 Heterocyclic compounds
US11/050,033 US7109333B2 (en) 1998-01-12 2005-02-03 Heterocyclic compounds
US11/532,926 US20070015775A1 (en) 1998-01-12 2006-09-19 Heterocyclic compounds
US11/752,582 US20070238875A1 (en) 1998-01-12 2007-05-23 Heterocyclic compounds
LU91475C LU91475I2 (en) 1998-01-12 2008-09-10 Lapatinib or one of its salts or solvates (TYVERB)
NL300360C NL300360I2 (en) 1998-01-12 2008-09-12 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
CY200800015C CY2008015I2 (en) 1998-01-12 2008-09-18 BICYCLIC ETEOAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
FR08C0038C FR08C0038I2 (en) 1998-01-12 2008-10-01 HETEROAROMATIC BICYCLIC COMPOUNDS ACTING AS TYROSINE KINASE INHIBITORS
NO2008017C NO2008017I1 (en) 1998-01-12 2008-11-13 N- [3-chloro-4 - {[(3-fluorophenyl) methyl] oxy} phenyl] -6 [5 - ({[2-methylsulfonyl) ethyl] amino} methyl) -2-furanyl] -4-quinazolinamine or salt or solvate thereof
US12/691,784 US8513262B2 (en) 1998-01-12 2010-01-22 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US13/943,049 US8912205B2 (en) 1998-01-12 2013-07-16 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US14/536,896 US9199973B2 (en) 1998-01-12 2014-11-10 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US14/887,434 US20160051551A1 (en) 1998-01-12 2015-10-20 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US15/226,949 US20160339027A1 (en) 1998-01-12 2016-08-03 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9800569.7 1998-01-12
GBGB9800569.7A GB9800569D0 (en) 1998-01-12 1998-01-12 Heterocyclic compounds

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US09/582,746 A-371-Of-International US6727256B1 (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US09582746 A-371-Of-International 1999-01-08
US10/071,358 Continuation US6713485B2 (en) 1998-01-12 2002-02-08 Heterocyclic compounds
US10/342,810 Continuation US20030176451A1 (en) 1998-01-12 2003-01-15 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
WO1999035146A1 true WO1999035146A1 (en) 1999-07-15

Family

ID=10825153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/000048 WO1999035146A1 (en) 1998-01-12 1999-01-08 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Country Status (48)

Country Link
US (11) US6727256B1 (en)
EP (3) EP1460072B1 (en)
JP (2) JP3390741B2 (en)
KR (1) KR100569776B1 (en)
CN (1) CN1134438C (en)
AP (1) AP1446A (en)
AR (2) AR015507A1 (en)
AT (3) ATE270670T1 (en)
AU (2) AU749549C (en)
BG (1) BG64825B1 (en)
BR (1) BR9906904B1 (en)
CA (1) CA2317589C (en)
CO (1) CO4820390A1 (en)
CY (3) CY1105618T1 (en)
CZ (1) CZ298047B6 (en)
DE (4) DE69918528T2 (en)
DK (3) DK1460072T3 (en)
EA (1) EA002455B1 (en)
EE (1) EE04616B1 (en)
EG (1) EG24743A (en)
ES (3) ES2319119T3 (en)
FR (1) FR08C0038I2 (en)
GB (1) GB9800569D0 (en)
GE (1) GEP20022678B (en)
HK (1) HK1031883A1 (en)
HR (2) HRP20000469B1 (en)
HU (1) HU227593B1 (en)
IL (2) IL137041A0 (en)
IS (1) IS2276B (en)
LU (1) LU91475I2 (en)
MA (1) MA26596A1 (en)
ME (1) ME00757B (en)
MY (1) MY124055A (en)
NL (1) NL300360I2 (en)
NO (2) NO316176B1 (en)
NZ (1) NZ505456A (en)
OA (1) OA11444A (en)
PE (1) PE20000230A1 (en)
PL (1) PL192746B1 (en)
PT (3) PT1454907E (en)
RS (1) RS49779B (en)
SI (3) SI1460072T1 (en)
SK (1) SK285405B6 (en)
TR (1) TR200002015T2 (en)
TW (1) TW477788B (en)
UA (1) UA66827C2 (en)
WO (1) WO1999035146A1 (en)
ZA (1) ZA99172B (en)

Cited By (282)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2345486A (en) * 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
WO2001004111A1 (en) * 1999-07-09 2001-01-18 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
WO2001021596A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
WO2001072711A1 (en) * 2000-03-28 2001-10-04 Wyeth 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
WO2002002552A1 (en) * 2000-06-30 2002-01-10 Glaxo Group Limited Quinazoline ditosylate salt compounds
WO2002056912A2 (en) * 2001-01-16 2002-07-25 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
US6462238B2 (en) 2000-05-02 2002-10-08 Array Biopharma, Inc. Process for the reduction of cyano-substituted sulfones to aminoalkylene-substituted sulfones
WO2002092578A1 (en) * 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
JP2003520855A (en) * 2000-01-28 2003-07-08 アストラゼネカ アクチボラグ Chemical compound
US6638945B1 (en) 1999-05-08 2003-10-28 Astrazeneca Ab Quinoline derivatives as inhibitors of MEK enzymes
WO2003101491A1 (en) * 2002-06-03 2003-12-11 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
WO2004056812A1 (en) * 2002-12-23 2004-07-08 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
WO2004060400A1 (en) * 2003-01-06 2004-07-22 Mitsubishi Pharma Corp Antipsychotic molecular-targeting epithelial growth factor receptor
JP2004524350A (en) * 2001-03-23 2004-08-12 バイエル コーポレイション Rho kinase inhibitor
JP2004528314A (en) * 2001-03-23 2004-09-16 バイエル コーポレイション Rho kinase inhibitor
US6809106B1 (en) 1999-05-08 2004-10-26 Astrazeneca Ab Quinoline derivatives as inhibitors of MEK enzymes
US6812251B2 (en) * 2001-03-15 2004-11-02 Rhode Island Hospital Taurine compounds
EP1488809A1 (en) 2001-01-16 2004-12-22 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
US6869962B2 (en) 2002-06-14 2005-03-22 Agouron Pharmaceuticals, Inc. Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
US6890924B2 (en) 2000-06-22 2005-05-10 Pfizer Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
WO2005046678A1 (en) * 2003-11-07 2005-05-26 Smithkline Beecham (Cork) Limited Cancer treatment method
US6919338B2 (en) 2000-06-28 2005-07-19 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
US6924290B2 (en) 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US6927220B2 (en) 2001-04-13 2005-08-09 Pfizer Inc Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
US6943172B2 (en) 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7053107B2 (en) 2002-12-19 2006-05-30 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO2006061253A2 (en) * 2004-12-10 2006-06-15 Glaxosmithkline Biologicals S.A. Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy
WO2005105094A3 (en) * 2004-04-16 2006-06-15 Smithkline Beecham Corp Cancer treatment method
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
US7074800B1 (en) 1999-02-10 2006-07-11 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
US7074799B2 (en) 2002-01-17 2006-07-11 Neurogen Corporation Substituted quinazolin-4-ylamine analogues
WO2006076646A2 (en) * 2005-01-14 2006-07-20 Neurogen Corporation Heteroaryl substituted quinolin-4-ylamine analogues
WO2006113649A1 (en) 2005-04-19 2006-10-26 Smithkline Beecham [Cork] Limited Pharmaceutical composition
WO2006066267A3 (en) * 2004-12-17 2006-12-14 Smithkline Beecham Cork Ltd Cancer treatment method
US7173136B2 (en) 2002-11-02 2007-02-06 Astrazeneca Ab 3-Cyano-quinoline derivatives
US7173135B2 (en) 2002-07-09 2007-02-06 Astrazeneca Ab Substituted 3-cyanoquinolines as MEK inhibitors
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US7208500B2 (en) 2003-08-29 2007-04-24 Agouron Pharmaceuticals, Inc. Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents
US7220750B2 (en) 1999-06-21 2007-05-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
EP1792902A1 (en) * 2000-06-30 2007-06-06 Glaxo Group Limited Processes for preparation of 5-(6-quinazolinyl)-furan-2-carbaldehydes
WO2007067506A2 (en) 2005-12-05 2007-06-14 Smithkline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2007082434A1 (en) 2006-01-20 2007-07-26 Shanghai Allist Pharmaceutical., Inc. Quinazoline derivatives,preparation methods and uses thereof
US7253184B2 (en) 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
US7262201B1 (en) 1998-10-08 2007-08-28 Astrazeneca Ab Quinazoline derivatives
US7268230B2 (en) 2002-02-01 2007-09-11 Astrazeneca Ab Quinazoline compounds
WO2007132308A1 (en) 2006-05-11 2007-11-22 Pfizer Products Inc. Triazolopyrazine derivatives useful as anti-cancer agents
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US7371765B2 (en) 2000-08-09 2008-05-13 Astrazeneca Ab Quinoline derivatives having VEGF inhibiting activity
WO2008076278A2 (en) 2006-12-13 2008-06-26 Schering Corporation Methods of cancer treatment with igf1r inhibitors
WO2008098485A1 (en) 2007-02-14 2008-08-21 Shanghai Allist Pharmaceuticals, Inc. The salts of 4-aniline quinazoline derivative
US7432275B2 (en) * 2002-12-13 2008-10-07 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
US7488740B2 (en) 2003-07-14 2009-02-10 Neurogen Corporation Substituted quinolin-4-ylamine analogues
WO2009033094A2 (en) 2007-09-07 2009-03-12 Agensys, Inc. Antibodies and related molecules that bind to 24p4c12 proteins
US7504408B2 (en) 2002-07-09 2009-03-17 Astrazeneca Ab Quinzoline derivatives for use in the treatment of cancer
US7547702B2 (en) 2000-09-20 2009-06-16 Ortho-Mcneil Pharmaceutical, Inc. 4-amino-quinazolines
EP2116245A2 (en) 2004-08-07 2009-11-11 Boehringer Ingelheim International GmbH EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
WO2009140144A1 (en) * 2008-05-15 2009-11-19 Teva Pharmaceutical Industries Ltd. Forms of crystalline lapatinib and processes for preparation thereof
WO2009140863A1 (en) 2008-05-21 2009-11-26 上海艾力斯医药科技有限公司 Compositions comprising quinazoline derivatives, preparation methods and uses thereof
US7625908B2 (en) 2003-11-13 2009-12-01 Astrazeneca Ab Quinazoline derivatives
US7648986B2 (en) 2002-01-10 2010-01-19 Bayer Healthcare Llc Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors
EP2158912A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
US20100063074A1 (en) * 2004-06-03 2010-03-11 Berger Mark S Cancer Treatment Method
EP2166859A1 (en) * 2007-06-11 2010-03-31 SmithKline Beecham (Cork) Limited Quinazoline salt compounds
EP2167092A2 (en) * 2007-06-14 2010-03-31 GlaxoSmithKline LLC Quinazoline derivatives as pi3 kinase inhibitors
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
EP2194067A2 (en) 2001-01-05 2010-06-09 Pfizer Inc. Antibodies to insulin-like growth factor I receptor (IGF-IR)
US7772243B2 (en) 2004-05-06 2010-08-10 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
US7812022B2 (en) 2004-12-21 2010-10-12 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
US7820683B2 (en) 2005-09-20 2010-10-26 Astrazeneca Ab 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
US7829297B2 (en) 2003-08-01 2010-11-09 Glaxosmithkline Llc Treatment of cancers expressing p95 ErbB2
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
US7858643B2 (en) 2004-08-26 2010-12-28 Agouron Pharmaceuticals, Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
EP2281901A2 (en) 2005-08-02 2011-02-09 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
EP2292233A2 (en) 1999-11-11 2011-03-09 OSI Pharmaceuticals, Inc. Pharmaceutical uses of N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
WO2011027249A2 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
US7935702B2 (en) 2004-10-12 2011-05-03 Neurogen Corporation Substituted biaryl quinolin-4-ylamine analogues
WO2011058164A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US7947676B2 (en) 2004-12-14 2011-05-24 Astrazeneca Ab Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
US7973160B2 (en) 2000-10-20 2011-07-05 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic derivatives
EP2343086A2 (en) 2001-11-09 2011-07-13 Pfizer Products Inc. Antibodies to CD40
EP2348110A1 (en) 2003-05-30 2011-07-27 AstraZeneca UK Limited Process
WO2011098971A1 (en) 2010-02-12 2011-08-18 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2384751A1 (en) 2004-12-24 2011-11-09 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
US8058474B2 (en) 2003-11-11 2011-11-15 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
WO2011146710A1 (en) 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination
EP2390251A1 (en) * 2009-01-23 2011-11-30 Cen, Junda Optical pure quinazoline compounds
US8080558B2 (en) 2007-10-29 2011-12-20 Natco Pharma Limited 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent
EP2405270A1 (en) 2006-06-30 2012-01-11 Schering Corporation IGFBP2-Biomarker
WO2012010091A1 (en) * 2010-07-23 2012-01-26 江苏豪森医药集团有限公司 Optically pure quinazoline compound
WO2012010088A1 (en) * 2010-07-23 2012-01-26 江苏豪森医药集团有限公司 Optically pure quinazoline compounds
WO2012031027A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
EP2444421A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
EP2444099A1 (en) 2005-03-31 2012-04-25 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
WO2012052948A1 (en) 2010-10-20 2012-04-26 Pfizer Inc. Pyridine- 2- derivatives as smoothened receptor modulators
EP2447283A2 (en) 2005-09-07 2012-05-02 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1 (ALK-1)
WO2012069557A1 (en) 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US8211429B2 (en) 2005-11-08 2012-07-03 Genetech, Inc. Neuropilin antagonists
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
EP2476667A2 (en) 2003-02-26 2012-07-18 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
EP2489661A1 (en) * 2011-05-20 2012-08-22 F.I.S. Fabbrica Italiana Sintetici S.p.A. Impurity of lapatinib and salts thereof
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012122499A2 (en) 2011-03-09 2012-09-13 Pestell Richard G Prostate cancer cell lines, gene signatures and uses thereof
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
WO2012145183A2 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US8318932B2 (en) * 2002-02-06 2012-11-27 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
WO2013017073A1 (en) * 2011-08-01 2013-02-07 杭州民生药物研究所有限公司 Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
WO2013042006A1 (en) 2011-09-22 2013-03-28 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
WO2013050725A1 (en) 2011-10-04 2013-04-11 King's College London Ige anti -hmw-maa antibody
WO2013055530A1 (en) 2011-09-30 2013-04-18 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
US8426586B2 (en) 2003-10-17 2013-04-23 Boehringer Ingelheim International Gmbh Process for preparing amino crotonyl compounds
US8431585B2 (en) 2002-05-11 2013-04-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
WO2013068902A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
WO2013080218A1 (en) 2011-11-28 2013-06-06 Fresenius Kabi Oncology Ltd. Novel intermediates and process for the preparation of lapatinib and its pharmaceutically acceptable salts
CN103159747A (en) * 2013-02-26 2013-06-19 常州鸿创高分子科技有限公司 Synthetic method of lapatinib
WO2013113796A1 (en) 2012-01-31 2013-08-08 Smithkline Beecham (Cork) Limited Method of treating cancer
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
US8664389B2 (en) 2008-11-03 2014-03-04 Natco Pharma Limited Process for the preparation of lapatinib and it's pharmaceutically acceptable salts
WO2014059956A1 (en) 2012-10-17 2014-04-24 Zentiva, K.S. A method of producing the key intermediate of lapatinib synthesis
US8710104B2 (en) 2008-11-07 2014-04-29 Triact Therapeutics, Inc. Catecholic butanes and use thereof for cancer therapy
WO2014093383A1 (en) 2012-12-14 2014-06-19 Arrien Pharmaceuticals Llc Substituted 1h-pyrrolo [2,3-b] pyridine and 1h-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors
CN103896889A (en) * 2012-12-27 2014-07-02 上海创诺制药有限公司 Lapatinib intermediate as well as preparation method and application thereof
TWI448461B (en) * 2011-05-17 2014-08-11 Jiangsu Kanion Pharmaceutical 4-aniline-6-butenamide-7-alkyl ether quinazoline derivatives, methods and uses thereof
WO2014128107A1 (en) 2013-02-19 2014-08-28 Hexal Ag Pharmaceutical composition comprising n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014153030A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
US8859570B2 (en) 2003-12-24 2014-10-14 Astrazeneca Ab Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
US8877764B2 (en) 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
WO2014188226A2 (en) 2013-05-24 2014-11-27 Egis Gyógyszergyár Zrt. Lapatinib salts
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
EP2851091A1 (en) 2007-04-13 2015-03-25 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
US8993249B2 (en) 2010-07-09 2015-03-31 Genentech, Inc. Anti-neuropilin antibodies and methods of use
WO2015051302A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions and methods for treating cancers
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2015075598A1 (en) 2013-11-21 2015-05-28 Pfizer Inc. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
US9089571B2 (en) 2005-11-11 2015-07-28 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US9090588B2 (en) 2011-03-04 2015-07-28 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2015128837A1 (en) 2014-02-26 2015-09-03 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015166373A1 (en) 2014-04-30 2015-11-05 Pfizer Inc. Cycloalkyl-linked diheterocycle derivatives
US9180129B2 (en) 2010-05-21 2015-11-10 Novartis Ag Combination of lapatinib and trametinib
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2016019280A1 (en) 2014-07-31 2016-02-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies against epha4 and their use
WO2016059600A1 (en) 2014-10-17 2016-04-21 Novartis Ag Combination of ceritinib with an egfr inhibitor
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2016097918A1 (en) 2014-12-18 2016-06-23 Pfizer Inc. Pyrimidine and triazine derivatives and their use as axl inhibitors
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
WO2016120789A1 (en) 2015-01-28 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Agonistic icos binding proteins
US9453836B2 (en) 2012-05-14 2016-09-27 Richard G. Pestell Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
WO2016178876A2 (en) 2015-05-01 2016-11-10 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
WO2017025871A1 (en) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
EP3135692A1 (en) 2010-06-16 2017-03-01 University of Pittsburgh of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
US9586953B2 (en) 2012-09-13 2017-03-07 Glaxosmithkline Intellectual Property Development Limited Prodrugs of amino quinazoline kinase inhibitor
US9604938B2 (en) 2011-08-18 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino quinazolines as kinase inhibitors
US9604963B2 (en) 2011-03-04 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
US9650364B2 (en) 2013-02-21 2017-05-16 GlaxoSmithKline Intellectual Property Development Limted Quinazolines as kinase inhibitors
EP3170840A1 (en) 2003-09-10 2017-05-24 Warner-Lambert Company LLC Antibodies to m-csf
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
WO2017093942A1 (en) 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
WO2018025221A1 (en) 2016-08-04 2018-02-08 Glaxosmithkline Intellectual Property Development Limited Anti-icos and anti-pd-1 antibody combination therapy
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP3233085A4 (en) * 2014-12-15 2018-06-13 The Regents of The University of Michigan Small molecule inhibitors of egfr and pi3k
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018217651A1 (en) 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3409278A1 (en) 2011-07-21 2018-12-05 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
WO2019051291A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
US10240207B2 (en) 2014-03-24 2019-03-26 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with HGF expression
US10259791B2 (en) 2014-08-28 2019-04-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
EP3545956A1 (en) 2013-04-18 2019-10-02 Arrien Pharmaceuticals LLC 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h- pyrrolo[2,3-b]pyrazine dual itk and jak3 kinase inhibitors
WO2019213526A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019241157A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
WO2020004938A1 (en) * 2018-06-27 2020-01-02 Oscotec Inc. Pyridopyrimidinone derivatives for use as axl inhibitors
EP3590932A1 (en) 2013-03-14 2020-01-08 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
WO2020050890A2 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020070239A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
WO2020102730A1 (en) 2018-11-16 2020-05-22 Amgen Inc. Improved synthesis of key intermediate of kras g12c inhibitor compound
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020106647A2 (en) 2018-11-19 2020-05-28 Amgen Inc. Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132649A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132648A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
WO2020160365A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Belantamab mafodotin in combination with pembrolizumab for treating cancer
EP3699290A1 (en) 2014-12-24 2020-08-26 F. Hoffmann-La Roche AG Therapeutic, diagnostic, and prognostic methods for cancer
US10766865B2 (en) 2012-10-16 2020-09-08 Sumitomo Dainippon Pharma Oncology, Inc. PKM2 modulators and methods for their use
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
US10835537B2 (en) 2015-08-03 2020-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of cancer
WO2020261097A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021046289A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
WO2021092115A1 (en) 2019-11-08 2021-05-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2021091967A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021097212A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021152495A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
US11090386B2 (en) 2015-02-25 2021-08-17 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
US11236091B2 (en) 2019-05-21 2022-02-01 Amgen Inc. Solid state forms
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2022060836A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
WO2022140427A1 (en) 2020-12-22 2022-06-30 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
US11426404B2 (en) 2019-05-14 2022-08-30 Amgen Inc. Dosing of KRAS inhibitor for treatment of cancers
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
US11547705B2 (en) 2015-03-04 2023-01-10 Merck Sharp & Dohme Llc Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2023060253A1 (en) 2021-10-08 2023-04-13 Revolution Medicines, Inc. Ras inhibitors
US11673876B2 (en) 2020-12-22 2023-06-13 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US20050176740A1 (en) * 2002-04-08 2005-08-11 Spector Neil L. Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
US20040048887A1 (en) * 2002-07-09 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
JP4703183B2 (en) 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． Receptor kinase modulator and method of use thereof
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
TW201319088A (en) 2003-07-18 2013-05-16 Amgen Inc Specific binding agents to hepatocyte growth factor
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
EP2409704B1 (en) * 2003-09-26 2017-09-20 Exelixis, Inc. c-Met modulators and methods of use
DE602004012891T2 (en) * 2003-12-18 2009-04-09 Janssen Pharmaceutica N.V. PYRIDO AND PYRIMIDOPYRIMIDIN DERIVATIVES AS ANTI-PROLIFERATIVE AGENTS
CA2569404A1 (en) * 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
JP2008501708A (en) * 2004-06-04 2008-01-24 スミスクライン ビーチャム （コーク） リミテッド How to treat cancer
EP1765313A2 (en) * 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20100226931A1 (en) * 2004-06-24 2010-09-09 Nicholas Valiante Compounds for immunopotentiation
CA2587642C (en) 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
DE602005014382D1 (en) * 2004-12-21 2009-06-18 Smithkline Beecham Corp 2-pyrimidinyl pyrazolopyridine ERBB Kinase Inhibitors
MX339142B (en) * 2005-02-18 2016-05-13 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy.
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
AR059066A1 (en) * 2006-01-27 2008-03-12 Amgen Inc COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF)
BRPI0706781A2 (en) * 2006-01-31 2011-04-05 Hoffmann La Roche 7h-pyrido [3,4-d] pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
PE20070978A1 (en) * 2006-02-14 2007-11-15 Novartis Ag HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks)
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US20090203718A1 (en) * 2006-04-13 2009-08-13 Smithkline Beecham (Cork) Ltd. Cancer treatment method
EP2010521A1 (en) 2006-04-19 2009-01-07 Novartis Ag Indazole compounds and methods for inhibition of cdc7
ES2318616T3 (en) * 2006-06-01 2009-05-01 Cellzome Ag METHODS FOR THE IDENTIFICATION OF MOLECULES THAT INTERACT WITH ZAP-70 AND FOR THE PURIFICATION OF ZAP-70.
PE20121506A1 (en) 2006-07-14 2012-11-26 Amgen Inc TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
AU2007288204A1 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-aminoquinazoline derivatives and methods of use thereof
US20110053964A1 (en) * 2006-08-22 2011-03-03 Roger Tung 4-aminoquinazoline derivatives and methods of use thereof
WO2008041118A2 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008054633A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Hydrazone derivatives as kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079291A2 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
US7759344B2 (en) 2007-01-09 2010-07-20 Amgen Inc. Bis-aryl amide derivatives and methods of use
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
CA2685888A1 (en) * 2007-05-09 2008-11-20 Pfizer Inc. Substituted heterocyclic derivatives and their pharmaceutical use and compositions
CL2008002444A1 (en) 2007-08-21 2009-09-04 Amgen Inc Antibody or fragment thereof that binds to human c-fms protein; nucleic acid molecule that encodes it; vector and host cell; production method; pharmaceutical composition comprising it; and its use to treat or prevent a condition associated with c-fms in a patient.
US20090215802A1 (en) * 2007-09-13 2009-08-27 Protia, Llc Deuterium-enriched lapatinib
AU2008312400A1 (en) * 2007-10-19 2009-04-23 Albert Einstein College Of Medicine Of Yeshiva University Improved antitumoral treatments
UY31545A1 (en) 2007-12-20 2009-08-03 NEW DERIVATIVES OF 2-CARBOXAMIDE CIANOAMINOUREA, ITS SALTS AND PHARMACEUTICALLY ACCEPTABLE PROFARMS, PREPARATION PROCESSES AND APPLICATIONS
CN101492445A (en) * 2008-01-22 2009-07-29 孙飘扬 Heteroaromatic compound, preparation method and uses thereof
CA2713459A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
RU2010140890A (en) * 2008-03-07 2012-04-20 Фарма Мар, С.А. (Es) IMPROVED METHODS OF ANTITUMOR TREATMENT
NZ709293A (en) 2008-03-18 2017-01-27 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
US20100197915A1 (en) * 2008-08-06 2010-08-05 Leonid Metsger Lapatinib intermediates
NZ594594A (en) 2009-01-16 2013-11-29 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
US8481503B2 (en) 2009-03-06 2013-07-09 Merck Sharp & Dohme Corp. Combination cancer therapy with an AKT inhibitor and other anticancer agents
MX2011009729A (en) 2009-03-20 2011-10-14 Genentech Inc Bispecific anti-her antibodies.
US8816077B2 (en) 2009-04-17 2014-08-26 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
CA3080511C (en) 2009-08-21 2022-05-24 Novartis Ag Use of lapatinib for treating cancer
EP2484678B1 (en) 2009-09-28 2015-01-21 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors
US20120245351A1 (en) * 2009-09-29 2012-09-27 Natco Pharma Limited Process for the preparation of lapatinib and its pharmaceutically acceptable salts
CN102079759B (en) * 2009-12-01 2014-09-17 天津药物研究院 6-substituted quinazoline derivative, preparation method and application thereof
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
SG182297A1 (en) 2009-12-31 2012-08-30 Ct Nac Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2011089400A1 (en) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
EP2536720A1 (en) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Triazolo [4, 5 - b]pyridin derivatives
US8710221B2 (en) 2010-03-23 2014-04-29 Scinopharm Taiwan, Ltd. Process and intermediates for preparing lapatinib
CA2793742C (en) * 2010-03-23 2015-06-23 Scinopharm Taiwan Ltd. Process and intermediates for preparing lapatinib
CA3087813A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
NZ703047A (en) 2010-03-29 2016-11-25 Abraxis Bioscience Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
NZ604031A (en) 2010-06-04 2015-05-29 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
AR082418A1 (en) 2010-08-02 2012-12-05 Novartis Ag CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
CN102558159A (en) * 2010-12-20 2012-07-11 天津药物研究院 4-subsittution m sulfonylurea amide aniline-quinazoline derivate and preparation method and application thereof
CN102558160B (en) * 2010-12-20 2015-09-23 天津药物研究院 4-replaces Toluidrin anilino-quinazoline derivatives and its production and use
WO2012083440A1 (en) 2010-12-23 2012-06-28 Apotex Pharmachem Inc A process for the preparation of lapatinib and its ditosylate salt
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
PT2670753T (en) 2011-01-31 2017-01-10 Novartis Ag Novel heterocyclic derivatives
WO2012125913A1 (en) 2011-03-17 2012-09-20 The Trustees Of The University Of Pennsylvania Methods and use of bifunctional enzyme-building clamp-shaped molecules
WO2012125904A1 (en) 2011-03-17 2012-09-20 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of egfr
US8623885B2 (en) 2011-03-23 2014-01-07 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
US9346789B2 (en) 2011-04-01 2016-05-24 Genentech, Inc. Combinations of AKT inhibitor compounds and abiraterone, and methods of use
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
DK2710018T3 (en) 2011-05-19 2022-03-21 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio MACROCYCLIC COMPOUNDS AS PROTEIN INKINASE INHIBITORS
JP5414739B2 (en) 2011-05-25 2014-02-12 三菱電機株式会社 Semiconductor test jig
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
EP2771342B1 (en) 2011-10-28 2016-05-18 Novartis AG Purine derivatives and their use in the treatment of disease
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
EP2890696A1 (en) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
CN102942561A (en) * 2012-11-06 2013-02-27 深圳海王药业有限公司 4-amino quinazoline heterocyclic compound and purpose of 4-amino quinazoline heterocyclic compound
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JP2016510000A (en) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
CN105705494B (en) * 2013-07-18 2017-12-15 锦州奥鸿药业有限责任公司 Quinazoline derivant and its pharmaceutical composition, and the purposes as medicine
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN103554091B (en) * 2013-11-05 2016-05-18 沈阳工业大学 Quinazoline derivant and its production and use
PT3076969T (en) 2013-12-06 2021-11-23 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
EP3636650A1 (en) 2014-01-24 2020-04-15 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
EP2937346A1 (en) 2014-04-24 2015-10-28 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Co-crystals of lapatinib
CN105801565B (en) * 2014-12-30 2020-04-03 天津法莫西医药科技有限公司 Preparation method of N- [ 3-chloro-4- [ (3-fluorophenyl) methoxy ] phenyl ] -6- [ (5-formyl) furan-2-yl ] -4-quinazolinamine
CN107517589A (en) 2015-01-08 2017-12-26 小利兰·斯坦福大学托管委员会 The factor and cell of the induction of bone, marrow and cartilage are provided
US20180050993A1 (en) * 2015-02-03 2018-02-22 Trillium Therapeutics Inc. Novel fluorinated derivatives as egfr inhibitors useful for treating cancers
EP3611506B1 (en) 2015-04-20 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
JP6510075B2 (en) 2015-05-18 2019-05-08 トレロ ファーマシューティカルズ， インコーポレイテッド Alvosidib Prodrugs with High Bioavailability
CN106279307B (en) * 2015-05-19 2019-07-26 正大天晴药业集团股份有限公司 Fragrant ammonia is for glucosan derivative, preparation method and anticancer usage
ES2882255T3 (en) 2015-07-01 2021-12-01 California Inst Of Techn Delivery systems based on cationic mucic acid polymers
JP6871903B2 (en) 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Chiral diallyl macrocyclic molecule as a modulator of protein kinase
RU2728579C2 (en) 2015-07-21 2020-07-30 Тёрнинг Поинт Терапьютикс, Инк. Chiral diaryl macrocycles and use thereof
US11124483B2 (en) 2015-09-02 2021-09-21 The Regents Of The University Of California HER3 ligands and uses thereof
CN106632276B (en) * 2015-10-28 2021-06-15 上海天慈生物谷生物工程有限公司 Preparation method of medicine for treating breast cancer
MX2018005298A (en) 2015-11-02 2018-06-22 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor.
JP2019527230A (en) 2016-07-28 2019-09-26 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Macrocyclic kinase inhibitor
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324251A1 (en) 2016-09-08 2019-03-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
AU2017379847B2 (en) 2016-12-19 2022-05-26 Sumitomo Pharma Oncology, Inc. Profiling peptides and methods for sensitivity profiling
TWI808958B (en) 2017-01-25 2023-07-21 美商特普醫葯公司 Combination therapy involving diaryl macrocyclic compounds
CA3069232A1 (en) 2017-07-28 2019-01-31 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
US11708335B2 (en) 2017-12-18 2023-07-25 Sterngreene, Inc. Pyrimidine compounds useful as tyrosine kinase inhibitors
PL3728271T3 (en) 2017-12-19 2023-01-23 Turning Point Therapeutics, Inc. Macrocyclic compounds for treating diseases
US20220041579A1 (en) 2018-12-19 2022-02-10 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN115397514A (en) * 2020-03-02 2022-11-25 特普医药公司 Therapeutic uses of macrocyclic compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019774A1 (en) * 1994-01-25 1995-07-27 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1998002437A1 (en) * 1996-07-13 1998-01-22 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4074057A (en) 1973-12-12 1978-02-14 Takeda Chemical Co., Ltd. 2-Halopropionic acid and its derivatives
US4166735A (en) 1977-01-21 1979-09-04 Shell Oil Company Cycloalkanecarboxanilide derivative herbicides
WO1986006718A1 (en) 1985-05-17 1986-11-20 The Australian National University Antimalarial compounds
US5141941A (en) 1988-11-21 1992-08-25 Ube Industries, Ltd. Aralkylamine derivatives, and fungicides containing the same
US5034393A (en) 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
EP0452002A3 (en) 1990-03-30 1992-02-26 Dowelanco Thienopyrimidine derivatives
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE4131924A1 (en) 1991-09-25 1993-07-08 Hoechst Ag SUBSTITUTED 4-ALKOXYPYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PEST CONTROL
GB9127252D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
WO1993018035A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
US5326766A (en) 1992-08-19 1994-07-05 Dreikorn Barry A 4-(2-(4-(2-pyridinyloxy)phenyl)ethoxy)quinazoline and analogues thereof
DE4308014A1 (en) 1993-03-13 1994-09-15 Hoechst Schering Agrevo Gmbh Condensed nitrogen heterocycles, processes for their preparation and their use as pesticides and fungicides
GB9312891D0 (en) 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (en) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
PT831829E (en) 1995-06-07 2003-12-31 Pfizer PYRIMIDINE DERIVATIVES FROM HETEROCYCLICS OF FUSED RINGS
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (en) 1995-10-11 1998-09-30 Glaxo Group Ltd HETERO CYCLIC COMPOUNDS
HUP9801177A3 (en) 1995-11-14 1998-11-30 Pharmacia & Upjohn Spa Tetrahydronaphthyl, indanyl and indolyl substituted pyrido[2,3-d]pyrimidine and purine derivatives, process for their preparation and pharmaceutical compositions containing them
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
PT912559E (en) 1996-07-13 2003-03-31 Glaxo Group Ltd HETEROCYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS TYROSINE KINASE
ID18494A (en) 1996-10-02 1998-04-16 Novartis Ag PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ES2236240T3 (en) * 2000-06-22 2005-07-16 Pfizer Products Inc. SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH.
TWI307339B (en) * 2000-06-30 2009-03-11 Glaxo Group Ltd Quinazoline ditosylate salt comprounds
ES2236481T3 (en) * 2001-01-16 2005-07-16 Glaxo Group Limited PHARMACEUTICAL COMBINATION CONTAINING A 4-QUINAZOLINAMINE AND PACLITAXEL, CARBOPLATIN OR VINORELBINE FOR CANCER TREATMENT.
JP4608215B2 (en) * 2002-02-01 2011-01-12 アストラゼネカ アクチボラグ Quinazoline compounds
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019774A1 (en) * 1994-01-25 1995-07-27 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1998002437A1 (en) * 1996-07-13 1998-01-22 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Cited By (427)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
US7262201B1 (en) 1998-10-08 2007-08-28 Astrazeneca Ab Quinazoline derivatives
GB2345486A (en) * 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
US8492560B2 (en) 1999-02-10 2013-07-23 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
US7074800B1 (en) 1999-02-10 2006-07-11 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
US6809106B1 (en) 1999-05-08 2004-10-26 Astrazeneca Ab Quinoline derivatives as inhibitors of MEK enzymes
US6638945B1 (en) 1999-05-08 2003-10-28 Astrazeneca Ab Quinoline derivatives as inhibitors of MEK enzymes
US7220750B2 (en) 1999-06-21 2007-05-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US8722694B2 (en) 1999-06-21 2014-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
US7084147B2 (en) 1999-07-09 2006-08-01 Smithkline Beecham Corporation Anilinoquinazaolines as protein tyrosine kinase inhibitors
US7507741B2 (en) 1999-07-09 2009-03-24 Smithkline Beecham Corporation Heterocyclic compounds
US7265123B2 (en) 1999-07-09 2007-09-04 Smithkline Beecham Corporation Heterocyclic compounds
US7189734B2 (en) 1999-07-09 2007-03-13 Smithkline Beecham Corporation Anilinoquinazaolines as protein tyrosine kianse inhibitors
WO2001004111A1 (en) * 1999-07-09 2001-01-18 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
JP2003509499A (en) * 1999-09-21 2003-03-11 アストラゼネカ アクチボラグ Quinazoline derivatives and their use as pharmaceuticals
JP4870304B2 (en) * 1999-09-21 2012-02-08 アストラゼネカ アクチボラグ Quinazoline derivatives and their use as pharmaceuticals
US7709479B1 (en) 1999-09-21 2010-05-04 Astrazeneca Quinazoline derivatives and their use as pharmaceuticals
WO2001021596A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
EP2292233A2 (en) 1999-11-11 2011-03-09 OSI Pharmaceuticals, Inc. Pharmaceutical uses of N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
EP3100730A1 (en) 1999-11-11 2016-12-07 OSI Pharmaceuticals, LLC N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine for use in the treatment of nsclc
JP2003520855A (en) * 2000-01-28 2003-07-08 アストラゼネカ アクチボラグ Chemical compound
US6977259B2 (en) 2000-01-28 2005-12-20 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
WO2001072711A1 (en) * 2000-03-28 2001-10-04 Wyeth 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
CN100439340C (en) * 2000-03-28 2008-12-03 惠氏公司 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6689772B1 (en) 2000-03-28 2004-02-10 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6462238B2 (en) 2000-05-02 2002-10-08 Array Biopharma, Inc. Process for the reduction of cyano-substituted sulfones to aminoalkylene-substituted sulfones
US6890924B2 (en) 2000-06-22 2005-05-10 Pfizer Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
US6919338B2 (en) 2000-06-28 2005-07-19 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
AU2001273071B2 (en) * 2000-06-30 2005-09-08 Glaxo Group Limited Quinazoline ditosylate salt compounds
KR100815681B1 (en) 2000-06-30 2008-03-20 글락소 그룹 리미티드 Quinazoline ditosylate salt compounds
CN1305872C (en) * 2000-06-30 2007-03-21 葛兰素集团有限公司 Process for producing quinazoline ditosylate salt compounds
JP2008050363A (en) * 2000-06-30 2008-03-06 Glaxo Group Ltd Quinazoline ditosylate salt compounds
KR100850393B1 (en) * 2000-06-30 2008-08-04 글락소 그룹 리미티드 A process for preparing quinazoline compounds
CZ299561B6 (en) * 2000-06-30 2008-09-03 Glaxo Group Limited Quinazolinamine derivative and pharmaceutical composition
WO2002002552A1 (en) * 2000-06-30 2002-01-10 Glaxo Group Limited Quinazoline ditosylate salt compounds
EP1792902A1 (en) * 2000-06-30 2007-06-06 Glaxo Group Limited Processes for preparation of 5-(6-quinazolinyl)-furan-2-carbaldehydes
US7157466B2 (en) 2000-06-30 2007-01-02 Smithkline Beecham (Cork) Limited Quinazoline ditosylate salt compounds
CZ300945B6 (en) * 2000-06-30 2009-09-23 Glaxo Group Limited Process for preparing 5-(6-quinazolinyl)-furan-2-carbaldehydes
US7371765B2 (en) 2000-08-09 2008-05-13 Astrazeneca Ab Quinoline derivatives having VEGF inhibiting activity
US7547702B2 (en) 2000-09-20 2009-06-16 Ortho-Mcneil Pharmaceutical, Inc. 4-amino-quinazolines
US8372981B2 (en) 2000-10-20 2013-02-12 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic derivatives
US7973160B2 (en) 2000-10-20 2011-07-05 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic derivatives
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
US7504416B2 (en) 2000-11-02 2009-03-17 Astrazeneca Ab 4-substituted quinolines as antitumor agents
US7253184B2 (en) 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
US7402583B2 (en) 2000-11-02 2008-07-22 Astrzenca Ab Substituted quinolines as antitumor agents
US8586608B2 (en) 2000-12-20 2013-11-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
USRE43431E1 (en) 2000-12-20 2012-05-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
EP2194067A2 (en) 2001-01-05 2010-06-09 Pfizer Inc. Antibodies to insulin-like growth factor I receptor (IGF-IR)
EP2796468A2 (en) 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
US9234041B2 (en) 2001-01-05 2016-01-12 Pfizer Inc. Antibodies to insulin-like growth factor I receptor
EP1488809A1 (en) 2001-01-16 2004-12-22 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
US20120058113A1 (en) * 2001-01-16 2012-03-08 Karen Elizabeth Lackey Cancer treatment method
WO2002056912A2 (en) * 2001-01-16 2002-07-25 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2002056912A3 (en) * 2001-01-16 2003-05-22 Glaxo Group Ltd Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
US7141576B2 (en) 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
EP1512413A3 (en) * 2001-01-16 2009-09-23 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
US8444988B2 (en) 2001-01-16 2013-05-21 Glaxosmithkline Llc Cancer treatment method
US6812251B2 (en) * 2001-03-15 2004-11-02 Rhode Island Hospital Taurine compounds
JP2004528314A (en) * 2001-03-23 2004-09-16 バイエル コーポレイション Rho kinase inhibitor
JP2004524350A (en) * 2001-03-23 2004-08-12 バイエル コーポレイション Rho kinase inhibitor
US6927220B2 (en) 2001-04-13 2005-08-09 Pfizer Inc Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
WO2002092578A1 (en) * 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
EP2343086A2 (en) 2001-11-09 2011-07-13 Pfizer Products Inc. Antibodies to CD40
US7648986B2 (en) 2002-01-10 2010-01-19 Bayer Healthcare Llc Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors
US7074799B2 (en) 2002-01-17 2006-07-11 Neurogen Corporation Substituted quinazolin-4-ylamine analogues
US7304059B2 (en) 2002-01-17 2007-12-04 Neurogen Corporation Substituted quinazolin-4-ylamine analogues
US6943172B2 (en) 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US6924290B2 (en) 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US7268230B2 (en) 2002-02-01 2007-09-11 Astrazeneca Ab Quinazoline compounds
US8318932B2 (en) * 2002-02-06 2012-11-27 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
US8431585B2 (en) 2002-05-11 2013-04-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
WO2003101491A1 (en) * 2002-06-03 2003-12-11 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
US6869962B2 (en) 2002-06-14 2005-03-22 Agouron Pharmaceuticals, Inc. Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
US7045528B2 (en) 2002-06-14 2006-05-16 Agouron Pharmaceuticals, Inc. Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
US7173135B2 (en) 2002-07-09 2007-02-06 Astrazeneca Ab Substituted 3-cyanoquinolines as MEK inhibitors
US7504408B2 (en) 2002-07-09 2009-03-17 Astrazeneca Ab Quinzoline derivatives for use in the treatment of cancer
US7173136B2 (en) 2002-11-02 2007-02-06 Astrazeneca Ab 3-Cyano-quinoline derivatives
US7432275B2 (en) * 2002-12-13 2008-10-07 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
US7053107B2 (en) 2002-12-19 2006-05-30 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO2004056812A1 (en) * 2002-12-23 2004-07-08 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
WO2004060400A1 (en) * 2003-01-06 2004-07-22 Mitsubishi Pharma Corp Antipsychotic molecular-targeting epithelial growth factor receptor
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
EP2476667A2 (en) 2003-02-26 2012-07-18 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
EP2348110A1 (en) 2003-05-30 2011-07-27 AstraZeneca UK Limited Process
US7488740B2 (en) 2003-07-14 2009-02-10 Neurogen Corporation Substituted quinolin-4-ylamine analogues
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
US7829297B2 (en) 2003-08-01 2010-11-09 Glaxosmithkline Llc Treatment of cancers expressing p95 ErbB2
US7208500B2 (en) 2003-08-29 2007-04-24 Agouron Pharmaceuticals, Inc. Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents
US10280219B2 (en) 2003-09-10 2019-05-07 Amgen Fremont Inc. Antibodies to M-CSF
EP3170840A1 (en) 2003-09-10 2017-05-24 Warner-Lambert Company LLC Antibodies to m-csf
US9718883B2 (en) 2003-09-10 2017-08-01 Amgen Fremont Inc. Antibodies to M-CSF
US8426586B2 (en) 2003-10-17 2013-04-23 Boehringer Ingelheim International Gmbh Process for preparing amino crotonyl compounds
WO2005046678A1 (en) * 2003-11-07 2005-05-26 Smithkline Beecham (Cork) Limited Cancer treatment method
US8058474B2 (en) 2003-11-11 2011-11-15 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
US7625908B2 (en) 2003-11-13 2009-12-01 Astrazeneca Ab Quinazoline derivatives
US9890140B2 (en) 2003-12-24 2018-02-13 Astrazeneca Ab Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
US9556151B2 (en) 2003-12-24 2017-01-31 Astrazeneca Ab Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
US8859570B2 (en) 2003-12-24 2014-10-14 Astrazeneca Ab Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
WO2005105094A3 (en) * 2004-04-16 2006-06-15 Smithkline Beecham Corp Cancer treatment method
US8623883B2 (en) 2004-05-06 2014-01-07 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
US8466165B2 (en) 2004-05-06 2013-06-18 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
US7772243B2 (en) 2004-05-06 2010-08-10 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
US20100063074A1 (en) * 2004-06-03 2010-03-11 Berger Mark S Cancer Treatment Method
EP2116245A2 (en) 2004-08-07 2009-11-11 Boehringer Ingelheim International GmbH EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
US8785632B2 (en) 2004-08-26 2014-07-22 Agouron Pharmaceuticals, Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US7858643B2 (en) 2004-08-26 2010-12-28 Agouron Pharmaceuticals, Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US9504746B2 (en) 2004-09-17 2016-11-29 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
US7935702B2 (en) 2004-10-12 2011-05-03 Neurogen Corporation Substituted biaryl quinolin-4-ylamine analogues
WO2006061253A3 (en) * 2004-12-10 2006-11-16 Glaxosmithkline Biolog Sa Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy
WO2006061253A2 (en) * 2004-12-10 2006-06-15 Glaxosmithkline Biologicals S.A. Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy
US7947676B2 (en) 2004-12-14 2011-05-24 Astrazeneca Ab Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
WO2006066267A3 (en) * 2004-12-17 2006-12-14 Smithkline Beecham Cork Ltd Cancer treatment method
US7812022B2 (en) 2004-12-21 2010-10-12 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
EP2384751A1 (en) 2004-12-24 2011-11-09 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
EP2878297A1 (en) 2004-12-24 2015-06-03 Boehringer Ingelheim International GmbH Medicaments for the treatment or prevention of fibrotic diseases
WO2006076646A2 (en) * 2005-01-14 2006-07-20 Neurogen Corporation Heteroaryl substituted quinolin-4-ylamine analogues
WO2006076646A3 (en) * 2005-01-14 2006-08-17 Neurogen Corp Heteroaryl substituted quinolin-4-ylamine analogues
EP3300739A2 (en) 2005-03-31 2018-04-04 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
EP2444099A1 (en) 2005-03-31 2012-04-25 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
WO2006113649A1 (en) 2005-04-19 2006-10-26 Smithkline Beecham [Cork] Limited Pharmaceutical composition
AU2006236423B2 (en) * 2005-04-19 2009-12-10 Novartis Ag Pharmaceutical composition
EP2444420A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
EP2444421A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
EP2444419A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
EP2281901A2 (en) 2005-08-02 2011-02-09 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
US8969344B2 (en) 2005-08-02 2015-03-03 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
EP2447283A2 (en) 2005-09-07 2012-05-02 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1 (ALK-1)
EP2960253A1 (en) 2005-09-07 2015-12-30 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
US9221915B2 (en) 2005-09-07 2015-12-29 Pfizer Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP3381945A1 (en) 2005-09-07 2018-10-03 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2372363A1 (en) 2005-09-20 2011-10-05 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1
US7820683B2 (en) 2005-09-20 2010-10-26 Astrazeneca Ab 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
US8795660B2 (en) 2005-11-08 2014-08-05 Genentech, Inc. Neuropilin antagonists
US8378080B2 (en) 2005-11-08 2013-02-19 Genentech, Inc. Neuropilin antagonists
US8211429B2 (en) 2005-11-08 2012-07-03 Genetech, Inc. Neuropilin antagonists
US9539258B2 (en) 2005-11-11 2017-01-10 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US9089571B2 (en) 2005-11-11 2015-07-28 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
CN101326182B (en) * 2005-12-05 2011-09-28 史密丝克莱恩比彻姆公司 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
JP2009518310A (en) * 2005-12-05 2009-05-07 スミスクライン ビーチャム コーポレーション 2-pyrimidinylpyrazolopyridine ErbB kinase inhibitor
WO2007067506A3 (en) * 2005-12-05 2007-08-16 Smithkline Beecham Corp 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2007067506A2 (en) 2005-12-05 2007-06-14 Smithkline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
US7807673B2 (en) 2005-12-05 2010-10-05 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
US8044063B2 (en) 2006-01-20 2011-10-25 Shanghai Allist Pharmaceuticals, Inc. Quinazoline derivatives useful as anti-tumor medicament
EP1990337A1 (en) * 2006-01-20 2008-11-12 Shanghai Allist Pharmaceutical., Inc. Quinazoline derivatives,preparation methods and uses thereof
EP2248806A3 (en) * 2006-01-20 2011-02-23 Shanghai Allist Pharmaceuticals, Inc. Quinazoline derivatives as tyrosine kinase inhibitors
EP1990337A4 (en) * 2006-01-20 2009-07-22 Shanghai Allist Pharmaceutical Quinazoline derivatives,preparation methods and uses thereof
WO2007082434A1 (en) 2006-01-20 2007-07-26 Shanghai Allist Pharmaceutical., Inc. Quinazoline derivatives,preparation methods and uses thereof
EP2248806A2 (en) 2006-01-20 2010-11-10 Shanghai Allist Pharmaceuticals, Inc. Quinazoline derivatives as tyrosine kinase inhibitors
US8309563B2 (en) 2006-01-20 2012-11-13 Shanghai Allist Pharmaceuticals, Inc. Quinazoline derivatives useful as anti-tumor medicament
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2007132308A1 (en) 2006-05-11 2007-11-22 Pfizer Products Inc. Triazolopyrazine derivatives useful as anti-cancer agents
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2405270A1 (en) 2006-06-30 2012-01-11 Schering Corporation IGFBP2-Biomarker
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8877764B2 (en) 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008076278A2 (en) 2006-12-13 2008-06-26 Schering Corporation Methods of cancer treatment with igf1r inhibitors
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
WO2008098485A1 (en) 2007-02-14 2008-08-21 Shanghai Allist Pharmaceuticals, Inc. The salts of 4-aniline quinazoline derivative
US8349854B2 (en) 2007-02-14 2013-01-08 Shanghai Allist Pharmaceuticals, Inc. Salts of 4-aniline quinazoline derivative
EP2851091A1 (en) 2007-04-13 2015-03-25 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
EP2166859A4 (en) * 2007-06-11 2011-09-07 Smithkline Beecham Cork Ltd Quinazoline salt compounds
EP2166859A1 (en) * 2007-06-11 2010-03-31 SmithKline Beecham (Cork) Limited Quinazoline salt compounds
EP2167092A4 (en) * 2007-06-14 2012-07-25 Glaxosmithkline Llc Quinazoline derivatives as pi3 kinase inhibitors
EP2167092A2 (en) * 2007-06-14 2010-03-31 GlaxoSmithKline LLC Quinazoline derivatives as pi3 kinase inhibitors
WO2009033094A2 (en) 2007-09-07 2009-03-12 Agensys, Inc. Antibodies and related molecules that bind to 24p4c12 proteins
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
US8080558B2 (en) 2007-10-29 2011-12-20 Natco Pharma Limited 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2009140144A1 (en) * 2008-05-15 2009-11-19 Teva Pharmaceutical Industries Ltd. Forms of crystalline lapatinib and processes for preparation thereof
US8507010B2 (en) 2008-05-21 2013-08-13 Shanghai Allist Pharmaceuticals, Inc. Compositions comprising quinazoline derivatives
WO2009140863A1 (en) 2008-05-21 2009-11-26 上海艾力斯医药科技有限公司 Compositions comprising quinazoline derivatives, preparation methods and uses thereof
EP2158912A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
WO2010027848A3 (en) * 2008-08-26 2010-05-06 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
US8664389B2 (en) 2008-11-03 2014-03-04 Natco Pharma Limited Process for the preparation of lapatinib and it's pharmaceutically acceptable salts
US8710104B2 (en) 2008-11-07 2014-04-29 Triact Therapeutics, Inc. Catecholic butanes and use thereof for cancer therapy
EP2390251A4 (en) * 2009-01-23 2012-08-01 Cen Junda Optical pure quinazoline compounds
EP2390251A1 (en) * 2009-01-23 2011-11-30 Cen, Junda Optical pure quinazoline compounds
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
US10004743B2 (en) 2009-07-06 2018-06-26 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
WO2011027249A2 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
WO2011058164A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP3150610A1 (en) 2010-02-12 2017-04-05 Pfizer Inc Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
WO2011098971A1 (en) 2010-02-12 2011-08-18 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
EP3597651A1 (en) 2010-02-12 2020-01-22 Pfizer Inc Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US9180129B2 (en) 2010-05-21 2015-11-10 Novartis Ag Combination of lapatinib and trametinib
WO2011146710A1 (en) 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination
EP3135692A1 (en) 2010-06-16 2017-03-01 University of Pittsburgh of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US8993249B2 (en) 2010-07-09 2015-03-31 Genentech, Inc. Anti-neuropilin antibodies and methods of use
CN102344444A (en) * 2010-07-23 2012-02-08 岑均达 Optically pure quinazoline compounds
CN102344445A (en) * 2010-07-23 2012-02-08 岑均达 Optical voidness quinazoline compound
WO2012010091A1 (en) * 2010-07-23 2012-01-26 江苏豪森医药集团有限公司 Optically pure quinazoline compound
WO2012010088A1 (en) * 2010-07-23 2012-01-26 江苏豪森医药集团有限公司 Optically pure quinazoline compounds
CN102344445B (en) * 2010-07-23 2015-11-25 岑均达 Optical pure quinazoline compound
WO2012031027A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
EP3264089A1 (en) 2010-08-31 2018-01-03 Genentech, Inc. Biomarkers and methods of treatment
WO2012052948A1 (en) 2010-10-20 2012-04-26 Pfizer Inc. Pyridine- 2- derivatives as smoothened receptor modulators
WO2012069557A1 (en) 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
EP2853542A1 (en) 2010-11-24 2015-04-01 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
WO2012085229A1 (en) 2010-12-22 2012-06-28 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
US9494572B2 (en) 2011-01-11 2016-11-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012113819A1 (en) 2011-02-23 2012-08-30 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
US9090588B2 (en) 2011-03-04 2015-07-28 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
US9604963B2 (en) 2011-03-04 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
US11524956B2 (en) 2011-03-04 2022-12-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
US10952415B2 (en) 2011-03-09 2021-03-23 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
WO2012122499A2 (en) 2011-03-09 2012-09-13 Pestell Richard G Prostate cancer cell lines, gene signatures and uses thereof
EP3597761A1 (en) 2011-03-09 2020-01-22 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012145183A2 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EP3536708A1 (en) 2011-04-19 2019-09-11 Pfizer Inc Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
TWI448461B (en) * 2011-05-17 2014-08-11 Jiangsu Kanion Pharmaceutical 4-aniline-6-butenamide-7-alkyl ether quinazoline derivatives, methods and uses thereof
US9187459B2 (en) 2011-05-17 2015-11-17 Newgen Therapeutics, Inc. Quinazoline-7-ether compounds and methods of use
ITMI20110894A1 (en) * 2011-05-20 2012-11-21 Italiana Sint Spa IMPACT OF THE LAPATINIB AND ITS SALTS
EP2489661A1 (en) * 2011-05-20 2012-08-22 F.I.S. Fabbrica Italiana Sintetici S.p.A. Impurity of lapatinib and salts thereof
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US11598776B2 (en) 2011-06-03 2023-03-07 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
US10875864B2 (en) 2011-07-21 2020-12-29 Sumitomo Dainippon Pharma Oncology, Inc. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors
EP3409278A1 (en) 2011-07-21 2018-12-05 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
WO2013017073A1 (en) * 2011-08-01 2013-02-07 杭州民生药物研究所有限公司 Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament
US9499530B2 (en) 2011-08-01 2016-11-22 Hangzhou Minsheng Institutes For Pharma Research Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament
US9994529B2 (en) 2011-08-18 2018-06-12 Glaxosmithkline Intellectual Property Development Limited Amino quinazolines as kinase inhibitors
US10717711B2 (en) 2011-08-18 2020-07-21 Glaxosmithkline Intellectual Property Development Limited Amino quinazolines as kinase inhibitors
US9604938B2 (en) 2011-08-18 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino quinazolines as kinase inhibitors
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
WO2013042006A1 (en) 2011-09-22 2013-03-28 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
WO2013055530A1 (en) 2011-09-30 2013-04-18 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
EP3275902A1 (en) 2011-10-04 2018-01-31 IGEM Therapeutics Limited Ige anti-hmw-maa antibody
WO2013050725A1 (en) 2011-10-04 2013-04-11 King's College London Ige anti -hmw-maa antibody
WO2013068902A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
WO2013080218A1 (en) 2011-11-28 2013-06-06 Fresenius Kabi Oncology Ltd. Novel intermediates and process for the preparation of lapatinib and its pharmaceutically acceptable salts
WO2013113796A1 (en) 2012-01-31 2013-08-08 Smithkline Beecham (Cork) Limited Method of treating cancer
EP3045543A2 (en) 2012-01-31 2016-07-20 Novartis AG Method of treating cancer
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US11633397B2 (en) 2012-05-14 2023-04-25 Richard G. Pestell Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
US9453836B2 (en) 2012-05-14 2016-09-27 Richard G. Pestell Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
US9586953B2 (en) 2012-09-13 2017-03-07 Glaxosmithkline Intellectual Property Development Limited Prodrugs of amino quinazoline kinase inhibitor
US10766865B2 (en) 2012-10-16 2020-09-08 Sumitomo Dainippon Pharma Oncology, Inc. PKM2 modulators and methods for their use
WO2014059956A1 (en) 2012-10-17 2014-04-24 Zentiva, K.S. A method of producing the key intermediate of lapatinib synthesis
WO2014093383A1 (en) 2012-12-14 2014-06-19 Arrien Pharmaceuticals Llc Substituted 1h-pyrrolo [2,3-b] pyridine and 1h-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN103896889B (en) * 2012-12-27 2016-05-25 上海创诺制药有限公司 Lapatinib intermediate and its preparation method and application
CN103896889A (en) * 2012-12-27 2014-07-02 上海创诺制药有限公司 Lapatinib intermediate as well as preparation method and application thereof
WO2014128107A1 (en) 2013-02-19 2014-08-28 Hexal Ag Pharmaceutical composition comprising n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof
US9650364B2 (en) 2013-02-21 2017-05-16 GlaxoSmithKline Intellectual Property Development Limted Quinazolines as kinase inhibitors
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
CN103159747A (en) * 2013-02-26 2013-06-19 常州鸿创高分子科技有限公司 Synthetic method of lapatinib
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2014153030A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
EP3590932A1 (en) 2013-03-14 2020-01-08 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
US10752594B2 (en) 2013-03-14 2020-08-25 Sumitomo Dainippon Pharma Oncology, Inc. JAK1 and ALK2 inhibitors and methods for their use
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
EP3545956A1 (en) 2013-04-18 2019-10-02 Arrien Pharmaceuticals LLC 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h- pyrrolo[2,3-b]pyrazine dual itk and jak3 kinase inhibitors
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
WO2014188226A2 (en) 2013-05-24 2014-11-27 Egis Gyógyszergyár Zrt. Lapatinib salts
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
EP3650023A1 (en) 2013-10-04 2020-05-13 Aptose Biosciences Inc. Compositions for treating cancers
WO2015051302A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions and methods for treating cancers
WO2015075598A1 (en) 2013-11-21 2015-05-28 Pfizer Inc. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015128837A1 (en) 2014-02-26 2015-09-03 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
US10240207B2 (en) 2014-03-24 2019-03-26 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with HGF expression
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015166373A1 (en) 2014-04-30 2015-11-05 Pfizer Inc. Cycloalkyl-linked diheterocycle derivatives
EP3556757A1 (en) 2014-04-30 2019-10-23 Pfizer Inc Cycloalkyl-linked diheterocycle derivatives
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
EP3473271A1 (en) 2014-07-31 2019-04-24 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Human monoclonal antibodies against epha4 and their use
WO2016019280A1 (en) 2014-07-31 2016-02-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies against epha4 and their use
US10259791B2 (en) 2014-08-28 2019-04-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10407393B2 (en) 2014-08-28 2019-09-10 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US11186547B2 (en) 2014-08-28 2021-11-30 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10822307B2 (en) 2014-08-28 2020-11-03 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
WO2016059600A1 (en) 2014-10-17 2016-04-21 Novartis Ag Combination of ceritinib with an egfr inhibitor
US10206924B2 (en) 2014-12-15 2019-02-19 The Regents Of The University Of Michigan Small molecule inhibitors of EGFR and PI3K
EP3233085A4 (en) * 2014-12-15 2018-06-13 The Regents of The University of Michigan Small molecule inhibitors of egfr and pi3k
US10842791B2 (en) 2014-12-15 2020-11-24 The Regents Of The University Of Michigan Small molecule inhibitors of EGFR and PI3K
US11607414B2 (en) 2014-12-15 2023-03-21 The Regents Of The University Of Michigan Small molecule inhibitors of EGFR and PI3K
WO2016097918A1 (en) 2014-12-18 2016-06-23 Pfizer Inc. Pyrimidine and triazine derivatives and their use as axl inhibitors
US9593097B2 (en) 2014-12-18 2017-03-14 Pfizer Inc. Axl inhibitors
EP3699290A1 (en) 2014-12-24 2020-08-26 F. Hoffmann-La Roche AG Therapeutic, diagnostic, and prognostic methods for cancer
EP3575324A1 (en) 2015-01-28 2019-12-04 GlaxoSmithKline Intellectual Property Development Limited Icos binding proteins
EP3572432A1 (en) 2015-01-28 2019-11-27 GlaxoSmithKline Intellectual Property Development Limited Icos binding proteins
WO2016120789A1 (en) 2015-01-28 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Agonistic icos binding proteins
US11090386B2 (en) 2015-02-25 2021-08-17 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
US11547705B2 (en) 2015-03-04 2023-01-10 Merck Sharp & Dohme Llc Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2016178876A2 (en) 2015-05-01 2016-11-10 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US10835537B2 (en) 2015-08-03 2020-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of cancer
WO2017025871A1 (en) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
WO2017093942A1 (en) 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP4015537A1 (en) 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
US10265279B2 (en) 2016-03-15 2019-04-23 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2018025221A1 (en) 2016-08-04 2018-02-08 Glaxosmithkline Intellectual Property Development Limited Anti-icos and anti-pd-1 antibody combination therapy
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
EP4001269A1 (en) 2016-12-22 2022-05-25 Amgen Inc. Benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
US10532042B2 (en) 2016-12-22 2020-01-14 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11285135B2 (en) 2016-12-22 2022-03-29 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018217651A1 (en) 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11905281B2 (en) 2017-05-22 2024-02-20 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US10519146B2 (en) 2017-05-22 2019-12-31 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3974429A1 (en) 2017-05-22 2022-03-30 Amgen Inc. Precursors of kras g12c inhibitors
WO2019051291A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
US11306087B2 (en) 2017-09-08 2022-04-19 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
EP4141005A1 (en) 2017-09-08 2023-03-01 Amgen Inc. Inhibitors of kras g12c and methods of using the same
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
WO2019213526A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11045484B2 (en) 2018-05-04 2021-06-29 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11766436B2 (en) 2018-05-04 2023-09-26 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US10988485B2 (en) 2018-05-10 2021-04-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019241157A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
EP4268898A2 (en) 2018-06-11 2023-11-01 Amgen Inc. Kras g12c inhibitors for treating cancer
WO2020050890A2 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
WO2020004938A1 (en) * 2018-06-27 2020-01-02 Oscotec Inc. Pyridopyrimidinone derivatives for use as axl inhibitors
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
WO2020070239A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
EP4234546A2 (en) 2018-11-16 2023-08-30 Amgen Inc. Improved synthesis of key intermediate of kras g12c inhibitor compound
US11299491B2 (en) 2018-11-16 2022-04-12 Amgen Inc. Synthesis of key intermediate of KRAS G12C inhibitor compound
WO2020102730A1 (en) 2018-11-16 2020-05-22 Amgen Inc. Improved synthesis of key intermediate of kras g12c inhibitor compound
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020106647A2 (en) 2018-11-19 2020-05-28 Amgen Inc. Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
US11918584B2 (en) 2018-11-19 2024-03-05 Amgen Inc. Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
US11439645B2 (en) 2018-11-19 2022-09-13 Amgen Inc. Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
US11530231B2 (en) 2018-12-04 2022-12-20 Sumitomo Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
WO2020132649A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132648A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
US11236069B2 (en) 2018-12-20 2022-02-01 Amgen Inc. KIF18A inhibitors
WO2020160375A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
WO2020160365A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Belantamab mafodotin in combination with pembrolizumab for treating cancer
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
US11712433B2 (en) 2019-03-22 2023-08-01 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
US11426404B2 (en) 2019-05-14 2022-08-30 Amgen Inc. Dosing of KRAS inhibitor for treatment of cancers
US11236091B2 (en) 2019-05-21 2022-02-01 Amgen Inc. Solid state forms
US11827635B2 (en) 2019-05-21 2023-11-28 Amgen Inc. Solid state forms
WO2020261097A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021046289A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
WO2021091967A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021092115A1 (en) 2019-11-08 2021-05-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021097212A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021152495A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
WO2022060836A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
US11673876B2 (en) 2020-12-22 2023-06-13 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors
WO2022140427A1 (en) 2020-12-22 2022-06-30 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2023060253A1 (en) 2021-10-08 2023-04-13 Revolution Medicines, Inc. Ras inhibitors
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Also Published As

Publication number Publication date
NO20003561L (en) 2000-09-11
MA26596A1 (en) 2004-12-20
KR100569776B1 (en) 2006-04-11
HUP0100941A3 (en) 2002-09-30
DE69930773D1 (en) 2006-05-18
JP2002326990A (en) 2002-11-15
CA2317589C (en) 2007-08-07
US20070015775A1 (en) 2007-01-18
GEP20022678B (en) 2002-04-25
ES2319119T3 (en) 2009-05-04
US20160051551A1 (en) 2016-02-25
DK1460072T3 (en) 2006-07-31
BG104668A (en) 2001-04-30
US20050130996A1 (en) 2005-06-16
AU2010276460A1 (en) 2011-02-17
HK1031883A1 (en) 2001-06-29
US8912205B2 (en) 2014-12-16
CN1292788A (en) 2001-04-25
TR200002015T2 (en) 2001-01-22
PT1047694E (en) 2004-11-30
ES2221354T3 (en) 2004-12-16
SK285405B6 (en) 2007-01-04
KR20010015902A (en) 2001-02-26
CY1105618T1 (en) 2010-12-22
RS49779B (en) 2008-06-05
DE122008000048I1 (en) 2009-01-02
ATE322491T1 (en) 2006-04-15
YU44800A (en) 2002-11-15
US20030176451A1 (en) 2003-09-18
LU91475I9 (en) 2019-01-02
EP1460072A1 (en) 2004-09-22
NZ505456A (en) 2003-06-30
CY2008015I1 (en) 2009-11-04
SI1460072T1 (en) 2006-08-31
EP1047694B1 (en) 2004-07-07
CO4820390A1 (en) 1999-07-28
DE69918528D1 (en) 2004-08-12
US9199973B2 (en) 2015-12-01
CZ20002587A3 (en) 2001-05-16
AU749549B2 (en) 2002-06-27
ES2262087T3 (en) 2006-11-16
BR9906904A (en) 2000-10-17
HRP20060387A2 (en) 2008-02-29
PL341595A1 (en) 2001-04-23
US8513262B2 (en) 2013-08-20
US20070238875A1 (en) 2007-10-11
AP1446A (en) 2005-07-19
NL300360I1 (en) 2008-11-03
SK10502000A3 (en) 2001-08-06
FR08C0038I2 (en) 2012-02-22
AU2278399A (en) 1999-07-26
DK1047694T3 (en) 2004-11-08
MY124055A (en) 2006-06-30
DE69930773T2 (en) 2006-09-28
US6727256B1 (en) 2004-04-27
PL192746B1 (en) 2006-12-29
IS5549A (en) 2000-06-27
DK1454907T3 (en) 2009-03-09
US20150065527A1 (en) 2015-03-05
PE20000230A1 (en) 2000-04-03
NO2008017I2 (en) 2011-10-17
JP2002500225A (en) 2002-01-08
HRP20000469B1 (en) 2007-05-31
OA11444A (en) 2004-04-29
CY2008015I2 (en) 2009-11-04
CZ298047B6 (en) 2007-06-06
EP1047694A1 (en) 2000-11-02
CA2317589A1 (en) 1999-07-15
IS2276B (en) 2007-09-15
CY1108859T1 (en) 2014-07-02
EG24743A (en) 2010-07-14
US7109333B2 (en) 2006-09-19
GB9800569D0 (en) 1998-03-11
NO316176B1 (en) 2003-12-22
NO20003561D0 (en) 2000-07-11
ME00757B (en) 2008-06-05
EP1460072B1 (en) 2006-04-05
US20130310562A1 (en) 2013-11-21
EA002455B1 (en) 2002-04-25
JP3390741B2 (en) 2003-03-31
EE200000411A (en) 2001-12-17
BR9906904B1 (en) 2011-05-03
AP2000001861A0 (en) 2000-09-30
US6713485B2 (en) 2004-03-30
EE04616B1 (en) 2006-04-17
DE69918528T2 (en) 2005-07-28
FR08C0038I1 (en) 2008-11-14
LU91475I2 (en) 2008-11-10
EP1454907A1 (en) 2004-09-08
HU227593B1 (en) 2011-09-28
AR015507A1 (en) 2001-05-02
IL137041A (en) 2006-10-05
ATE270670T1 (en) 2004-07-15
UA66827C2 (en) 2004-06-15
US20160339027A1 (en) 2016-11-24
US20100120804A1 (en) 2010-05-13
DE69940128D1 (en) 2009-01-29
ATE417847T1 (en) 2009-01-15
IL137041A0 (en) 2001-06-14
PT1460072E (en) 2006-07-31
EA200000637A1 (en) 2001-02-26
NL300360I2 (en) 2009-02-02
NO2008017I1 (en) 2008-12-01
AU749549C (en) 2003-03-20
HUP0100941A2 (en) 2001-09-28
US20020147205A1 (en) 2002-10-10
BG64825B1 (en) 2006-05-31
SI1047694T1 (en) 2005-02-28
HRP20000469A2 (en) 2001-06-30
PT1454907E (en) 2009-02-18
ZA99172B (en) 2000-07-11
AR066982A2 (en) 2009-09-23
SI1454907T1 (en) 2009-04-30
TW477788B (en) 2002-03-01
EP1454907B1 (en) 2008-12-17
CN1134438C (en) 2004-01-14

Similar Documents

Publication Publication Date Title
AU749549C (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
GB2345486A (en) Heteroaromatic protein tyrosine kinase inhibitors
US6391874B1 (en) Fused heterocyclic compounds as protein tyrosine kinase inhibitors
WO2001004111A1 (en) Anilinoquinazolines as protein tyrosine kinase inhibitors
WO1999035132A1 (en) Heterocyclic compounds
MXPA00006824A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-448/00

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 137041

Country of ref document: IL

Ref document number: 99803887.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 22783/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 505456

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09582746

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2317589

Country of ref document: CA

Ref document number: 2317589

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10502000

Country of ref document: SK

Ref document number: 1999902522

Country of ref document: EP

Ref document number: 2000/02015

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/006824

Country of ref document: MX

Ref document number: 1020007007635

Country of ref document: KR

Ref document number: 200000637

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: P20000469A

Country of ref document: HR

Ref document number: PV2000-2587

Country of ref document: CZ

Ref document number: IN/PCT/2000/130/KOL

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 1999902522

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007007635

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2000-2587

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 22783/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999902522

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1020007007635

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV2000-2587

Country of ref document: CZ